var title_f32_4_32832="Asymmetric inguinal folds";
var content_f32_4_32832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Asymmetric inguinal folds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 671px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKfAeYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKQmoZZNoyDQOxPRVa3u45X8vIWQfw+v0qzQDVgooooEFFQXd3BaJunkCA9B3P0FY1zrsrnFpEFH96Tk/lUuSW5cYSlsdBVO41KztyRLcRhh/CDuP5Dmuane6uiftEzsD/AA5wv5Dio1tFA6VDqdjVUO7N2TxDZL9wTSf7qY/nioG8SxZ+W2lI9yBWUbcelMaAelT7RlqjA1T4mT/n1b/vv/61A8Uwg/PbSgf7LA/4VivCKryRUvaSK9jDsdRF4o05yPMM0X+8mf5ZrStdRs7ogW9zC7H+EMM/l1rzuSH2qtJF7U1VYnh4vZnq9FeZWmtajY8Q3DMn9yT5h+vT8K6HS/GMEhWPUk8h/wDnovKH69xVqomZSw8o7anWUUyKRJY1eJ1dGGQynINPrQwCiiigAoopGIVSSQAOpNAC03eCeOazZb3zmIj4j/U1LE9TzF8j6l4GlqFXqQGncmw6iiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQmkJqKR8UmxpXFdwBVK4k4NOlkqnK+RWcpGsYmXqTN95GKuOQR1Favh3XF1AG3uCFvEHTpvHqP6isq9GQa5y6eW0uY7q3bbNE25TUKdmbumpqx6oeKwdT1s5MWn4Y9DKeQPp6/Xp9ax7zxIurRJDa7o49o83PBJ7r9B+v06thZVUVU6nREU6NtZEiRF3LyszuerMcmrCqo9KjEgpQ4NZXNrEuQKQtTM+9JmlcLDiaYxozTSaLjI3NQPU71C4oGQPVeQDFWHqvJSGipKoNUp46vSE1Wc0Foi0zVr3RrkS2jkp/HEx+Rx7j+tel+HtftNbhzCfLuFGXhb7y+49R715fKqkHNV4LtrK6SezdxOhyrR/5x+FXCbiRVoqor9T3CiuAXx7cG3Qf2WDNj5iZcKT7DFRN431U/dsrRR7lj/WtvaROP6vU7Holc7quoi4uDbwtmFDhiD94/4Cuc/wCEt1W6UwmO2j8wFdyKcr7jmrdhHsRR6CplUvoi4UXHWRrwGrcb4qjGcCp1ekmDiaCPU6PWcj1YjerTM5RL4OadVeN6mBq0zJodRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSE0pqJ24oAR2xVSWTrT5XqlK9ZyZtGI2WSqzvRI9Qs1Ytm8Ykc/INYl+mQc1tPWZeLkGpuao5mOBReEFQQ3qK1orHAzGSn+6cfyqJYc3CnHet6CMeWKRbkZDvd24+WTcPRuf/AK9S2mqh32SDZJ6Hv9KvXMQKnisG+gHPFAKzOnimDDrTmlVQSSAB3rjoda+xqYptzydEH976mplguNSIe8lYp2jU4Wi4uTuat1r9lCxVZDK47Rjd+vSqn9uyOf3VnIR6scf41ZttNhiUBI1H4VaFqo/hoD3UZT6vdDn7Kv8A33/9aoxrkg/1tsR/utmtWW2BHSs64tMfw0DVhYtZtZDhy0Z/2x/WrbOrpuUgg9CDWDcW6jOVrPBmtpN9tIUI7dj9RQVyp7HRy9aoXkyxL3Lnoo71HFq8bxkTjy5wOF/v/SpbC0ed/NlGXbn6UBa25BBay3JBnOR/dHStSGwVRworWtrMKo4qwYQtFiXO5jm1AHSq1xCFFbci4rOuxxQJMr6dFm4UnoK6eBcKKwdPGHzW9CflFMmRPuxTg/NRE0gNO5Fi2j1Yjes9WqaN6pMmUTUierSNWbE9XImrWLMJItg06okNSA1aMmLRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUhoARjVeVqkkNVJmqWy4ohmeqcjc1JM1VXNYSZ0xQ1jmozSk001BqhrniqVwM5q43Sq0ozSGijHH+8zWrEPlFU41+er6DimDIph8prHvk61sz9DWVd85pDRymtQ/uTKn3ozuFdFocgngRh0IzWXfJuR1PcU7wXKTbeWT9wlaRq9YnYIoAp+KRPu0m7mqMQZaqzxjaatE1BMeKQzEu4xk1jzxYYkCugukyTWZPHwaC0zH0+D7TquCOIx+pru7G2CqOK5Tw6n/ExuCeu7+ld1arhRREKrH7ABUT1ZfpVZutNmKK8orNulrUk71QuRxQWiO0XBrYhPy1mWgrRiOBQJkxpKM0lAhwNSK2KiFKDQDLsT81dhesqN6uQyVpFmM0akbVOpqnC3SrSGtkc8kSiikFLVEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNNONMagCGQ9apTNVqU1QnPWspM2gitK1V2PNSyGoWrFnTFDTTaWkqShGqCQcGpzUMnSgYyFfmq4o4qCBcVYPApgyvcHism4PNadyeDWTcHmgaMy8HBqn4P+W5uF7B6t3jdah8JJ/pdye2+kzX7LO0j5Wq9w+w5qzFwtU7/7poMUEdwHGM04/NXNXGoiymHmfcJwT6Vt6PI15GJiCqn7oPcetBTjZXJJosisy4TGeK6CSPisq8jxmgEzG0EbdVuR7g/pXcW33BXD2Z8nWTn+NR+ldpaNlBREKhYk6VWarL9KrtTZmiCSqsq5FW5OlVnpFkduMGrq9KqJ1q2lMGSg0tIKCaRIuaTNNJpjNigCYPirEMlZ+/mpYX5qkyZI3Ld+lX4jWPav0rUgbit4s5potinCmL0p4rQxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADUTnipDUTmkxorTHrVCY1dmNUJj1rKRvArSGojT3NRmsmdCEpKWkqRiNUeMmntSAUAOjGBTnPFIOBTXPFAFW4PBrMuT1rRnPBrKu2wDQWjHvpME1peFYdtsZCOZDurDvC00wij5Zjjiuy02ARQIgHQYoLlojQHCVm378GtCQ4Wse9fk0Mzicl4lO6Mj3H867bw8P9DQewrhfEDfMo9WH867rQD/oqfSkjWfwmo44rMvFzmtVhxVC5XOaoxRzOoIYrqGYdjtP411Omy74lPtWPeW4ljZT3qTRJWQeU/wB5aWxb1R0hORUL9aVWyKQ0zMjcVWkFWzUTrQMrL1qzGahK4NPQ4pDLGaRjTd3FMZqBCs1Qu9I71XZ6B2JS/NTRPzVLdzU0Tc00Jo27Rula9u3ArBs25FbVqcgVvE5aiNFOlSCoohkVLWpgwooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACN0qGQ1PUE64G4dO9JjRSnPWqExq5M3WqExrKR0QK7mmZoduaj3VkzdEmeKKjDU4GpGOIpKAaCaAAmonNPJqJqYyrcNgGse9JIIXqa1rnoRVaO23tkikUilpGnbZPNk5btXSQptWooIggAAqwThaBSdyvcvgGsW7fJNaN3J1rGun5NJlRRzWvtll/3h/Ou60Bv9FX6VwGutll/wB4fzrufDrZtVpI0qfCdBniqs461ODxUcgzVmBnyLUcUQWUMKtutMC4NIq5bjbIqWq0ZxU4NBI6mtQTTS1ADGWm9KVmqF3oGSM+KheSo3kqBpPekNIkd6iZqjZ6jaSgdiYNU8T81QD81atzkiqQmblkckVvWKF+B0HU1jaTA08gVR7k+grqoYliQKnQfrW8EcVWVtB4AAwKKKK1MAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDNv4CgLoMp39qxp2611Z5GDWDq+ntErTQcx9Svdf/rVnOJtTl0ZiyPUe/mo5WqEvzWDOtFsPTw1Ulk96lWSpGWg1KTUAanBqYEhNMajNFAERjycmpEQCnCgkCgYucCo5ZMA0ySXFVJZcg0gSILqTrWTct1q7cPmsy5fg1LNYo53Wjll/wB4fzruvDbf6Mv0rw74wR6rPp6DSROVx+9CsuwjcuPlwWLZxjGMDOa9U+G322Lw9AuqGY3oLeYZXRyTuPKlQBt9BgEDGadtLhOV3y2O8U0p5quklSq2adzEGWo9uDUxNRsaAADFOzUZbFMeQCgdiUsBUTyVC8tV5JqQ7E7y1C8tVpJqgeagqxYeX3qFpPeqzy1UvL1LaMM+4ljtVVGSx9AKB2L7S1SvNSgtZYkmcqZM4OMgYx1PbqKy76/MluskLNGEf5yQQYz/ALQ9PX2Oa56RZJ9Te7t5Qf3gVw5ysb8ja/YqQSoYdOM96aQm7bHoETbjW3o1lLeTBIVz/eY9FHvWN4P0e9vWESrsgABPmcmH/ZJHUeleqadZRWFssMI4HVj1Y+prWEL6mFaqo6LcfZWsdpCI4h9SepNT0UV0HC3fVhRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOc13RSVaexXnq0Y7+4/wrky/JB4Ir0+sLXtAjv8AM1uRFdev8L/X/GspwvqjopVraSOL8zFPWaq9zHNazGK5jaOQdQwqIvWDR2I00mHrUolFZAlxT1n96QWNcSCnh6yln96lSf3oCxpb6hlk4qv5/HWopJQe9ILCyy5NV5JKa789agkei5aRHM/Wsy6firU8lZd3J1qWzSKMTVXy34j+ddh4elxAtcRqJy2fcfzrp9Dl2xqM0FSWh2EctWEmrHSXjrUonx3qjBo2PNFMaSs0XPvSG596BWLry471BJNVR5896geXPegaRZkmPrVd5qrvL6moXmpFJFh5agaWq7y+9QtJQVYsvNWZqMu26sZG+4spUn0LKQD+fH41PuJpfJE48pk8wP8ALsxnPtii4NGfrEbyMq2u77TKNrqrY3Rjrn09AfU11XgjwwmpmO4tgyWIBUORjapIJQDvyO/Tn6Vs+EvAoTE+oRmGM8+USS7/AO8TyB7fyr0WKNIo1jiRUReAqjAH4VvCm3qzjrV0tI7kVhZwWNusFsgRB+ZPqT61YooroOFu+rCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigClqmm22pQeVcpk/wuPvL9DXCa34dvNNBljBuLYcl0HK/Uf1r0iiplBSNadWUPQ8ZMoPem+Z716RrHhSw1AtJGptp2/ij6E+69K4PWvDuqaWGdovOgH/LWLkfiOornlBo7adWM/Uqib3p4uMd6xjckUn2v3rM35TcFz7003HvWMLnPelNx70rjUTVafNQyT+9ZpuPeoZLj3qSlEtXE9ZdxNkmiWbPfiqMsmWwvNFikh8NlLqV2ttbDMhVnA9dqlj+grR0yXaor0f4Z+EZNNX+1NTQrdyIViibrGp6k+59Ow+tcx438MXGh3st1aRM+mSNuBUZ8on+E+g9DWrptRuYKvGU3AhiuMDrU3ngjrWBBdAgc1YE/oazvY15TWM3vTTPWZ9oPrQZ/ei4uU0vPpjzVQ873pDJ70XDlLTy5qJnJqAyDualtY5ryURWkMk8h/hjUt/KgewhJNNOB1rrdK8C6ldYa+dLOP0Pzv+Q4H512WkeEtK01g4g+0TD/AJaTfNj6DoPyrSNKUjCeJhDbU8/0LwvqOrbXWP7PbH/lrKMA/QdT/KvRPD/hqy0YB0HnXJ6zOOR9B2rcorohSUThq4iVTTZBRRRWhgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGTqnh3StTBN1Zxl/76fI35jr+Nchqfw0jcltNv3j/ANidd36jH8q9FoqXCL3RrCtOGzPGrn4e6/BnyhbXA/6Zy4/9CAqjJ4Q8SR9dNkP+7Ih/ka9zorN0Ymyxk10R4I3hbxITxpVx+a/40q+DPE8nTS3GfWVB/wCzV71RR7CI/rs+yPF9P+G2uXLD7Y9vaJ33Pvb8l4/Wu88MeBdM0NxO4N5eDpLKowv+6vb68mrniHxnoHh3WdJ0rWtRS0vtVcx2cbxuRKwIGNwBVeWUfMRnNW/DviHS/Edrc3Gi3X2mG3uZLSVvLZNsqHDLhgM4PccVUacYmU8TUno2atIyhlKsAQeoNLRWhgcvrPgfRtSdpBC1rMeS9udoP1XpXLXvw0vEJNjqMMg9JlKfqM16jWB4c8U2Ov6tr2n2cVyk2jXQtLhpVUKzlQ2UwSSMHuBUOnF9DaGIqQ0TPO5Ph7r6n5Tav9Jf8RTU8AeIWOCluvuZh/SvZaKj2ETX65U8jyaD4cawxHnXdnGO+GZj/IfzrXtPhpCMfbdTmk9oYwn6nNehUVSpRRDxVR9TndO8GaHZYIsxO4/iuDvz+B4/St+KGOFdsMaRr6KoAp9FWklsYynKXxMKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5p8UPhp/wAJ54n0W4vXtxpNrZ3dvMCzCZZJQvlyRjGMqy55I6DrXE6J8GvElhoWk2+q3Gia7JaahfXdzYXksgtbzz4wqyOfKY+YhBbBUjngg819A0UAeG+H/gndJrfhW48U30OsWujaR9lLGeZJDci4M0ZAGN0aAhRuP8I+X0x9E+A2pWejaTaXY0CSaHRb+wu2XeRPPK7tA5JjywTcvJ5UjgHAr1jT/HTajZQ3lh4W8RXFpMu+KVY4AHU9CMyg/nTrnxubNY5L/wANeILS3aWOEzSxwbULuEUnEpONzDoDQB5N4v8Ag34x1zRNLslvPDv2mw0u0tYr0gJcJPEQWJmNu8rJwdu148Z5B5z6r4D8K33h/wAReMdQvpraSLWb9buAQsxZVEYUh8gAHI7ZrtKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+bviJqpk+DfgHwhA0/neImgimFvC80i2seHlZUQMzY+XgA5Gam+GWrSP8H9T8M3Zm+1+HNatbP8AfxNFI0DXkbRMyOAy5G4YIBAUV6Jo3g3xBpUGlLHL4UuLnS4Ps9re3GlyNcRpgggP5uRkE5xgHNOvvBmt3807zP4Wt5Lye3lvLm00t47icQyo4BcyHP3ABnOKAPRaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACikJxQrBuhoAWiiigAooooAKKRiFBJIAHc1mXeu2FvkCUzN/diG79en60m0txqLlsalFcpc+Jbp8i0tUQdmlJY/kMfzrPk1HVpfvXbgeiKq/yGah1UjZUJPc7uivO5DeSf6y5uH/AN6Vj/Womhm7yOfqxpe18ivq/mek0V5oUlXo7j6Mact3fQ/6u7uAPTzCR+VHtV2D6t2Z6TRXAweI9UgwGkSYDtIg/pitSz8YQkhb23eL/bjO4fl1/nTVSLIdCaOqoqnY6nZX/FpcxyEDJUHBH4HmrlaXuZNNaMKKKKBBRRRQAUUUjMFUsxAA7mgBaKq/aN5wvC/zqVGzSuOxLRSA0tMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFITSE1DI+KTY0hZXwDWXd3DxtvjbDCrM0nFZl4cg1m5G0ImppeqRX26M4SdPvJ6j1HtWjXm968tvOtxbsUmQ5BFdroerw6npgusiNkyJVJ+4w6/h3qoTvoKpS5dVsadY9/rsMDtFbL58o4JB+UH69/wrM1LVZL9mity0dt0z0L/AOAqrFCqKABUSqdEXCj1kFzLd3x/0qUsp/gHC/l/jSR2qqOlT8ClzWV77m600QwRKO1L5Y9KdmjNIBpQVGyCpjUbUwIHQVXkjFWXNQMaRSKskQqlNFWi5qpKeKCkZUgeNw8bMrqchlOCPxre0jxpdWYEWoobqIcbwcOP6GsqUA1SmiBoUmthyhGatJHr+n31tqNstxZSrLE3cdj6Edj7VarxfSr680i88+yk2k8Mh5Vx6EV6n4f1mDWbTzIvklTAliPVT/h710QqKRw1qDp6rY1aKglvbWH/AFtzAn+9IBUB1jTR1v7T/v8AL/jV3MeVvoXJHWNGdyFVRkk9hWFPetdy/LlYh91T39zVPW9WS8uBbWkgeBMF3U5DHsM+3+elNtzwKzlPojeFOyuzVhercb1mxtVhHoUgcTRR6kBqkj1YR6tMycSeimqadVEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNJpSaikbik2NDZHxVWWSllkqnK9ZykbRiEklVJjkGld6hc5FZNm0YmVfpnNc9NPcWTusLkQykeYmcBsdM11F2Mg1z2oRbgRU3NolqDUpgoP2dSPUP/wDWq3HqycCRJI/cjI/Sq2mQ7ogCKuy2qleRSHoTw3sUoyjqw9jVlJA3Q1y91btE/mRMVcdxVjT9SO8RzcP29GoBx7HR5pCwHesu81WC1QeYxLkcIoyxrLkv9SvOLaNbaM/xN8zf4UCUWzpWlAqJ7hB1YD6mua/sy5mObm6mk9txA/Knf2PGq9M/WgfKu5vGdG6MD9DUbMPWuam0xVOVGKg2XEJzFPIvtu4ouPlXc6Z+aqy1kJq9zBxcRiVfVeDV+C8hvIy0L5I6qeCPqKB8rQyXrVKedIzhjz2UdTU97N5WFQZkboOw9zUNrZEsXf5nPUmkUvMhCzz/AHR5a/mali01hkmR8nr8xrXt7fpV1YAB0pkuRz39mxryVyaatuiMfkFb08YANZ4TMvTvQF7mrpEISBeK2Y+BVGy4QCrgNO5k9Syr1Kj1TBp6vVJkOJoRvVqN6y0erUT1aZlKJpo1Sg1TiarCGtUzFomopAaWqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACg0U0mgBrmqsr1LI1Upn61EmaRRFK9VJGp8rc1Xc1i2dMUNY00mg001BoV7jkGsm5jya15e9UpVyaCkP09Ai4q444qG2XC1M/SkBm3kYINc9qEbAboyVdeQR2NdLddDWHfDGTQVFlHw+ftDM853zbiGJ9a623hG0cVxGkS+TrckfRZMMPrXf2/KihDqbiiIelI0QNTZopmZQmtgR0rLurfHSt+ToazrsZzSKTOauoyCeKzps2/76Jtki8git25TJNY9/HmSJD0Zx/jSZrFmlpUEtyPtFzgyNjoOB9K3ILbGOKXTYQIEAHatFEHpTRnJ6kccQHanleKmA4pG6UyDPuBwaoIv7ytO4HBqjGv7ykUadocKKtg1UtxgVaFMljqcDTKXNAiVWqzE9UwalRqaZMkacL1bjbisuF6vQvW0Wc80XlNPFQoalFaIxYtFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAajc09qikNJjRXmbrVGZqsznrVGU1lJm8EQSGoWqRzURrJnQhKQ0ppKkZDIKrOvNW3qDGXpjRLEuBSv0pyjApknekBQujwax74ZBrWuj1rIvD8poLRzjMY9Zt29TivRbI5jX6V5xc/wDIRtz/ALdejWXEa/ShFVNkWJDgZpiyZ4p0/wB2siW5MUhyeKDNK5qO1VJl3Cmi6UoCTVgDcgJHWgNjJnjrE1FMXFuf+mn9K6a5SsHV1wqN/ddT+tDNIPU6bTx+5X6VeAqhprZgX6VoDpQZvcWmNT6Y1AirMM1UVcSVdk61AR82aBlqHpUy1BCeKnFMQ+igUhNIQ7NKGxURNIWxTAuxvzV6CTpWOklXrd60izKaNmJs1YWqMDZq4h4rZHNIlFFIKWqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAa1QSHg1O9VpTUsqJUnPWqMp61bnPJqlIaxkdMCFutMNOammszVCGkpTSHpSGRvUarzmpDSgUxiiopOlSmoJ2wDQBnXbdaxL6TCmtO9k4Nc7qE4yeaRpFFWJDPqduoHRs16HbDaoFcT4ZiM980x+6owK7eLgUIKnYWdvkrndWPyNW3dNxXPas37tqTCCKXhKR7m8fznLCFiig/zrt2HFcR4KA8+c+shruCMimgqblSdcqawtYiL2smByBkV0Mg4rOuY9wIPegUXYNBm8y2XntW2vSuW0djbXDwt0zx9K6eI5WhCktSSmtTqQ0ElaUVDjmrUi5qBlxQMfDVlaqx8GrCnigTH5phNBao2agBWbiomemu9Ql6B2LKPV62fpWUjc1etm6VcSJI3rZulaERrKtT0rThPFbxOSaLApaRelLVmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJKqymrMo4z2qpMamRcSlOapSGrU561SkPWsZHTAYTSZppakzWbNRxoNJmlzSAbiinHpTCaBgxwKoXcuAannl2g1iX9zgHmgaRS1C4wDzXMXkjTTiNOWJxV3Ubng81d8LaY0shuZl/3c0Gy91XNvw7YfZLNAfvHk1udFpI49oFJMcA0GLd2U7p+K5/VWzC1a92/BrC1Rv3TVLNYIZ4JPzzf9dDXdj7tcB4Jb97J/vmu/TlRTRNTcikFVZVzV5xVeRetMgyp4P3iuvDCti0YmNc9arFeeaniOKBt3LdLTVORS0EiEVEy1KTTWNAEIGDTwcU1iKjZsUDJGeoXeo3kqF3oGkOZ6YXqNnphekOxaRqvWzcislH5rSszkiriRI37M9K17dcjPas3TIWlP+yOpraUBQABgCuiKOGo9RaKKKszCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADyKo3kZQbh90/pV6kYBlIYZB7UmrjTsc9O3WqErVqapbNB865MR7+lYszc1jJHVB3EL0b6rs9N8ysmbIt7qXfxVQS0jS0h2LTSCopJsCqjzVVmm4PNA0h93ccHmuf1G5wDzU19dbQeaoWVrJqVxznygeT60GiVhulabJqVyHcYhB/Ou7tLdYI1VRgAUyxtEt4lVFwBVonAoIlK4vQVUuX4NSySYqhcydaQJFK6frWHqb/u2rUuG61z3iG5a2sLiaOMyvGhYIGC7sDpk8D6mkbR0LHgo/vpP9816HEflFeF/B/xiviHVr23itiEikdvM3qNqZGwEbiST82SOOOvNe4Qv8oqrNOzMpyUtUTkZqJ0zUgalNBBVKc0oXFSsKQYoGOQ07dUecUxnouBKzVEz1E8tV3l96AsTvJUDyVA83vUDy0irE7yVC0lQNLULS+9BViw0lN8yqhlyadGSTQFi/Acmui0Syku5MIMIPvN2FZ3h/S5dQnwvyxL99/T2+tegWlvHawLFCuEX9fc1vThfU5a1Tl0W4+GJYYwiDCin0UVucQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIyhlIYAg9Qa5jW9Le3BmtwWh7jun/wBauooIyMHpScblQm4u6PNnfmoy9dJr+gMd1xp689WhH/sv+FckXwSDwRwQe1c8o2O6ElJXROZMU0ze9VnaomeoNUiy8o61m3dzgHBp8jnnFQxWxlky/SkUirDbSXkuMHbXWaZZpbQqqgCq9nGkQGAKvrIMUEydywWwKgllxTHl4qrLJQJIdJL15qpO+QaHeqsr0i0iC4esDWkiuLaSG4jSWJxtdHXKsPQg1r3L9awtSkypqTWKK3gXS7Cwv5p7e2jWZpXffjLDdjcAewO0cDjivToJflFebeGpNs7/AO9XdW0vyjmnfUicV0NmOX3qYOMVkpNUyz+9MysX2aomfFVzOPWonmFAWLLy1BJN71Vkmqu81BSRaef3qtJN71XeSoHlpFJFh5feoXlqs81RPLQOxZeX3qFpc96rlyTT0FA7E6ZY10nhvQ5tTlDkMlqp+aT19h6n+VWPDHhWS8VLm/DRW55WPozj+gr0GKNIY1jiVURRgKowAK3p076s5K1dR92O4y1torWBYbdAka9AKmooroODcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxNc8PwajuljPk3X98dG+o/rW3RSaT3HGTi7o8nv7W4sJzDdxtG3bPQ/Q96psa9dvLWC8haG5iWSM9mFcRrnhCeEtLpZM0fXymOGH0Pf+f1rCVNrY7addS0loctuFSRyBaq3Ikt5WinjeOReqsMEVD5w9ayOm1zYSf3qZbnjrWF9ox3pwufekPlNprjjrUbzA1lG596abj3pXGomg8o9aqzS8daqvce9Vpbjg81NykhbmXjrWNeNuBqe4lzVPa9xKsUKs8jkKqqMkk9hQWh2httlc/7Rrr7afCjmm+MfDTeHhpsqL+5eBY5XHTzgOfz7fQ1l21zx1qpJxdmQpKouZHQibI4NHnkd6yVuMDrTvtAPei4uU1PtJ9aabjPeswze9J53vRcXKaLTe9QPNVQze9RmTNFx2LLze9QPJUW7JpCR3NK47CsxNJVzTdLvtSbFhayTDONwGFH1J4rttE8Aom2XWJvMPXyIjhfxbqfwx9aqMJS2InVhT3Zxel6bdancCGyhaRu5/hX3J7V6R4d8I2unbJrzbc3Q5GR8iH2Hf6mujtraG1iEVtEkUa9FRQBUtdMKSjqzgq4mU9FogooorU5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCjqelWWpxbL23ST0bow+h61xOrfD6UFn0u7Vh2jm4P8A30P8K9EoqZQUtzSFacNmeFarour6Zk3dlMqD+NRuX8xkVji6INfRtZ15oml3pJutOtJWPVmiXP59aydHszqjjP5keDi7B70jXQ9a9km8C+HZTk6ftJ/uSuP61Vb4deHmP+onH0mao9hI1WMp+Z5A92PWoHuga9nX4c+HB961mb6zv/Q1atvA3hy3YMmmRsR/z0dnH5EkUKgweMp9EzxGxs73VrhYNPtpZ5CcYQcD6noPqa9c8C+B49DK3uoFJtRI+UDlYvp6n3rsra3htYhFbQxwxjokahQPwFS1rCko6nNVxUqistEVdTsLbU7KS0vYhJBIOQf5j3ry/Wvh1qFm7S6RKt3DnIiY7ZAP5H9K9aoqpQUtzKnWlT+E+erqK7sH8u+tpoHHaRCv86h+1CvomSNJFKyIrqeoYZBrLl8N6LKSX0qyyfSFR/KsXh+zOuONXVHhX2oUv2oV7afCGgE5/su3/AH/ABqaHw1okX3NKsv+BQhv50vYPuV9dh2Z4ek5dgqAsx6ADJNatjoWtXxH2fTbjH96RfLX82xXttvbQWy7beGKJfREC/yqWqVBdWZyxr+yjzCy+HuoSgNe3kEGeqoC5H8hXU6V4K0mwIeSNruUfxTnI/756V01FaKnFdDnniKkuo1EVFCooVR0AGAKdRRWhiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct8T/ABb/AMIN4F1TxH9i+3fYhGfs/m+Vv3yKn3trYxuz0PSuprA8d+FrHxr4Uv8Aw/qstzDZXgQSPbMqyDa6uMFgR1UdulAHMad8ULWC/wDEFj4stodJuNHktY3a1ne8jma4UmNI8RK7Px9wJn0zWp/ws3wn5VsyajPLLc3EtrFaxWNxJcmWIAyIYFjMgKggnKjGR60/WPh34c1DQYNKtbGLSIbe7jv7eTTIo4GhuIzlZVAUqW6jlSOa5/UfgvoOoaZdWVzf6hJ9suJru7nlgs5ZZ5pQAz7ngbyzgceVsxn1xQBH44+L1r4YttYmTTxfNYCyYW4NxFPi56GVWgxFgA4G5iT8pCsQDrzfE/QrLU9Qh1W4Wztbb7IA8kF0JlNwDsE0TQKIgSMAlj/tbeAad98HfDt7Y6raS3GqiLUbWytHInUtGtrjymQlSd3HJbcD6Crl98MNI1JfEf8Aa17qN/Jr9nBZ3kkzRKcRA7JFCRqofJz0xkDjtQBcufiT4Ut/ODam8jxXc1iY4bSeV2mhAaVUVEJcIDlmUFR3NaF34y0C08Hf8JVNqKf2B5azfa0R3G1mCg7VBbqQMYyO9cndfBbwtcaBoemN9pJ0dpXgupVgnkkMpzIZVljaOQseeU4IGMVu6p4A0vUvh1L4MuJriPTJIxG0ltHBBIAJA/CpGI15HZAPx5oAy7b4t+F7q7Elvqti2jixlvWu3M6OBHL5bYQxbSuSBnfkk8KRzWV4z+MFha6K8/hSQXV9bX1lBdwXthcRGOK4J2sFYIxJUEjGe3HIrX8ffDLS/FQuLm5We4ujpTaXHbtciCJl8xZAxYRuysGRTkAj/ZNczoHweu7y41678a6nJJNqN1YTxiznWR0FopCb5DDGrZzziNeB1zzQBs+IPjHodgNHbS4LvU0vNX/si5CW1xHLaSAZfdEYi5cZGI8Bm5xnBx6ZG4kjV13AMARuUg/iDyK8+u/hNos73Msd/qtvdS65/wAJAlxFJEWhucY+QNGVKezBvrXoMalUVWdnIABZsZPuccUAOooooAKKKKACvPfi18Sl+HcmhmXSZtRg1CaRZmhl2vBHGoZ5Au078Lk4yPu9a9Crn/EXhPT9f1rQ9Tv2mMukSSyQxKV8uTzIzGwkBU5GD0BH40Act4b+LuharBqtxdH7Nb2+qtpdmYN91JfkKrK8ccabzkNnADYHU1fn+LPgqKxtrv8AtlpYLi1e9Q29nPMywIxV5HVEJRQwIJYDBGKwIfgJ4Pg0dtOh+3CEai2pQNIYpfIdlClFWSNkaPCgYdW6dayfGHwbumtmh8HS29tPcaZLpVzdSyw2ivDJIXKtbw2mxsE5ypjb1J60Aeh3nxC8N2f9ntd3d3DBqHk/ZrmTT7lbeTzQDGPOMflgkHoWBHfFctp3xitL221uV9PNl/Zut/2QGvPtKRyjcqh9627bZCW/1RGR/EQDmorn4FeH76e0uL/UdUkuIIbOPKmEgG2VVUoXjZ4w235lVgDnkcDGtdfCbRrgatGdS1dLTU9VXWZbZHi2LdBgxZSYywB2jILEemKANeD4jeFZpYY01UCWW6uLII8EqMssC7pgwKgoEXks2FA71P4Y8deHfFF89not+01ysAuhHJbSwl4S20Sp5irvQnjcuR71kp8KfDI8Y634ikiuZbjV7eS3uLZ5B5CiRVWVkUAEM4UAnJ6npS/D/wCGOi+Bbwz6PJI/7g26iW0tFcKWDcyxwrK/3R992z3yQCAChpPxMgi1rxXbeJJLe2t9O1aPTLBbaCWSa4ZowwXYu5nfrwq9O1ZeufGC3m8T+HrDwtItzYXsE93dXB0y6uHCxHBiWNArK5IYEkHZwSvIzra58HfDWtTalPfPeNPe6iuqF28pxFKqbMKjxsrIR1VwwNXNC+F2i6Pq+m6lBPctNYQT28aLDbW8TrMRu3JBEi544IA980AXvhZ41j8feD7TXI7GewebcHgkVyqkMR8sjIokGB1XIByOoNddXOeAvCVt4J0CPRdOvr650+FmNul2Y2MKsSxRSqKSMkn5snnrXR0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV494z8UXOg2HirxBq/ibxHa6bpuqLYx2mlW1i+1THEQf30JJ+aQ5JavYa8K+J/hnV/F3gHx7pHh60+2ahJ4gjdIvMSPIWK3J5cgdPegDV0PWrvWdW1fRh4q8a6ZrWn2i3jW1/a6Ud8bDKsrRQOpHIyMg8/XHpHg28n1Hwhod7eSeZdXNjBNK+ANztGpY4HA5J6V5X4N8I63pnjnW9bXTb7SdDn0YW80WqXqXl1cXCjhg4klZUCjABf6D09N+Hv/Ig+Gv+wZbf+iloA36KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArntS8EeFNUvpb3U/DGh3l5KcyT3GnxSSOcY5ZlJPAFdDRQByv8AwrjwP/0Jvhv/AMFcH/xNdNbwRW1vFBbRJDBEoSOONQqooGAABwAB2qSigAooooAKKKKACiiigAooooAKKMg0UAFFFFABRRRQAUUhIAySAB61nXOt2MBI83zGHaMbv16Um0txqLexpUVzM/iWUnFtaAD1kb+g/wAaqPr2pMflEKj2T/69S6kTRUZM7GiuHfWtVJOJwv0jX/CoTrWrj/l8P/ftP8KXtUV9Xl3O+orgR4i1aMcyo/8AvRj+mKki8X30Z/fQQSD2yp/rR7WIfV5ndUVzNr4xspCBcxSwH1+8o/Ln9K3bO+tr1N1rPHKO+05I+oqlJPYzlTlHdFmiiiqICiiigAooooAKKKZLKsfU8noKAH0VEshapAaAsLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUE0ABNMZsChmxVeSTik2UlcZcy4HBwaitNVjaUQXBCSHhWPRv8A69QXL5Brn9UXeDWbnY2jTT0Z3VFcz4V103T/AGC8b/SlGUc/8tAP6itnU9Qi0+INJlpG4SMdW/8Are9WpK1zJwkpcpallSGMvK6og6sxwBWHe6/klLCPcenmOMD8B3/Ssq6mn1CbzLhvlB+VB91f8+tPRAorKVW+xvCilrIjl+0XbbrqZ5PYngfh0pyWyjtU2aXNZ3NvQYIVHakMS+lSZpCaAIGiX0qGSJatMagkNIZTkhFVZIBV9zUL0FIzJYPaqjK8Tbo2ZWHQqcEVqyHNVZQDSLRoaT4wvLIrHfKbqAdycSD8e/4/nXcaVq1lqsW+ymDkfeQ8Mv1FeVTRg1WgluLG5S4tJGilQ8Mv+elaRqtbmM8PGeq0Z7bRXNeFfE8erD7PdKsN6BkDPyyepX39q6WuhNNXRwyi4OzCiiq2oXcdjaPPMflXoB1Y9gKYkr6Ibf3qWqgcNK33V/qazopWdizsSx6k1kpcSXUzTSn53OeOg9BV+Fqxc7m6p8qNON6so9ZqPVhHqkyXEvg04GqyPUynNWmZNWH0UA0UxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABNRs2KVjUEr0mykhsslVJZKWWTrzVOR6ykzaMRZXyKy70ZBq47ZqrPyDWbZvFHN3Ty2lzHdW52yxNuU1LHrrX07z3gcynso4Ueg9qffpkGs2xixcMMcGpv0NUluzdi1W3OAWK/7ykVbS6RxlWVh6g5rPWzUrnbVK6szGd0RKsOQRwaQWTOjSQN3p4Ncxa6lJC+y5PHZ+341uQ3Ksmc0CcbFzNNLgVj3ut21uSqMZpemyMZ/XpWa+o6rc/wCpgigQ92yx/wA/hQCgzpmkFRO4rnBFqT8y3b/8BAX+QqKWC8XkXU//AH2aLlcvmdExFQvXOefqEXSdm/3gDUkesTx8XMAceqcH8qLj5Ga8tVJaWC/t7sYhkG/up4I/CkkoFsVnbFVJp0DFR87+i0k7tdPshOIu7D+L6e1XLOzCAYUUi9tyjGl2ZFkiPlMpypXqD65rWm1HW7g5m1S5H/XMiP8A9BxVyG246VI0AA6VSbRDae6MSSS9PMl/ev8A707H+tW9OWSWcCSaWRV5w7kjNLcoAcVc0lArE+tFwexs267VFXUbFVU6CpA1O5k0W1ep0kqgrVKj1SZm4mnHJVmN6zInq3E9aJmUol5TTwaro1TA1omYtDqKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAppNONRuaGMjkbAqnM9TTNwaozPWUmawiRyvVZ2p0jVCTWTZ0RQhNRSdKeajfpUlmZdpnNVbSH99mtCdc0y2T56RVy6ijaKrXMeQauqMLVe46GgRzt9F14rI+23ImSxL7Ij0YdSPTNdBfDrXL6z+7aOZfvRsD+FDNoanU6dZRIg2qM+taqW4xwKp6O4lgRh3Ga116UGbepX8gYqKW3BFXeDSMKZJg3NpjNZdzFtzxXT3KjBrGu05NItM5ySHL7lJVh0I4NTwXtxd5tGGWH3pB3X0qW4jwGIqTwtbh3klbks1I0vpdmnaWexAMVpQ2+KsxwjHSplTFMybIljwKjlXireKhmFAjHuV+ardgMVDcL81WbQUDZpoeKdUSdKkoIHA09TUeaUGmBajercT1nK2KsxPVxZlJGpG1WUNZ8L1cjbpWyZzyRYBpaYpp4qzMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooNADWNQympW6VWmNSyoorTt1qlK1TzGqchrGTOmCI3NRmnN1phrNmqENMen01qQyrIKLdfmp8tPt1oGTdqqXJ4NXD0qjdHg0AjKu+Qa5rWV3RSD2rpLk9a5/Vfut9KDWO5teEZvMsIjntXTZ+WuR8Ff8eC+1daPu0ImfxDA/NKz8VSu5DGabDchxjNBNieY5rOuI+tX1YOSAckVHNHxQMwLyP8AdtxUnhH/AFB+tTXifI30qt4VbZ5qdw5H60upf2WdjGvFOIpsBytSNVGJEaglqc1DJQMz515qe1HFJIM0+DikMtrTxUa1IKCRaXNJSZoAeDUkb1X3UK/NNCaNSCStCFs1iQyc1p271tFmE0aSHipBUER4qYVqjnY6iiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkNLSNQBG9VJjVqQ1TmPWokaRKcx61Uc1YlPWqzmsJHTEjNNpTSVJoJSNS01qQETDJqeJcCkVak6CmA2Q8Vn3R4NXZTxWbdvgGgaMy6bGa5/UHB3CtW+lAB5rn7mTe+1eSxwKRtFHUeD4ymnISOvNdLnC1m6VD5NrGgGMCr8hwtBnJ3Zn6gcg1yl1fz216kcRyJTtGexrpb1+DXH3vz6ta+0n9DSNII73TY9tspJyxHJ9alkFFiP8AR1+lPkFMye5kXicMKw9Kk8jU5kPds10V4vWuV1Mm2v45RwG4NDNIa6HfWb7kFWj0rF0e4EsKkHtW0ORTMnoRNUMtWHFROOKQFN6WMYNOdaReDQMsp0qQcVEhqTNAgJphNDNUTNQArNTQ/NRM9MDUwsaED8itW1fpWFA3IrWtG6VpFmM0bcJyKsLVO3PAq4tbo5ZD6KKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNanUjDIoAgkNUpjVuQ1SnNZyNYlOU81WY1LKarMaxZ0xFNIabmjNSWLSYpaUUgFAxSMaCaidsCmAyZsA1jX02AeauXk2M81zmo3PXmkaRRQ1O5wDzUHh21a+vxIw/dof1qlP5l3cpBEMsx/Ku+0HTUsrRI1HPc+tBbfKjShTaoplw2BVkjatZ92+KDJGddt1rk7g/wDE6tf98/yNdLdP1rlp2/4nNr/vn+RqTeKPStP5gX6VNIvFQaUcwL9KuuuRVI53uZk6ZU1zmuWvmwsK6qVetZd/DuUjFBUXYxvDF4VHlufmU4NdxA+5BXnEoaxvfOUfIT8w/rXaaRdCWNeQaaHNdTXYVEwqUcimOKDNEDrUJXmrLVE1AxFOKcW4qMnFRu9IY93qCR6Y8lQs9A7D2ekDVCWpA9A7GhA3Na9melYVu2SK27HnFaRMZm5bdKvoMDnrVezhKoGYcnoPSrVdCRxSeoUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAILiMldyj6isudq26ztRtSQ0kQz6r/hUyRcJGNM1VXapJm61Td+awZ1xJd1KGqr5lHmVBoWw1LvHrVTzaY03vSCxaaQVVuJwBUEk/vVC6uMAkmgpIZfXHXmuav52dtqZZjwAKtX13k7V5J6CtLw/o58wXFwMv2HpQafCrsk8LaMYFM84zM/J9q62NNopkMYRQAKlZgopmUndkc7ALWPdv1q7cy8Gsi6fNJjiijdN1rmJ2/4m9t/vn+VdBdNwa8+8ReKtM0TXbOC/m8uRpQDkbQqlWO/J6jjHGeSBUpXehsmoq7PbNHb/R1+lavUVz/hy6jutOt7iLd5cqK671KnBGRkHBH0NbqNkVSMJbkUyZqlPFkdK0X5FQSLkUxI5bU7XcDxVTRrprO4EMhOw/dJror2LOeK5++t8HI60jRO6sdnaziRAQamZhiuT0bUSh8qU8iugWcMuc0yHGxI7VE71HJKKrPLSGkTPJUDyVC8tQNLSGkTtJUTSVXaWoml96CrFkyUK+TVLzCTVmAZpiZqWnJFdjotgVVZplx/dU/zNUfDmikIlzdrjPKRkfqf8K6euinC2rOGtUvogooorU5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxdY0zejTWw+fqyDv9K5aVsEg9a9DrF13RheqZbbCXA7dA/19/es5wvqjelVtpI48vTTJUc4kglaKZGSReCrDkVCzcVg0diLJmqN5c96qGQ1G0hpFJEs8wAPNZN3cM5wKmnZnOFqewsRu3ScmkUtCPRtLMsommGfQV1sCBFAHFVbfaigDFT+YAOtBEncslwBVWefrzUcs2B1qjLISTzQJIdNLnNZ879alkeqU78HmpZqkU7t+DXnfibwxZ65rljcXck2Yplbb5jY2gHhcEbSSQcjn5RXd3cnWuclfN9F/vf0oTs9DTlUlZno/h3Fvp8EIkkkEaKm+RtzNgdSe5963oZeOtcrpM37lea2I58d6aZjKJs78io2NU1uBjk0pmHrTIsFzyKx7tetaM0oI61nXDAg0ikjJlXa2V4NaFjfkAK5qpKOaruCpyKC7XN9rncODUDze9ZsczAYJpzTUgsWml96haWqzy+9QtLQOxZaWo95JquGJq3ZW8tzMsUEbSSt0VRkmhDehLAhZh6ntXfeGPDohVLq/T95wUiP8Puff2qx4a8NR6aFnutsl32HVY/p6n3ro66adO2rOCtXv7sQooorY5AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDN1jSLfU4sSDZKB8si9R/iK4HVtNutLl23KfIT8si8q3/1/avUKjuIIriFop41kjYYKsMg1EoKRrTrOGnQ8iY5qJjnvXYa54QZQZdJJbuYXPP4H/GuMuRJbytFPG0ci9VYYIrnlFx3O6E1NaEiYBq1HKB0rL80etAnx3qTSxuJP60/7QKw1ufenfafekHKazzA96geSs83NMa496TZSiW5H4qhcSdaZJce9ULifrg1JaRHdyZzWJJ/x9xH/a/pV6aXk1e0PQZdU07Vr5EZhZRKyY7sWBP1wgb8xTim9im1FXZp6XNhBzWsk+R1rl7Kfao5rSjuD60ENG155Hej7T71lC4yOtBn96dyeU0nuMjrUDyZqkZvemmX3ouHKTSNmonYEc1E0lML0XHYk3YpjPUZJpD70rlWFLE0D3rQ0nRNR1Zh9it2MfeVvlQfj/hXf6J4IsrPZLft9rnHO0jEY/Dv+P5VcacpbGVStCnvucd4e8O3usHfEvlWw6zOOD9PWvS9D0W00eDZbrulI+eVvvN/gPatNVVFCqAoAwAO1LXTCmonn1a8qmnQKKKK0MAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqmo6bZ6jEY7y3SUdiRyPoeoq3RRa402tUed614DmQNJpM4lHXypThvwbofxxXGajY6hpx/021mhHqy8H8ele70jKrqVcBlPUEZBrKVJPY6YYqUfi1Png3WDT1uwe9ezah4Q0O/YvNYRq56tESn8uKw7n4Z6U5zBdXkXtlWH8qydGR0xxdN76Hm5uR61G10PWu/k+F0RHyarKPrED/Wof8AhVQJ51d8e0H/ANlU+xkX9Zpdzz97oetVpJxzzmvTo/hTagjzNUuGHoIwP8a2tL+HmhWLB5IZLtx3nbI/IYFNUZCeLprY8p8N+G9R8RXQFrGUtgcPcOPkX/E+wr3XRNJtdH02Oxs48RKOSeS57k+pNXLeCK3hWK3jSKJBhURQAPwqSt4U1E4a1d1fQ8s8W+AbiGd7vQF82JiWa2zhk/3fUe3X61xchns5TDdwyQyr1V1IIr6HqveWVrepsu7eKdfSRA1TOinsa08XKKtJXPARcj1pRcj+9Xrd54C0G5Ysts8B/wCmUhA/I5FUZPhrpDfcnvE/4Gp/pWXsJHQsXTZ5l9oHrS+ePWvTIvhrpCn5571/+BqP6VftvAWgQkE2skpH/PSVj/IihUJA8XTR5GbhR3q/ZaZqV+A1nYXMqnowQhfzPFey2eiaXZYNrYW0ZHcRjP59a0elWqHdmUsb/Kjy7TPAWp3DK1/NDaR91U+Y/wCnH612Gk+ENJ07DeR9pmH8c/zfkOg/KuhorSNOMTmniJz6iKoVQqgADoB2paKK0MQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvf3trp1nLeahcwWtpCu6SaeQIiD1ZjwB9ap6H4i0XX1lbQtY07U1hIEhsrlJghPTO0nHSsX4uaPfeIPhr4h0rSIPtF/d2rRwxb1Te2RxliAPxNeSaf4K+INvD4lutHiu7HULzR7S1judRntRdtNEyhkha3JjSPy9wDN827BJ7gA9/1DUrHTRbnUby2tBcTLbwmeVY/Nlb7qLk8scHAHJqpo3iHS9ZvtUs9NuvOuNMn+zXaeWy+VJjO3JAB47jIrwjxF4D8aazH50lnrUmlWfiCxvrDSrrWQ97HbojC4Im84ruLFSmZNy84K5ObkfgfxnZeIdR1XRrfU7KS48T2t0FGpqBLYbMS+anmlXIwM7st6ZycgH0BVS21Kxur67sra8tpryz2C5gjlVpINwyu9QcrkcjPUV518ZtL8WajNpknhH+1pWt0kZ7a3uFt7adyAFEsiXUEy46/LuHtXOa1oHxLlk8RNaPfx208ujmK3t9V+ZoY4SLyO3d3zGxfHzMULYzk5oA9e0HxDpevtqS6TdfaDp15JYXX7tk8udMbk+YDOMjkZHvWrXzdb+B/iHp+nX66LBf2FldeJru/mtBfBrua1kjjETGRblCxBVtwM6knBJbvoTeHPiTGmgGGbxFqk9tAsE8eo3aWULfvmJkd7a+3lwm0ciUH6kgAH0DRXk3xxv7+117wHa2L6s0N5qMsVxaabeNayXK+UTs3iRB155YY9a5NfDHxSXQ9Kj1SfWb0rpl3GsNjrCwz2140hMEk8vmJ5yqm0H5n5B4buAfQtZVl4j0O+ktI7LWdNuZLzzPsyw3SOZ/L+/sAPzbe+OnevI7TQviNF4x0O6vH1LUYl+xR3/m3v2azi2RjzpIvJugZCzdVlgIY56LxWbpPgTxh/wkHgPWvEVpq+oT6dNqEd95er/vokkkYwNnzlBXBG4KxJUBSCAFoA940vUrHVrNbvS7y2vbViVWa2lWRCQcEBlJHBBB+lW6+eLjwt8WYdB0h9Ov9ROqXIvdO1GO41MOLeGWZmiuVJkI3op4K5cDAHTjS1bwr8RYvHjyW2ra3JosE1obGa1mWUCKNQJEmSS7iDFjyzNHKW6gjoQD3WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK+oXttp1jPeX88dvawIZJZZGwqKOpJ7Cud/4WJ4Q/6GPTf+/wAKPir/AMk48R/9eUn8q5OLX9e8WfFvxH4a07WJtD0nw/BCZHtYIZJ7mWVdwOZUdVQDsFyfXmgDttK8Z+G9Wv4rLTdasbm7lyUhjlBZsDJwPYAmugrjNXiuoNf8BxX9yt3dJdTrJOsXliQ/ZJvm25OCfY4+nSuzoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn/iBp11q3gnWrDT4hLd3Fq8cUZYLuYjgZPA/GuF1fRNTvPFT+JNN8O+JtF1qWAW9xcafqFhi4QfdEiSl0JHY4z7161RQB59p1rrV1rXhZJ9E1K2tNKllklu7++hnkfdBIgyVcsSWcdsV6DRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Normal inguinal folds do not extend beyond the anal aperture (*).",
"    <br>",
"     (B) The inguinal fold on the right extends beyond the anal aperture, suggesting possible developmental dysplasia of the right hip.",
"     <br>",
"      (C) The inguinal folds on both sides extend beyond the anal aperture, suggesting bilateral developmental dysplasia of the hip.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32832=[""].join("\n");
var outline_f32_4_32832=null;
var title_f32_4_32833="Malignant pleural eff II CT";
var content_f32_4_32833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant pleural effusions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 349px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFdAWoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKnS1ke0kuFMXlocEGVQ3bopO49eoH8qgoAKKsWFrJfXkNtC0KSSsFVp5khQH/AGnchVHuSBU9rpdxc3c1tHJZrJESGMl5DGhx/ddmCt07E57UAUKKdIoV2VWVwCQGXOG9xnmm0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFX/7Mn/sr+0MMId2MeVJyM4zu27cZ4+9nNVpokRYik8cpdclUDZQ+hyBz9MigCGirF1Z3FpOsV7BLbSHnbMhU46ZwRnHWoXUK7KGDgHAYZwfcZ5oAbRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUuDx70AJRTgpI4H6VreHvD95rt0IrVcRjl5T91R/jQBkqrOwVQST0AGauLpOosMrp92RjORC3T8q900fwbY6BZRPaIs0zKGkmc8njoKuSrdv5cRmcbhtCjg+uKdhHz9/ZOo/8+F3/wB+W/woGl35zixujj/pk3+Fe3K149xIm8kDjP0qeOxvrxQYJWAU/MTxRYZ4Yuj6kzALYXRJ6fum/wAKVtF1NQSbC6wPSMmvef7Eu1Zd9wqAYY4OcGqc9pqFv/x7qZyo57Bf8iiwHhFxbT2zBbmCWFj2kQr/ADqGvZLnWLjy3W+tCUPygbVfd24zzWVd2mh3mFOlxBlxuaElAufXH0pAeYUV3c3hbSLlpPsl7Lb7Rn95hh9exx71mXvg29iObOaC6XsFba30wf8AGgDl6KsXlnc2Umy7gkhY9A64z9PWq9ABRRRQAUUUUAFFFFAHVXlzBfeF4pJmtIpo40gAS7kaZtgIXMRO0A8ZIxjr14MeoRSXSeG/tOs2RZoRCsizlmtFDkqJAF+TG7tnoa5migDb8TRCGaJIZ7JrdsukVrOZhGcKp3MecnaD6emKxKKKACiiigAooooAKKKKACt+xstJlutLS8eS3imkVZz9rRsKTgkkJ+7x7hvwxWBW5JrGq67d29vNcQtI86yKxijT58YDEhQTx9aAK2s2cVr9na2QiOReXFws67uMruVQARkZHPUetSaPp0U9pc3t0rtaQMkUhQ48vfkBz7DHA7n6GtvWbS41Y2OoS6j59uUyyfZkjljIMQIESfKxYypt5yR12gVlXhn8N6kP7L1BJoZo1lR1AYFTnAdTld68jjIBGVJ4NAGdq9olhqdzaxTefHE5VZNmwsOxK/wn1HY5FU6KKACiiigAopQCxAUEk8ACuu0L4eeI9YVZEsjawMMiW6Plg/QHn9KAOQor3XQ/gfAVLapqcs7bdwW2jwB9Sa9I0z4S+GLOOKP+x4HUj5nuCZX/AJ+pp2A+RAvXJAx71asrGa8mMVpDLcSAFikUbO2PXA+tfc+kfDTwLFGBf+FdJlKHPmCLk56ZGcGvRtEsdE0oImlaXaadvARRBbpHuHp8o6fWkB+dVt4P8R3Chrfw5rcqN3jsJWBP4CpoPBHimadYE8M62JSQuHspFx9SRwK/SoVFdzpa20s8gYpGpZtoycCgD4Y0f4EeImCz61BdwW6rudIrdmYj0BPv7V6LpvgTUrCH7LpelX32RlAG22b9a+oLG5F5aQ3CIyJKodQ/XB6Z/CpznHGCfc0wPAE8C68bCGNNNm3R7cbio7k+tWbD4X65c/NNBaW23PM8uSxPsoOK92oouFjxaz+C9zskF5rFuu8N/qrcsVz7lhWl/wAKcgS0WOHXLmOUSBiwhXaV7jGc/jn8DXWya3dya9cx281tHZ20sUMiSj5jlgGYH8SPwzW5rN1PaWgktYfNcuARycD1OKBHEP8ACzTRIpGpXnlAH5XCE56dQBWPrfgrRrW3Isry7W9XgkplNo9eO/1r0HTbtNR1FvOi2ukZG3cSuMj8D1q8NJshnEAwRhvmPI9+eaLgeAL4W1C7kBnsY5lYHBKgce1UL74fWsw33dpdW0ceXk28gnnAx3r2ZSw8TW9m8kS20hdVZT99QCQB6HtWrr99ougRW8t/CMuTHGiJuYjvx3HPJ96APl7Ufh3byLCfPIklyyIxwAo9SOlc1qPgzULNma0yRkDfGeDjr9B0/L619Nan/Yl9C1xBCqwDkRDAI+o7Z9KxJvD9lJbqiK0bn94Sh+6Ow/HOaAPnVrXUIiIb6FLiI/6zzIwVx/dx3rB1TwzpN8C9mWsJyenWL8c9Pwr6NvtBuJAY3gjmQLuwAASPc+tcLqfhu2u8pZAxyFvuyDCjn360WA8A1fw9qOlqZJod9vnAmjO5T/h+NY9e06ho95p8ztE7gk4c9RgdgvSue1Tw5Yai37uP7JcnJLx/dPuV/wAKQzzeitXV9BvtMBeaPzLfOPOj+ZOvf0/GsqgAooooAKKKKACiiigAooooAKKKKACiiigAq1pcl3FqNu+myyw3oceTJE5R1bsQwIwfeq6ozBiqkhRliB0GcZP4kfnWzLpuo6FPHeRyW3n2rhibe4jnMLAjBYKTjnA54zxQBrKmpW8ltf2t4kOlyROkrQDy0K4jEyNEGDMG3xjBwHDL0HC4niWC5h1BWuXV45olmtyuAvksMoAoJ28cbexzVkeI5IbpJLGH7LEYmjliV8hy6hXKkj5furtHO3aMcjNZep3YvLndFCsFug2Qwqc+WmSQM9zycnuTQBUooqW2gluZ0ht42klc4VFGSaAIq6Pw54SvtaUTZFvaH/lq4ySP9le/6V1ngzwMiuJ9TTz7ocrbqMiM+p9f5V6np2lC32mThgCGjHfuAKdgMXwN4AghlLaXZNPIi7nnmxnHqD0H4V7H4I0C2vtQMWrvhUUsPmwN3GFB9cc/hXCzeIL6WJLGA/ZLZ1yQMAsF7ZrIn1KTPlS6iBHt+5v4Ht+FMR6941vtG0qSKDQ4DNKG2zNGxKAjpz0J+lYE/iB7aRtpPllRwDzk9815Rq/i2100bJdRjiwQQm7cxHrgVz1x8SNNikcI99dq4AyqBQOvHODQB9RaDrM1xY28yp2Klz/F75rcivGEe3coXDKQX+6RzXzJqf7RU0uk6fp2neHIoLe0Ay5uMNJgegXgd+pqjbfGxLiQG/0uaAkEFopt6j0PakB9maNc/aTOyOGiG0DBz82Mn+lS61aSX+mzWsUhiaQBd47DPP6V478B/Ful6zNrWoDVURI4Yy1u8mAq8ku2e46fnXTQfGbwtcRzy2yapJbxdJTaFA/uAxDfmBSGejQoY4Y0Zt7KoBbAGffA6U+vnTxh8eP7Qt3tdGsbqwj34aaaRRI47bQpO0fjnt9fLh4+8bTXTCHxPqtpAB8qLIpAHbGQT+tAH25UdxPDbRGS4ljijBwXkYKPzNfBz+L/ABUk8sv/AAlGuSFz5jf6YSHP4cDgHpUeoaxqPiHZNLrV/dXKEH7PPdMwPuqk4yB3xQB9z2ulaWJ5rqC3gd523vJ9/JznIzkDnniub8d/ELw/4c0ufz9TtHumUqsSzA4PQ5I6Y/OvjW0fU7Qywxahqln5g+ZILyWNG9chWwf0rjPEEE8FwsU4BiUZQ465PJPqSe5oA+htW+O2mWUqvaSPNcQZUfZ88qeeDwKda/tOwQQTpJY3kgdMJkAlT0zkmvmE+mMe3+f8mmHr2GDz0/Gi4H03L8cvC7aVHeyNqr6sm0i0Ee3awOQVfOBXm3jX43+IvEVxvSO3tkUFI3I3yBc9z0/SvKmzyOmB0zUZ560XA9Dsfi54lt02Sta3CYxh4uR9CK6Sz+PGpDCXVggiJAPktzivGKKLgfWfwp+IuneNfFNlou6WG5umdiHHJCqTwe/A6V7Zc/DvS7tpftEs5DNuUptVl49cfyxX5zWV3cWN1Hc2VxLbXMR3RywuUdD6gjkV1Nt8TPGttpd3p8XifVfsl1nzVe4LlsjBwzZYZ9iKdwPqHxL4XXSYhI94NR01n2JcQHO0js+OK4PUtGti0jWzJKpPy453+tcp8Kfi9/YEqWushpbCUkXETfMjqeuPRvevXNX8Owz6d/wkfgq6S60aYbjCvLwHqcj0oEeVzWLQgtGWjGeUbp+I71yet+E7O5RpbbbZ3HoBiNvw7fhXtcNlb6xZeYyIt6pKtnoRnrx6/wD665TWdEeKYJLwW4G/v7UAeCajp91p8vl3cTRk52nHDY9D3qpXrmqQ+WpgvbZZrUqSwK9Menv9K4fVPDbhZLjSS1zAvLxY/eRj3HcUhnN0UUUAFFFFABRRRQAUUUUAFFFFAD/MbyvLz8mdxHqff/Pc+taev67ea3dzS3UjeW8hkEfy4U4wOgGcDjpWTRQAUUV1vgHwHrPjW6kXS7eQWkLBZrooWRCei8dWPpQBl+F/Dt94ivjBZJiOMbppmHyRL6n+g71674N8Fw2KsbZC5AxJcnhiM9vQew/WvU5vCukfD7wwujW6FZzEtxcyvxwOWLn1/l+FeP6z8VLCwiurbRLeSedcpHK2BEeeuM5I/nTEex6DqVh4TMepSJZ/Y1Xy55rptqsp6jOMZrA+KXx+8NwQPaeENFtLy+bP+muoVIzjqMDLH8ccV83+JfFeseJGQareNJDGxaOBRtjjJ9FFYVAzrJPH+vS+Z508Ugdi2GT7uewxXM3FxLcSO8sjMzHJyc1DRSAUGl3cknnNNpRyaAJB3B4HHtUgY/8A16iIA5PSpFBA4PSgDQ0rU7vTLkT2U8kMnfY23P19fxzXpHhnU9R1Hw9cSX7tIkj5Qn+IenT1rzCztZby4gt7dS0szCNRjvXuv9gtpmjLaeW4ihj2jcOvGTTQHEWmJZ5sRKUDMpHY885P9Oanitr29IjhiLI3GOny12/gTwe+qb5kV2RZMYxnPPavofwd8NNK0eOKe+iW6ugAQrD5E/DvQB8y6d8M9Z1eCM6ZY3Lh1DM+07WPrnpVu8+EOv6evmzWE4YHcJAhIXH07V9nIixoqIoVFGAoGAB6UtID4rvfDOqwR+RNG24DlwckD+lcz4k0SeHTLKS7hcW9xG219pwccHHqa+4Nd8OWGr2rxSxiJmA+eMYPHrXkHirwlqR+C2t2ctrL9r0rUJbuBGTLSQqQx2exUt064pgfHV/YyWpVmBMTn93Jjr+nWqRX5fy6CvcdF0W01qQwRlZfNA8sJzuHb8KXxv8AAzVrTTft+kWzvKpAeADh8jIKn1osB4UwxnsM5PtUbDHTpV27t5baeSGaN4pomKvG4IZW9D/nFVWXAPcdsCkBFRRRQAUUUUAFdh4E8faz4QulawuD9nPDxMNykfQ8Vx9FAH0tpXxC0DW7yCe3aO11BkHmRsu0EjriumnNvqsOYlLMSSrhQOK+RFJUgqSCOQR2rvPBHxDvtFuo4tQlkuLIkZJOWj9/encR6Zr2mvncI/MTbgHHbNcRNZy2129xaSeVIFOVCcH2Axk17BYX1jrFt5yyR+TOoKYfOOP61yWu6S0TboA6BT8x7f8A6qAPKdZ02HUHkmTbBdcsTtAWU98+h5rlLiCW3laKeNo5F6qwwRXr17pSI+59wkAPXoM9MD2rG13T4dRgiW7+WQYVJhnI5wM56j2pDPNqKuanp1xptx5V0mM8qynKuPUGqdABRRRQAUUUUAFFFFABRS17N+z/APB2Xx/eNq2t+ZbeF7NiJWU7Xu3HPloeyj+JvwHPKgHK/DH4c3njC9guLt3sNAEuya9KklsdUjH8TdvQfpX2zHa6b8PPBENpoNkkKKNtnbkHJcjmSQ9S3cn8Kk0ez07RNHl1a9tIrHS7IZsrOOMBYUXhSF/vHt9fevIfHXjS5127mYFokIzEoOQig9AfWmI4D45+Lru78MC1+0M11dXn+lyKMblCn5R6KTjj2+teBV7P4x0n+1dMMSNmT78bEY+YZwD9eRXjTo0bskilXU4KsMEGhjG0tJRSAKWkooAXtShemelJjBGc4p69RjHPPSgBUO44x1/OrVlP9luEnCJIE5KuMhhjGMVXUDoPw71qaBpc2tazZ6db7jJcyBCw52rn5m/Ac/hQB798N/AsMw0zWmtIvs6ojxtjd1Hb3wa6/wAeQCWa4W3K7JVyUH3h9fSu08PiG00KO2sgFgjRYggYfJgdT6Zrkb9Rs1YLGZDJwkjH5R649aoR3nwY0uCHRRcLCo8s7EYdz3NelVyPwoXb4E04FVVwG3bT33Hr74xXXVLGFFFFABTJo1mieOQZR1KsPUGn1HcyGG3llVDIyKWCA4LEDpQB4Z8FvhjJ4X8Ua5a6mUu7OxfyrSVh8zofmTd6EA9vSvdgigKAowvQY6VX02eK7s4ruFQBOokOByTgdf5fhVkEEnB6daAPJvjB8GNG8cWst5ZRpY64iHZNGg2y8HCuPrjnrXw3rmlXej6ndafqdvJbXdtIYpY5FwQw6/Ue/fr3r9Pa+bP2tvh1Hd6YfGemRAXNsFS+AP34+gf044z+FAHyAw9sU2pZVx0Hv07VFQAUUUUAFFFFABRRRQB1vgTxZJoN2Ibp3awkPIHJjPqPb1Fe828keq6cyiZtjICrrzn0596+Wa9L+GPiWfaukS4fbl4iz4G0dV9SR1GO2fSmmB2d2mwtEQdw+Vh1+lY97byTIuOADkgdf51t6sAl3HcAB0bBOB97NQ3yLwRtUN1A7fSgDi7+2imie1uI98Bc5AGXVv7wPv17frg8Rq+lzabIvmYeF+Y5B0YV6bqdkDJ+7CgsMkE8dc/nWHqNiGWQNFuhfAIfs2OopAefUVavrR7SUqSHTs69DVWgAooooAKKKKAOp+GXhC78deNNO0KzOwTvunl/55Qjl2+uOnuRX6EaLpen6dZWnhzRYRFpemxrGyKTxgfKpPcnqSev414B+x3p1vYeC/EXiKOJX1Oe8GnQZyfuojhfoWkBPsvtXvtzcS+F/Bd3e3jrNewwtNM4GBJKf/r4H0oA8m+NviuS91ibR7aVltrMYKjndNjJb8Adv515OWkZSHBYY6c9SKs3t0bwvdSvIzySF3JJ3bj1yfzqKTBRk24lxkEGmIjnIVYVYlmIzx6cVx/jXwjPqMU+q6bCzTxIHmjUZLqONw9x39frXboolCK4wQcKeteq/DLwk2o21xPKG2sgRSRwRjmgD4pKfKDg4PpSbfmx2r2748fCmXwrOdX0i2Y6e7H7Uitu8ts/eA9OufT6ZrxVl/8A14pDIwoyRn8RSAYPNPcHDcY5zjFN2sVyAcd6AHE4we57n/GhRkH09KVRhsDOM8Z7/SlHzDkgUAOAPf29817D+zrp0N94inLKnmIrLuxh+QMAHoBXkGMnJ+pH417j+zRJHHqEpX/WC4AkA7Kfun86aA9ghmbTZpbOdWj8uMPHuBG4+/f061zyXrSR7ijoiMQ4Iz1PPNafj7Tb9dd1qRZADESy5JJYHnA/CvL9IvNQvNS+zRx3MzyyAJHGGZgfoKYj6d+H2o2sEf8AZcWQQdwyMdRxXc15J8N/DOsafPFqev25tyAMIW3Mo6816xDLHMgeF1dD0ZTkUmMfTXRZEKSKGRhgqwyCKdRSAKp6vcC10y5mYgbUOM+vQVad1jQvIyqgGSWOAK4HWtcg8QeILTRrPEtosubhicBsdADQB2mjRGHSrSNuojXPGO1XKAAAABgDiigArn/iBpCa94H13S5F3C5s5UA99pI/UCugrO8QXkdlpNxJL/EpRV/vEigD8xGA2DIPA5HQ8VARg4NdD4z0xdI8T6lYROjrFKdu08KDyB+GcVz7daAG0UUUAFFFFABRRRQAVPZXU1ldxXNs5jmiYMrDsagooA+mtMt4vFPw+0+8s/km2MWwR1HUfgcj8Peuc8zYgWcDKck9SD069RT/ANl/VJL261Lw2w3sEN/bj+9tIWROvcEEAejetdd8U/Cj+H9RivIcNZXwLxkrwrf3T70xHGTRZkV8DawBHcn1oe3R027M7/XsPaiF9kasx3bs89hx2pxcvJycqR0x1oGeb+M9MNmrsrgxFgQPf+n/AOuuQr1bx5CH0G6YAKFCnAHfcM15TSAKKKKACiiigD6t/ZSvzY/DvUrqXaLez1SWRdw+9I8MSgfp+tej/F/UpYfBVrZmUtc3sizS5XHvt44//VXj/wCzT4tttG8E3elXdqJ47jVHkJY/KP3UQ/D7vWuj+I/iODWfIW2aQ+U5dmzxnpjFMRxZThtobB+9n6cGrFhaNO6sI92wc54JX1pkMbzPjOT0Yg4B59PyrpdFsJtqgFWAGCQfu+uaYDtE0RJpfNZT5QIw4Xgn6f1r6I8J2bWOkW0LwxqVAOUGOorzTwzp5ecDGXG390CctzjINex26GOJVIXIAHyjj2pMDgPiNphnW5Q4eOeMhkZMqRjkelfFvxB8HNoMv26zSQ6XOcAMpBhYk/KfQemf51+hWp2SXtuyOob5SNrdD9a8g8b+DIZIJkZEktXOyaIglcH09frRuB8QMv50sYkkUxIGYDL7QO+Ov+enNdv8R/Ad54Rv9yo8ulyNiKbb9w9kb3x3riSMHgn04PXikMi6YOcjqK0LeD7Tpc7Rr+8tD5jnHVDgfmD/ADqnjceOT9OldD4ICTapPYvKsX221kiUtyN23IX8QMCgDngOcDqOnqa7D4XapeaX4vtXsWIMoKuMnBCjcDjvgrXJPG0ZaNwQyHGDwciuv+GOmXV94202KAIGYSOd393YR0HU+1AH0v8ADnWz8Q7nxbf3sCxrE6qET5uQowR7etereBdB0+w0+G9isYob2VCHkC8kZ7egr5t/Z516PRrLxaZpG8l59uXUKeABz6V9G/C3V49X8Lo8bhjFKyEFsnGcgn8/0piOvPIwawL7Rbm3M9z4euhaXTneYZRugkb3Xqv1Fb/fr+FFIZ5/H4y12wsLn/hItCW1u4kLq8b5hfBxwef51Si+JsU2mxzuYYJpCcRfeOBXaeLtSsNL0G6l1Ta0LqUEZGd5I4AFfKsHhzU4LrzZElkilBlXIJOM5FMR6Pr/AIh1XVxK9vc3BjkQnGPlUZ5H8q6L4Y26W1yzXUTySTY+ZwGCgenpWD4fsjJDbeZ+7IQu3HrxmussClnCpHLfd87oMZpgeiwksVkiYmJs5Ddvcf4H9MYM9cVB4qiXjcBGr8c5wvvWVrXxOtdOjC/K0pVsYH5GlYZ6LdXEVrbyT3DrHFGNzMegFeXeNvFEd8yPaqzW0ROxscP6muW1Px3ea5bOhkxFnnjg57Vzt5rcNvFMZE+UKQU6ADnpQkI+b/HV2l/4v1i5jXCPORg+wwf5Vzp61a1GZbm8uZ0BCSzNIM9gSSBVUjBwaQxKKKKACiiigAooooAKKKKAOi+HviWbwf410fX4AxNjcB3Verxn5XUfVCw/Gv0B8YeFbTxV4KudPtpuZB9psZwc+Wx+ZSP9k5x9DX5uV95/su+Kl8Q/CewiuJU+1aOTp8o6YRceWTn/AGSo/A0AfPKo8YmhkASRGaP5+drg4IP0IqlcXk0cxQK7HHA3Y3EfhXtvx38JQ22vpqFrGsUV6DLKRxmQH5/zyp+pNeS3UcZdWHz5yN3UGmBzviicyeFbvzkxKVUkDkD5h3/L/PFeXV6t4zkQ+HrpCCHCDkjj7wxXlNIAooooAKKKKAPXfhQGj8JTzKD/AMfzBSD0IjT/ABFdI7LMGA4cHO3+8awPhuf+Le2wRmBOrXRc44AENtj+Zrd2kxqFfaM8HPT6UxG7oNm808RUMXYk8nAYDsM13+h2a7RcRjhlK4Xkg+pFcdoHmCOMMA8IIwRwVPtzXrvhfRpNRg2rmExr8rNyGB9xTAv+F7CUWVvd7QoDsflbn/61d3HIJEVxjawyKxtNtZILJ4pSuFkA6cHt26+9aCxPEY8bQijGBwoqRlzHOe9Z1/aCYNwSQuBwCvX/AD9KuRzwyO0ccqM46qG5FUNQ1GTTmLz27SWpPDxDJQd9woA5PXfCWnapplxpmrQfaLW8yrRydUb1B9f8K+PPi98ML/4e6mA8n2rTJnP2afGGx2Vh/eHrX2ufG/hsa3Npct9FFcJGJsudqsPb3Feb/GPStJ8Ui3ura+Esccio653IdwwDj/PWmI+LFQswRcEsQB7+ldf4I8E6l4i1yOwhL2kzAvBMRhS4GQB7ngD6Ve8b+EbrwX4kKXiebDxIsqjKEH19D9a6rwFrV7HepKrojW77kXrx6fhSGeWalpN7Y61dadfxSLqEMhWRHB3MwP65r2b9mbw/Jb6zqviy6gkQ6DbTP5cikb2MZ4wefxq38fPBhv8AT4PH+jQTRieFHvU3buR/y0X0966P4FaxJ4g+FPjLTrbTZ59YisZ42lgkI+1sYz5eOwbntQB5j8E47vU5vEYZDMt3GryIO8jMzAgfiK7qw8PfFDQnS+8KwzgBwcx7WV1z91kP3h7cY61u/srWVrbfC7U9VjFvcXUmp7JWJw0MaIgUHn8cejV9G6e8clnG8IIRhkZpgcx4D1/XtR0Vn8VaOthqUCDzUgYkOcZyqnkfTJrbe8vplh8m28gyd5edv1xWqQD1AopAc5rWgLq5gF0Q/kucs3O7PcDoKdfaEiWZFv8A6xU2glQRXQ1UvpVhiY78E++Pw9qAOGmsUtFvHaNTLjaGC4HTp9K5a+1IW0SRhVM6qGVSDtQd+K7HxTe+bbTFCIiqBmGep9Oa8e1W9mWZ2SJmRlA3EZOapCKereIJRcXITIV/4D2+lc7dGSWTcWJk25z1q3qNpJvWSTJLD5unP+c1Av7uGQbTn16dKAKq3MluDGHxwSx7H8K5PxxrbWmkPCru090Cgw3Qdz7Vf1fUorGF7meQBRwAo5Y+3vXmWu6pLq1608mFQcRx5+6OvPvSGZTZ6DPH4VHTzngg9+9NpAJRRRQAUUUUAFFFFABRRRQAV71+x/4nGm+P7nw/dSf6FrUBVUY/L50YLKfqV3jt29q8Fq9oWqXWiazY6pp8hjvLOZJ4m9GUgj8OOlAH6F/GPSBqfw/vS2WuLQLKrgc8EBj9NpJx7CvlJ2aJ5IGBBXGMmvtDRdS0/wAW+FbS/tWEun6paiQDIzsdeVOOhGSCOxBFfInivTH0nxHNbSuWMUjwn0yDimBx3jSRn8PXO5NwO35sf7Qry+vTPF0CweH7oLkL8pHofmFeZ0gCiiigAooooA9T+Gj7vCzR7iCt5KeTwcpD/h1rrVX96qIvJ5Iboa434ZqH8PTDJU/am5/4An+FdcjiNFZizEHkZHSmI7TwdAz34kH3EUc9Qf8APNezeGIpH24Zokb5B5ZIyBXlPgaQQrHMxbIfpvxvGD1/Ova/C8Mbr5wwGKhhhhtB+nrTYHSRoIoVRRgD0psgDBkdhtI/EVIfmHoe47U4gEYNSM8w1nwjq0njJtdtNTgigiUOPmOeOuR0NdBqXi6x03SrOa9IuYZ5fJlkUbQnuQa6OR7e2eRjCd4QZIX7wz6965HxPeaVfBra8tlMezeVKj5sHqD0NMR4X8XtX8MN4wW5WyafauwyWzYIHXn34rEbxN4cvAF0G6vltmQRvBdcNv65FdZ4o8E3mpLqGqaJZPLAw+RQQSB349a+d9QtbjS9Xt4LizuIL/cr/ZpUIYktgBQOvIwMfWgD6Y1600qDQ/Dmt6rZXOq6fqEgsLoMP9Vu43H3rE8feAF8HONW0r/SNFzt2gYeEEdD7Y/lXlEPjbxBp1wNIvpLsQWl15xsJlZPLfsCp6V9c+BNW0v4k+BpJgFLSgw3VsXDiNwMZx6Hg5oA8E8JfHKLRdOfStU05r7RwSnlYBAToc1f8I6jf/DnxCmseFUGo+E9SUyzWMfygIeQYzj7ynPXjBI46jE8b/CCSw1GQaW/ymYqY2PKjPBA7ivVfhJZ23hSxt7JLmO8nhQqr3A5Q9do9B/hQB5b+z3qAk+Juo6Rphmh0fWGluEsyfkUIxZQw9QGAyPT6Z+vNJgW3h8vd846oGyF9q+bfEfh7W/hx8TE8e+HdBN/o11KfOhtQCIllIEg2ryvOCGGRxyOa9tvp9Vjkm1F7ORLWVEfNvLvKrt6MuM5+gIoGdpSMQoyTge9eOyeObaS5ZvtE0TCMx4fgDnqPTFZWqePJfs/lxztMS27hienY+1FhXPWtc8R2mmQMzyLk4C56V57rPjVjcMlrIrqz7cM2QOOtedazrN3dBjJ54Q9AWOKy5rmXaSo6jJYck07Ad9c6tLqDtHdv5jHHI6DBxx61Zl0ldUSWN7iKGVF+UoOfbI71x1pf+ZcLEFIjwpYq2O3Wu50h3MLNIsCK8YHzk5GKAOP1rQZLVlU7nwOW5GB3zXIeIQ1ngOXwAT8vNe36xot3rKxJaZeSXlHLHB47/qefT1xXNTfCjX7mR5Ll4jn1fP5DNAHy/45E7zwM6N9nILL8pwD/nNcpIpwR3PqfrX2bonwjvru8VNTSOO0Xhi6g5HsO9YPx0+CXhfQ/CN54h0O2uoLq1jy9vHIfKlJ/jK9j7Lgc0hnyZ5bO6pGjMzkKqgZJJ6Y9abPE8ErRzRvHIpwUcYIPuK6HwT4p1HwR4ntNd0kQG8tsgJcR70YMMEEcEcHqCD71R8Wa9e+J/Eeoa1qro19eymWXy12qOwAHoAAPw6mkBkgE9B0GavX1lFDbwywXAkDxqzKw2kMeoHqBVW3me3njmjOHRgw/CpNRvJb+8luZsb3OcKMAewFAFaiiigAooooAKKKKACiiigD6y/Yy8Zh9K1bwpdysz2r/brVWYn90xCyKM9ArbWwOu9jWl+0FpRTxBd3UQSLfCkoyPvHoT+lfM3ws16Xw34/0XUYnKqs4ilw20GN/kYH2w2fwr6l+KOoQaxbaXPbksXtzGSRnoelNAeAeKrhLjwjcMzO7hUzxgE7h/KvLq77xcfs1heQFwAzAIoHvzXA0gCiiigAooooA9N+Gf8AyL1yc5xcMSM/7C//AF66jMaxleAWwV3DjH19a5X4ZkLoNwdpyblhuHUfKvGK6ln/AHOwPjafx/GmB3nhdh5SDftUAMoIycmvoDwoqnRYCUQBh8yo2dx9a+WdGvHSQMmUxjLZx+le/wDwhvDdaaw84SsDkDdxn+lAj0VdzLtbHHHHYUOxKjYNy4GT7UYDEYJ+U9AcfypsmVljRCQCTxjg/U0hjZ4VnR43JZXABUccVVbRLOSILJEGI+4xHK1chVg/7wBcEhQTyR/UU26vFt5I1KkhjjI7GgDz7x9Pqfg3QbzV/DVoZZInUyQMuV29CQor5m8R/GbXdZuo5LrS9HRreUtHJFGBKpB/vY9f5V9qzN9ss5tgEbnKDeflJ9DjqK+Lfir4QSPxTra2ds2n6pbhrmbT/LbyrlCQTJbt0752/WmBx3iHXtc8YavNr2pWcVzdDaktxbQFQSBgAgdSBzmvVP2YbTWpfiGtyFksbAQv5yfcE/AwNvfB71wPhG7udN0qwdIWn02/kdmZSww4PQkcA+1e3fCrQr3XtZtL2wNxY2drMZJbgufM6fdXtg9PpQB6f8UZfDul6dBqOtXIsC1wsXnouWyTzx+PWtLQfCuloovHgjlVgDG+cq6kZDfjU3jnwVpfjPQLvSdWEqxzEOksTbZIXHRlP9OhrwGUePvgZpD3cptNUsD/AKJE0s0kkAJOUO3cDGeOnTkgdjQB7tol6LzV57bRFZtOtpmivPM4Xdt6KDzV+HRpbe6iuNF1WWK2DHzLWT99CwzyFycoc+h/CvjLxH8XPGWvpqEUuppZ2+oMpnj0+HyC6rwE37iwB6HnJHBOOD3X7Keha0PEs2uWJntPC9vHJDcBJD5d5NtwFCH72zOd+OoxnrSA9w+JPg59V36laG2WZIwjRlNpk57t6815FJod5o9/LDqggsWUbpGdsDH1r2vxH4cF/aLfQSXRSGIyrDDIzSSnr3OD7CvlX4z+ONL8T2en6bb2k8N/DM0l7NM+TJjhItvXOcZHbHencR0us+M/CDkWx8R75AgQSR2rvGjegYDB+tanhrT49WsP+JZqCTMY2ZHKcOPY15Z4d+Hmp3Y06bVbK/tbS8mWFEht98mCOrKPu8euO30r6Ml+Fs+jRQxeHL42dmEGWuQNyt36DgUAcGlq1pf+TPhZMBSFHUd+a9b8HaTpOq23lecHngjDYjHJBFctJ4c1fUpbi5u7zSYha7R8kg/e+/I4qz4WsobbUt80oguWk2oyOccdOnamB614dtorfTo1jVgRlcsOeK1Kx7PU0+zh2mWXn5jjAXA55q1/atotolxJPGqMB0OcZ+lSMvVW1KK2msLhL9Ee1KEyBxkbRyc01NRtJIZJYp0lSMZcxndt+uOlfP8A8SPj74blvRo1jeX5sC5hvZ7SEFivQhSSB69KAPlHxNdQX3iHU7myBS1kuHMQHTZk4Pt/9esZh37V6Te+F/AV4Q3hzx48Jkl2JZavpzxvGvqZlzGecnnbXNeKPBmu+GtQa01bTplcHKvFiRJF7MrLkEEc596AOZop5QBsBufQjHNNoASiiigAooooAKKKKACiiigAr6dha41Lwxo18S5tiok+U9AR39K+Yq+9/AfheGTwjoNmkZNne6FbOZGXGxzGD0Pf8qaA+TPiTZRoJZkY/fyMtnOT+v8A+qvO69x+NelTWVlcw3SlJIGCEbMchsDP4c14dSYBRRRQAUUUUAek/Dct/YE65O03LdF77U711jqdrDhiDkqn9TXNfDlDF4Ve4fKxPdypvz1KpESP/Hh+ldIdigBG2Z4AOct9TTAmsZTDcJ5gj3EbtpFe2fCy5giu90SEeauCB0U+prw7B2YdFZA38P8AOtvw5r1zo0nmKzJHuyyZ+97UCPrjas0bRsQc4J2dPUCpsHbtX5e3vXAeCPG9pqdlAsyrAFU7jtOF9zXeQsrruQhsjcDn+YpDHx4IxsIyeSPWmpEPM4XI5Jc4JPt/n0qUMXHBG0jgg0hdExgdfQUAKEjSMoFUJ6Y4rn/FOgWWqQxXYtVnu7EM8Crj5uOV/Gt2T7o3HOTgFeP50hJaJTGQAeQScZoA8/8AEFzoGnfCTUprvSBbWMFu8k1isXzRvn7xHrnnNcv+z/8AEPRJ/DMunahfWtneW778SuEDoQOhPXFev38dpNbzLeQRsLiMwsJAMOpHQn0rw/XP2e9Iu7aaTQLgWDsN0cLnzYVbr1x0/wA9aYHukGqWNzEslrdQ3CMwUGFw+SfpXiHx48C+PfFk5+x6lb3WjNKq2+mRKYwjdA8rHO7nPPAGeleTfDPTb3wH8adM0fxLNNogndwzK58i4PG0gj5SCRjPGOhr6/8AE6TPodwtpNJDP8hSSMbmUhwc470gPmCD4BLosNveeOvFMFhbuAGt9MhLSs3GVWR84+oWvfPC2n2N34atdO8Kzpp/hy2h8iKK3wXJzzuPUE8k55JJJ61h+LNIh8V6mL+O/niewXyWWRdsYJ6kCtDwL4Q0vSdOuJrR50u58meeGVgr/UdP60xHblJVsGhsmjUhNkTjkLjj9K5fT/AOg6ZfNqH9mW82p7d3210BkLZ5PNdG89rp2nfaLm5WG2jAbLDb2/MmvC/HHxUvtRnuLXQ2+z6cQU5XEjEfxZ9KBnqXiHxZ4f8ADs0z3lw6TO4LLGAS5x1GK8Y8Z/EbVdaunSymni05H+RF4cj3IrjJp5Ljb5szSO4yWYlj170+MN5asCWOcfJ0/GgRck1O8kjmhlJWGQKCoY5Peu18L61BcoizMIb2NgoJPyMvqfeuD+UyxsVUA9QM8496YJfKmeQ+YpUEjHY0wPWdQ8dad4PuPM8TWt5Ho8zeTJPApdAx6MQOcfT179K9J0qw0i9s4JNJ1F5rW8i8+JopQyyIcfMDjpzXz02tJreiSaTrMSTW86hZMDg+hz2YHvXefC5T4RGnpB+68NLFJEVA3MkhYHceMkE56UgN3xVFJ4H03UJphNJ4cvB5V5cw8y2qN8pkYegBPI/GvinxvoDeGdblsI7mO+scb7K/i/1VzCeVcdexGRng5r7x+LV3Dd/DfXbC1ubf7XqNhLBbo7ffLIR069D+FfC+hawLzQG8MzW6OJ51lsZ3OTbykYKc5+Vj6Ywc+tAzk2II+Y8e/wDn9a9i/ZtV/EXxC0/QtRle50uOGSZYpDnZtGcD0B9K474faxe+BfiRpV9PBDDPb3AhlW8gLqqMdrMBweASQQc/XoftD4a6N4T03xFqTWFrpI8SsGllurNABPDIwYMgHAXlQQO9IDr9V8I+H9W0c6VqWjWNxp+MCF4Rge4PUH3HNfnt8W/D9r4W+I2v6Np4ZbO0uNsKs+4hCAwGe/Br9F9c1S00XSLvUdQnit7W2jaR5JXCqAB6mvzI1zU7rWtWu9T1CQy3l5K88rkk5ZiSevagChRRRQAUUUUAFFFFABRRRQAtfpD8OJUvvBHgy+QtGJNKg/djp/qV4/DFfm8OTiv0W+ChS8+EvgucghodPiVSePursP8AKgDxz9rLSxGl7coSomgjlYZ6kOF/wr5Lr7Q/aziB0R3zjNkwPA7SKe9fF9ABRRRQAUUUUAe3/DvT5JPg5DqMaApDr9zBI3f57e3IH0+Rvzq0HMcexXAHViR/I11HwK08ah+zZ4oUrueHWHmj5xhlit/6E1zDDMW0AIFPUjaPwBpgKMux8liXPpjinW6ylDkuxDcMTjH+fWo0LhY9wQ7TkgjH/wCumwyyF3EkPlqx6gnkUAa2m6jPZktbyyhicH2r0Hwz8UX0y0FvPElxbqdxOSGL/WvMFEpICM6Aj5V6hvr7VPCZS2PkPHRBj8aBHt2n/GG0M7/brd/LGNjQ4P516B4e8UaV4hgL6ddq7A4ZWGCPw/rXygF2biVJYcrgj8vatXwzr95ol/8AabGaMuVIZJB8p96APrYAdNw2ntimqpWRy2DngH29K8i8DfFZJZPs/iR0QSHEcyAkfQ46Cu+PjDRGKbNRiCNyTtJA9qQzoGVDjcoJPAIpyoo6AcdPauPufHmiwyrHJeJIzH5TEchh6j3rRg8X6HIMC/iibI3rL8pGfWgCTX/DOma4yf2paRTogwjFRuj9wTyD9Knkns9F0lJw889vCBGCh8xj2A96zJvEnhuad45tRTBOTljtNXLvxDoOl2KG4vrVLf8AhAO7P4DnNACQ6K8l9HeS3TeWTv8As5iABz/e96g8T+I7HwrYeddyxq7k+VAijMh7fT61xfiT4rWsFpcQ6AjyzMcLNMCoQ/Q9f0rxfWNQu9RuxdX80k07sQWcnb74FMRseL/Fup+J755LmQwxrwsKyZQD2FciVl3sMuSP0HtVgKoGVwMdiOTTUMqTMrq54yFYdaAGHCRqGJfPzFT2z6GrMOPlXBGV4Ge1RYDox8oDttHGDSphQhLEMD096ALJbEIbaoRG5Cnn6kVFI7Mx2uPmOeV70uAwLqAzkjDJ/WmqxhEgDttJ+8Ezt+nvQAmShBw4IIO3pW74a12fSS5GZ1cA+Xu4HPUViR5YoUMrMwP3hVpYztVigA3YB6UAeltrema9NDcCDyr9YmUqeufc+lfIN/Kun+L7iZlJS21BpNidwsmcCvobToZA6yRMP3OSFAySTXjfxK0K4i1e41S3icwTnfLgfcfufpQwKPjnxrqfim6nS9ujNZCbzYFZcFBjG0H05rrfgr48h8K22sSXU23Uba2L6Yz9CSfnQn9R+NeSsSFJxlSOtNVWZSAucDJwM8eppDOk8Z+NNc8U3Uh1bWL+9thIXjhuJ2ZUz6KeBXME560E560lABRRRQAUUUUAFFFFABRRRQAqnDA+hr9Av2fr1JvhD4OimULL5LIq5yflLYPHqMH8a/Pyv0G/Z6iP/Cq/DCPCYzb2nykjr5hLZ5Hv2oA4D9quYSWd6iuP3NgoYY6FpCcfjxXxxX1V8f70ahZeJ7lXUq2EQZ5whAr5VpgFFFFIAooooA+sv2amhb9nvxfHO6qP7QnxuOMkwQ4H4kVxEqsyHc2znAJBb6gc1Q+Dz3L+ANRgiDND9udyM/KD5cfPXnoKvPLtOPk6YOaYiFSpAAk3YOSxJH5U8O4bap+Ur0bIBpN6+WRsTjptIIBoB3/MGiDHouc80DJY8+WMIELDHXqKsRljjMrhQOinp/jUALYBn+UE4wfX29KazqAQxYHswGAPyoEPd/mIUBFI446Ee9OVRJu/ddffpx1qNPNKgLKPLBwd2GyPSj/lsvACgEkAkY5oAlhlQoAqAkcZ71chnzM3zyOc5+Y8VSjlO8eXsG7gjPGfepo1IjlZgFznjPDd6ALa3LquCyYXPOPu59BVqC8WNMONxJyxPIP+cVjsUBIV3HccdamWYOyhHcEY+6M8etAGjcahlQ8e0A9cd6cs0y2cjTBZkfnjjAqg8rsckLhflJCEZq/ZFplcDPHAJX7o+lMCt5rJGTsVQRjGDke9VppJJE+Q8DrnsPatS9ttu+ZzhCoAIOBnvms1lKh9yIxx1GSV/CgCvnKJy2GYkfNnH/1qfIXDFQQjqM5DE5p0qKBHkbipIx0qzDbSTRMqI6xk5ORnJ7dKQGaQxIDq5bOckcE1PCEnJSFQQp7r0NdS/gHxFFB502nXUdsF3MQpYrgZ6dam8IeF5b/WI7a9s7qCAgukrKU3H8eooA5KJH2cKxYty2Mc9vwp4S6CsPLLIxII4r2fxH8N9Kg02aSztL2J4ojLJM0gwxA/ya8lsbeKK/jjaUyKzFgA/X3oAsaLpU1+YWKbIeRlx8oOK9I8OfD201O3kUI6mMht7H5XJ9KoeHfCep+J9nkJHZ6Uj8yhuH9cDvXuOmWMWnWUVtBnZGoXJ6nFAHl914J1TSPOu7RbSaLy9hjClmUevTJryzXNFlSSYz4cy5LDGRj05r6trzH4w6HbLp7auJTCxZY5F/hYnoeO9FwPjXX/AAVcm7mfR0WRMFzAThlx/d7Y9qh8NeJIl1OaDxJbG8sprWSBliURSx/KcYwB3HSvTr5BBevHJlQvZeR7c1XtLDRrydRq2lQ3C85ctslHfhgOxoA8Gm2ea/k7vL3Hbv647Z96ZXp2t/DeG5vJT4c1a2dnfKWd43lSgezHhq4LVtF1PR5mi1OxuLZ1OD5iEA/Q9D+FIZnUUUUAFFFFABRRRQAUUUUAdJ8OfDcvi/xxo2gwjJvbhUc/3Yx80jfgisfwr9H7iGDTNFuRbjyreGA7UUDCKq9h+FfK/wCxX4Re41nV/Ftwi/Z7VDYW2VBzK21nYHOQVXaOnIkPoa+mfH98th4P1OVsktEYlAIBLNwBz9aAPk74kPjwbqKYyTGGbOB1YEe9fPle+/EuUf8ACN6qgCgiFM4yCPmUd68CpsAooopAFFFFAH1v+yFYW8ngW7ubhA6yatLasCM4BhhI/PkfifrWT8UfDDeEfFM9nH5j2V2DcWkpTIVc/Mh65IP6c1r/ALFeox3HhbxHokj7XW6W7jwcHlFUkfQon5ivWfjh4Wl8SeCpZbAO2qaa32q3CHBkA/1kf/Alz+IFMD5kAREUjaM9QRnP+H/16VQG9FI64Hao0YzRRzowZHwVc981MMgfvkVx/eWgCdI2bcAc9wrjIpzWbqodkJDjbwvQ02ExeWUWFih+ZjzxzVxm/wBH2bpRHnd8vWgRnyId4ZoSWPylhwCfWmIzrDlSwwcZI4NXUgE3mMuyQDDBASKbNEYo5Ue3ZTnhSOAfWgCEMu4ho0dcZPl9M1Io3q2Cu0E7Bk/LVYbFClUYP0CleCadzuByhHdR0HrQBZ+cxblV9wPcbv8AIpoTupY5bhgv6mom+6zh2LdcRnk1JEUxy0m4cgEcL9aAJYWZTvjnaJs7TuPUfSpf3iuFM6qCd5Yf5/nTEA2fvSeRnIGR+FMYxRoGUStJnH3cDHpQBtpcma1MUkcM0Xb5s4HuKz5VCs7K5hz1+QjAx/KrCSBwh27MABcHGeO9OYTNHtALLkYOclqYFaJPMi86S4BjB7jlvYCvor4deDYdHs4tQv1jl1OZFbhflhGOAo9fU/l78D8Pvhv/AG3bRahqcjQWkcn7uJR80uDyfYV7sihFCqMKBgD0FIBao63p66ppk9o7tGXHyyL1RuxFXJX8tCxVm9lGTTqQzw/x63jbR7dLWO9kltJlMTcbgw+vXmvNPCVhLcazHDPHIr79gVU5JJ/WvreeGOeNo5o1dCMEMM14x4v8IHQtZjurS4dbZiZISc5RxzjNMR7Hp1oljYQWsQUJEgUBRgflViqGg341LSLW6DBmdBvx2buPzq/SGFYHjyFbjwfqsTq5DQnGwcgjkH88Vv1zPxCv7az8N3KXEirLIpEak4yaAPlDVJ5Gn3GJckYY/dJ98etURJOJFeKIksQPmYD8a275Yp5XdSrLns2TULxWq20oEZeUqVVgw9OKYjzjXPGaRapOttZxTCM7A7NwcdenUZ96lm+Js134dn0jUNIt7iKQEBhKy7OOoHPP41wV5bS2dxJb3CFJo22spqCkMKKKKACiiloASipYYJZ5lhijZpWO0KBzmuk07wnK7H+0ZVt8j5UDAsxoA5qCGS4lWKBGkkboqjJNb2keGJ71wsrFHLBBGi7nyeB+prstI0q305cW0GH/AL7sMn6n8a6/wJaed4z0JZZFVFvEklVR/CDnrQB9UfDDwpB4K8C6TocHLW8WZn2gF5W+Zyce5I+gFch8eNdS2t9M0dFdpJn+0ybeyrkD8yT+Vek2+oxzvNIrotpEuWkbge5z0wAK+a/F/iaTxL4jvr+GRFtiwitwyn/VL0PPTPWmgOI8dW8lx4Q1N/JCKYw3PUhTnn/PevBa+ptS0gTfCTxxrEq829ssEGfVnXe35cfjXyzQwCiiikAUUUUAev8A7PviEeFddtNWaUxwLdeRdYBIaFwobPbg4bP+z6V95o6yIrxsGRgCGU5BHqK/Pj4cWyXHhi8VsENcOrAjO5diZGPxr6l/Z08XLe6CfDGo3sk+p6YP3DzD5pbbPyYP8RT7p78CgDhvi74Qi8MeJt9ha/8AEsvi08KqMLHISS6fmd3/AAKuGt1U8KvluGJyrDH5V9aePvDsPibw1cWTwpJcJ+9ti3G2UA457Z5H418r3ULW8zxXlqYp4yUdD1z70xEUsvyBWVjHwSwUDP5UhEM7hkEiMp4Leh9RTkaPCGLbkcbR0+hqxGWwyyIVibkMx/SgC0Ft5baNSpBGc7fX1qtej7Q+8uFVQMKTk8dhVssMKmzcOmVbANDRo6AxMXUDJ45FMDGnWZJQ0zKu4/LtGeKYqz7ceWOT2A5BxWlcQRT4lEbnsar2tuqhipYndhQRkfWkBWeLKquJB82B8oA/PtQ6Mnyl1Iz/ABDoKty2mFdQvmKp5YE/ypkcUOQ33RnbuAJH40AIqvtCqYeDyS+ePWleRyuQo2joY2PX8atLtDNhVO4c7Vzk+tI4jfgxW5GOVOVb/wCvQA61b922WAcHIzzmr1vD5s6oBJsb7xB/Uc1USBh5Z8jgjjD8/jV/SldLhvLt/kC5IY9OaYH0p4JjMXhiwjMYTbGBwc7vfNat5dJaxlnyT1Cr1NUvDEbReHrBH258lc4XA5HpVgqk15JG8SMAvLbs/h7VIxlreS3Uyj7M8cJUsHLde2KtyyrEpaQ4A74p6qEUKoAUDAA7UydGkjwpAOc89DQAQTCZdyhh6hhgisrxdosGu6FdWkw+coTE46o2OCK0LWCSBcFg+4ksTxj6VZoA+dfCfjG78MRMwnWdFk8ua2kOC2OM+xr1uw+IWgXVssrXQiJUMQSDj2rwXxw9s/ijUZBCxxISUZdpXn0rm7gqTzbjBXIZT0+opiPf9c+LVhaOy2Fus6Y+V5JNmT/u46fjXjni/wAaXmv3bzzEgvyPLBKqP7oH0rlrgsyLmXaB91StV2ZflbdgjHTPNAyaKWGWZk2yqG5B2Ff6U5yzhAPXHPU00TlB8ssjbuuVzio2l8xQHdJCfmxsx9CTQBk69o1jqqBr7IkXgSIcOo9Cccj61wWpeGLqCQi0YXMRPy44P4/y/wA8enMy+Xlcc+vHPpUccceGQiNTwWHXnsf8/wBKAPNLXwpqU6F5BHAucDzGOT78A8Vt6Z4Lt/J869u/M9Ej4H4n0+ldqhwBhiJB3AyDUDPukAUfL3+Xv9aAOe/4RHTSHYrwuOFZh/MmrVnoVjarutYTHIcjeTubHTj0rS4Qn5GyBnBHJFQ/akx+8jkXA3HIwR9QP88UANgs4YHLrG0eDweg9+PT2qVVt1zuSMbud2OPxqMfZ7iRTDNI2MZ46j0IqzEpj3NA6Ko4+YfLQAwKiRNKzswA+6c7nPAAVe5OQAO+fU19AfD/AOGUujafZX2rkR6xdSKyQKcfZ164J6lgOvas34C+CItX8rxTrUCzWdu+7TklQFXkX/luPUKeFPrlh2Ne5W4El1LfS5EaphN642Dvj/GgDx749+N5NE0x/DWmt89xETdz55CHjYo9T3rxvw/K0j5+chF9SB/9aoviJrk3i/xfe36tI9rLcHy327QsKHag+hAzn/GtLw5ZjYsMMk5mmZYlCLkcnGKBHr/xL0yPSf2aNbhClWks0mkz/feRD/hXwrX3p+0vIdL+BWpWUBYl1gtgQMkqrqT+imvgukMKKKKACiiigD1/4SXYHhae12HcLyR947Bo4xj/AMdrrrW6u9I1Oy1bSRIt9aMZI3zgsP4lYcZUjgjvXlPw5vjH9ptUmWKXcJV3HG4dCPr0/P2r0WDUGaPY7fPnk5piPrPwV4w0/wAWaDHqNkHjdflubZuZLd+6nHX1B7j8RXjvxh01JPFt1c6aUaR0UuqfeJxz14J71wfhzXdS8I6/DrGkmN+Ns8Jb5ZoyeVOO/cHtj3rsNVubLxD4nj1DR98azxj/AEeX7yueo/PvQgOC23Bw2VLDqOOKkgtQFBlAKOeu/vW7qujPDI2+GSAqcPGy/wAXtWUbcFydxJzuXCjI/CgCe2aCGFQQuUJHzZOPf61cRklR1YMFUckcCsXzAG2PIxUN8xxjdzV+1fyzmJ2QleCRwcUwJmRgqsu4gDHD5NVnCIkh8tlPZmcjB9CBU1sZZJVJiLxnjceP/wBdWhP5czqqoWzwvXd9c0AZM8KsB5LK+5edj7sVY02N2KBvMc9dnHHarhWVt+HSM57qMVIs0lvCuyZGYMcrtzkUARSFbWNopAI1PdjyKQTySmNXijkAG3eMEn0qxJcykOqtGm4ZA2Bjn1qpGN8QLscnglQFwfagBZcjplZGbOOePr2pEcG1une4wdwUFSR+tPfZCyguAW+433gT9K19G8JXXiGaG2t9zk5eZgf3aDsxoA94+HuoLqPg3TpVk8544xE5DZO5eME/TFaemJOLm6ecAbmAA3A9O+AOKw/CWiW3hzQ7a1ssvauTJJNHkHcfUen+Fb1u8NnbByrL5rZbALc1Iy/RVSK9WcyCJJMKOGIwD9M1NI0n2fcoAkxnHX6igCViFBJ6Co4WDx7xvw3OGHP5VnHUJJpzbGzniEikLI44PrxVlYporPyUndpnziSTBK++PagD5o+IO2fXZ7n7Z5ryMQ3y4Oc1x7ssbEb0Ddt5YHP4V7F41+GzKtzcaLd/apLc+ZNAyjzBnkkGvH5MSFo8lXU4+YUxFJ3+5sOR3yf1qMNgMBEADk7ww49+f8/hU3ltGrK5BAP8OMVHIAXy7q4I4BoGNjZ1QFs7D338fpSF0RQSY1weQ3UemKSKMfMFDKScH5un4U4xuADJIFYcAlMj6n1oAjcpIWAMbA87s0wDlT5cXpljgcfT8KkcIc5IYHuBioiqiUr5ZzyQTyPy/rQBM6puwIwynsSeKi3HBXzDGD/CF/WhBJygjk+U5BU8EegpHBQgyLMT/CGb7v0oAVHUgbJS5x97aDmonDFCRIrD0IIJ/H/61OC7SfLjkODvCg9fWpGQuB5qhiPunoaAKny7vukAgcKOv0IruvhT8Ph481eWPUbeaPQbIg3cm7aZ36iFT16csR24zk1jeENA1LxT4itdJsAYfOJMlzx+5QfebB746D6V9b6PY6f4a0i30rSYfLgtkCjjv6se7HqaANS3ghtraO0tYVht4kEaRxqFVFAwFAHQY7CuA+NXiCTTPDY0nTrn7PqGpAxCTaSY4v42BHQ44H1rttW1O30XSpr7UpFjhiXc2O59BnqSa8qPhnXPH16+r3Mp0y1mwIXf52EfYInGB7nqeaQHiNvZR+c1taxoYoht+Zjnj+leufBLwlcX2pLr17GyadakraI6bRPJ0Mg/2V7HufpXe6Z8OPCmhaeZL63W78oeZNc377gcDkkcKB7YxXlvxE+L090zad4WV7SwhBVrhGEbFRxn/ZX26/SmI539qvxkt9Bd6XDLG1rC6wRbSctLkGQntgAba+Wa2/FmuS65qjTOx8iPKRLk4xn731PX8vSsSkMKKKKACiiigBQSCCOCK9D8I67/AGxIun3xSO9K4hnzgOw7HPf+f8/O6UEggjgigD3OOK7txHHPGSv3SwAGPfJq1ZXdzpeoLcWbMkqHOHIIOO4rznQPiDqUDWtnqTxXFiCEdpEy4Xpnd6ivRroWjW63FrMlzaSD928R3DHvTA+mPDGo6T8TPCMclzFtuogEmU4EkEmOCPY9fSvLvHHg/U/Dd200gjeyd8JcxocH0DD+E/5zXB+BvGdz4P8AEiahZyebaHCXEGeJoyeQv+0Oo96+udJ1HTfEuhwX1hJDfabeR7lbAZXU9iD+RBoA+TTHJI2VjbZkg9ufpUMomjRsLIhDdDyMfSvcfFPwhiuLg3Xh29a1PJNtMSyf8BbqPoc15brfh7VtAJGrafdrzt83ZuX2w4yKBGEk8+6ICZkKnKqW2gCrRfzCPNmfduOSozj/AIFTJQ2YxHFG7bs5PNRPMEY73SPc3QJkD2/z60wLjJhl2sjICTln4PtikljAXYZk3N8x2jOMj17VQd2l2q0rZDcAJ1qxEkhk8xA4VRywXBPbpQBE6ASMxljyBjEbZP0qWN0bMbeZjooKjOfarK2LyAFpjsYEg8Zq7o/hbUtVl2abDdTAHc2xQB+JPH40gItL0+S/1GKKJ94U4wOCfb3zX0X4K0keHPDcUdzDDDdud8+w/wARPAJ9h+HWuQ8FeHbHwT/xMvE91a292/y21uXDMmep9WY9OOAK63UdQttX0hpFyFXJ8tpApPoR60AbGmyES3cAX91G25HDZyG5x+FN8i9aUmMwRRHJHVmz79q5Twpp1/bakuqT6nIunum37Kw5c9Bn0xXeg5APSkM838cfES38MyHT7Ixalqg4aMnakP8AvEdT7CuOj+MWtEv9v06y+zZAItWdZAO/LEj9K5Txt58XjXW1uYURzdyHdIcMVzlSPbGKwiF2FJSrOwyAM5+tMR9U+HtUt9e0q11LTZvMhkTHz9Qe4PuK1gGAJOGbtgYry79nlZP+ESvndWWM3jBMng4RckV2fjaBrrQ5YYphbz5DRyk4wR70hmDB4na0vfnW1YNMxuAhJdecY/AV5d8ZvDq6bqw1GHEmkal+8iAXCrIRkrx0z1Ht9K1CXnkdGtf9NOA58zYM+oI61s6N4htFtbjQfF9vFLpU3ygHLCL6nrjPORyDTEeDvECmArgnoMHB/wAahOQu5ADg+hGK9U8UfC6/hRr3wrKus6SwLIEkBnj9h2f+ftXmd1bz2c7W17bS20inlZFKEH8aAGfM5cOBzg7tuMVGVTcTtLH6/wBKn8lmPyE4x69qasbrhMADB4JHXtQMrjyyCrfus9QzcGkGApVWG4DA5Jqy0Z6lEHbdTPJJBKKre2QCf880ARJ5gUjk4zk5AB+gp8iEx8KMjn5+M/SlSAA4wCc/fzmrNtaNczpHbiV5T/BCDIT+VAFNdxcFWAHfjp9RUixeY2WJYeoXA/8A1V3ugfC7xBqTI1xp8dnCRuEs/wAhI9x1rVl8A2tn5SJevfkZV1j42N7e1AhvwTf7PfXRspolll+V5JeCR6LXuCrBpsDajf3aR20CEsDhVB7n3PpXk2j3Nros0jWy29zdphcFQD9P/r1i+KdfvNQlBvd0VvFwkAk2qp9SBwaLAbV9rjeNfHGnpqibdBhmzFalTk4PVxnljwPYZHc16b4n8caH4aZLe4m827OAtrb4LKPU8gKPqfpmvmdvELw3IKNMshPEmc5/wqnd6kLmKSe+vRFaI2+R5/ug/X17D3oA6j4mePLzxQ00NxP9l0yF/wB3bRZ5x/FIc4c+nYemea8E8dayQ76XbDYoIM524YnsCf1P4e9auq/EeONLi30axBBBWO7uGy4PQMFxgY6j8PpXnDu0js7sWdjlmJySfU0DG0UUUgCiiigAooooAKKu2libiznuS4SKGREdjjjcHPAzkn5DwP0qW0sI7k2zh3SB3dZWODsCjccevy89uc0AZtbXh7xHf6E7C1cPbyH97BJyj/4H3FYtFAHquj6raa1E7adGY5oxvltXwWA7sh7gfn+lemfBf4iReCdamstXuCnhu9fLtglbSc/8tMdlb+L0PzdzXzHbXE1rOk1tK8MyHKujFWH4iu/0HxPY6nCsGuTi0vBwLnZlJf8AeA6H3pgfoZDNHPCksEiSRSKGR1O5WBGQQR1FI7q25JUOw5yWGVI9/wD69fH3hTxd4l8G2kcegauk+jyndHFKPtEA9lzyg68Age1ei6L8c9ZZ1/tTQ7CdDkf6HcMh+uGzSA9Z1rwp4X1CAyX9jZqjcCRD5f5FSKwR8JvDMqF4Jb3Y2cFZlYD6fLWOnxd0K4RV1Dw/doCRkGNJF+ue9a8HxH8IeQ0ca3MaKpYosRA98YOKYis3wp0CP5hqt3GE5z5icfpU5+HfhW2VWn1G6w33S1yoyfwFJpvjLwXelZ7YXa7ztxskAz7gHFasuseGmhiVXlYg5UKrbhj1zxigDKEngjRw6xafJcNHwWMbPyP97/CsPV/iFrk7C08NaVDYwH5d7qWYZ9AABWtfaj4XlMrSW+qzAckj3989Kh8O+JPDFtr9vBHDcxBvkSS5G5UY9Mf40AUrLwPf6nC2p+JZCkqvvYXPLEdyPT6V0lg+j6eVj0+zaUNhfMl+bB7Hmul8SR3Vza+TYu6yEZIHAI+tclpvhi9jMpmgmlmY7tzXGFHpxQB1VvqWnXEpjmnxJuChZVxg+mcYraiTYMBmYdsnOK5bTdF+w28s2sz28UTElskcf8COMU5fF+hW8/kWskkznnMak5A75NAyh8Qfh3ZeKs3cEn2PVguBPt3LIB0Vx6e45HvXC+Gfg5qMuped4ku4be0hcqIbJy7XC+pYgbF9gM/SvbLG8gvrZJ7WQSRN0I/lUEWrWM2PKuUck4AXk5zjpSAl06xttMsobPT4I4LWEbUjQYCiqOv3VhHpd2168UkYU/u3OeewxVfxN4qsfD7RJcx3E80gysUChmx68kVkpr3h7xcn2DzZre6mGFWWPYxPp3B+maAPPX1aaNGzb25t4/mTemNv09afp+nad4vlltYYjb320th3xv8A930rotZ8B3qWojt5UkQN1RCcj/d7H6E1gaVpk2h3yGx8xr2Nt22RC2DnoBVCKiWXijwVLONOLxKo3Nn5o29DjoT9K1LT4krfwLB4q8NwXf8ACZIVDKR67X6fnXY614n07+woj4gsXWV2A8goT83rnsKoW8Hg2/s/Oubf7LGOQHlYfoDSAzF0P4a63CZPsUdk59GaNv0JFOf4ReFL9B/Zl7cjB+cpcK+0YPbHXPr71u2kXgeAbYZbXDjGC7YP4VLBqngqCXzIbm2jcHG5S45+tAHKyfA3TXZSNYvhtORmNM1PB8ENEBzc6lqMuDxsKJ/7Ka7u38RaA8gEWoQbx3Zj/M0l14w8PWxIm1a0yOoV92PyzQM5+0+Fvg/TEDzWBn2ng3ErNz9BgH8q1dQuIPD9n5Wh6ZDbYXJK2+1Av0XrVS4+IvheCRAty8u85DR27Y+vIFZl/wDF7w/bJIYYryZ14wUCDP1J/pQBNC/iTWmMczxx23QssZ3HP06VheK9WHhiCSytJbOW+ZNrNEcMAfX3rk/FHxrvLtZILIQ2Fsw+8jFpcf73AH4AGvMZtSu9RcizikkkzhnUknHqSaBG3q2tpuO5YS6nBZXOW+tc5dXdxfSmKzZieyEEgViapq2laPPKupX8l5chuba1AJU56F+lcbrPjPUr8GGz26baZyIrUlSf95+p/Qe1AHoOq32n6AmdYuo5ZMZW0gbMp+vPy/U1554t8XXfiDZAsSWenx/ctojkZ9WP8R/ziubPPWkpDCiiigAooooAKKKKACiiigC9Z2s89nNJbzKDHImYd+GbhzvA9FCnJ7bqvz6RfWtzc2MUpl82UwxiBWZLoo3O3A5APfpVDTfMk324uPIhf53YKWPCt2UE4wzZ7YPNdBBdazHYx6j/AG7cW8PmSSR+Uswj3FzuJ2rsG5u3XB5HQUAcjRV02D/Zi4cGcKJGhCncsZAIcnpjkfnmkuNPlgF0ZGQC3l8k8n525+7xz0/UUAU6KKKANXRNe1DRnJsZysbffib5kb6j+vWu40rx5pcu37fZS2NxkZmtzvjPuVPI/DNeZUUAfQul6vHfKv8AZd7Z6moG/wAsNtkUe6nBFaEuoRYaK5sJIXPBXt9a+a1JVgVJBHII7V0Ol+NPEGmqEg1Od4sgmOc+ap9sNnH4U7iPdrWAeej2l/JAwHCBgAfwroLHU7raI5lMyqMF0b+Yrwqw+JAOF1fSIJwT80lvI0TAew5Ga6PT/HegzFD9svbBs42yRlgPxU0XA9fW9jG8JwB/Az8Ef0q9DNE8tvcpEss8BDNlsLweK840vXLW8lYWmr6bdhh915NjD8+lb1tc3jLIohQgjpHKCD9MHimB7xZfEDSLiKMXaTQyk4ZVQyqvvuWmar8SNBsIn8hri6dVyFjhZV4HdmAA6V4aLi6hVc290D03DPA9qfJcStAyus+QQNzxkg/hRYCn468Yya7fLd3eotcWRbm0XKrCO2B/Wue07xddprNrAqrJbhiFdiQQP610bwWKRCSK0JwfnBTk59Kkjit18jyLYKHySGX5gPqKAOp8M+Mn0fWIJIrvfbyMq3FqT8rqeMj0IJz+le0X/wBm0ZdQ1iV2MSwl/LAG3IGSQfU8Cvma7FsZUMNuyTLjGVxjH8zXceMPHt3rOhQaXKjW/nBRcFI8B8EYAOeBkdqQGHc+KptR1VrjUJBJcOS25MkJzwq47AVkzeKL2C7kW1gnnhZ8pKg27CPQ+tS20hikdYYXDrxhUxn3qRZ9QBYw6fJICejrkCmB02ifFvUrKKIT2k96HOMTnaRz13YrrIfi5ZTYMWkTmTo7GRQox74yfyryhp9QjjIexIY9GwAOfUU2O71BVcLb2qk9dzqFb9eKQHU+N/iH/atxEr2YihQgxRA7nf1LH0rK+3pJGXkxHEMEcH8v51zz3l1H5hKWaIeoa4Q4PtzVSXW0iLJNqukRAnOGnA2n6dKYHcDUraWAMIViCnhlO4kfSohqqL5kcSh1PzHocfQV5zceK7GP55PEOneYq4JQlyfpis6Xx9pMbf8AIbkkUdVS1Yn6AnFFwPR59UllVlARww+Vi23aayPtVpZytI7PK+cyDt+debX3xI00Fjb2V9dEnkTSiNWHrxmsS7+I96QV07TrK0TGAWBlYe/Jx+lK4Hqs2rS3fmQWFvcM55EhH3RXL6hqmi2ErNf61GZcEGG2BmY46gkcA/UivMdV8Ua3qqlL/U7mSMjBjDbEI91XA/Ssai4z0W88fafCjppejiUkcSXrdD/ur/jXM6r4u1rUonhlvGitm/5YwDy1A9OOSPqTWBRSAKKKKACiiigAooooAKKKKACiiigAooooAt6bcxWlw0s0Ly/IQoSUxlWPfI5/CpGu725tLayDv5G4hI1JCsS2TkdOp/lVCigDTW6lWycLA4uWQBrjdwYMBduOmMgDP4VXvL+a7jjSUjC8nH8bd2b1bGOfaqlFABRRRQAUUUUAFFFFABS9qSigAqe3u7m3Obe4miP+w5X+VQUUAasPiLWYXVo9WvgVOR+/Yj8s1qR+P/FMYwutXOPfaf5iuWpQcen5UAdbH8R/Faf8xeQjGCDGmCPyq0nxR8UoyEXseV7+UvNcRn6flRnkHjj2oA7l/il4pfLG8i3nq3kjP+f8KIfin4pjwHvIp1ByBLCCP0rh9xA7fkKXecEYXn/ZFAHY6n8TfFeoSbn1RoVGMJCiqB+mawZfEetysS+r6gSev+kOP61lsxPXH4DFIaALz6xqbgh9RvGB4IM7H+tVXuJpARJNIwPXLE1FRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral malignant pleural effusions in patient with metastatic carcinoma of the breast. CT scan shows bilateral posterior pleural effusions and passive atelectasis of the right lower lobe with marked enhancement after intravenous contrast material injection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32833=[""].join("\n");
var outline_f32_4_32833=null;
var title_f32_4_32834="Balantidium coli infection";
var content_f32_4_32834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Balantidium coli infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32834/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/4/32834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balantidium coli is the largest protozoan and the only ciliate parasite that infects humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10030159\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human balantidiasis occurs worldwide; it is most prevalent in tropical and subtropical regions and developing countries. B. coli generally occurs among pigs in warmer climates and monkeys in the tropics. Infection in humans is therefore also more common in those areas, especially in settings where hygiene is poor. Porcine fecal contamination of water or food consumed by humans is the principal means for acquisition of infection by humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Transmission between humans can occur via the fecal-oral route.",
"   </p>",
"   <p>",
"    Transmission of balantidiasis occurs via ingestion of cysts (",
"    <a class=\"graphic graphic_figure graphicRef65689 \" href=\"mobipreview.htm?14/32/14855\">",
"     figure 1",
"    </a>",
"    ).&nbsp;Following ingestion, excystation occurs in the small intestine and the trophozoites colonize the large intestine.&nbsp;The trophozoites reside in the lumen of the large intestine of humans and animals, where they replicate by binary fission; conjugation may also occur.&nbsp;Trophozoites undergo encystation to produce infective cysts.&nbsp;Some trophozoites invade the wall of the colon and multiply; some return to the lumen and disintegrate. Mature cysts are passed in the stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three forms of B. coli infection can occur: asymptomatic cyst excretion, acute colitis and chronic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Most cases are asymptomatic; patients with debilitating conditions or other infections are at increased risk for developing symptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of acute colitis include nausea, vomiting, weight loss, and abdominal pain. Stools may be watery or dysenteric [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/7\">",
"     7",
"    </a>",
"    ]. Rarely fulminant disease occurs; it is generally associated with dysentery, with or without multiple intestinal perforations. Similar to amebic dysentery, formation of colonic ulcers leads to deep invasion of the submucosa, microperforations, and subsequent sepsis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p>",
"    Chronic infection is relatively uncommon; it consists of intermittent episodes of abdominal pain and bloody diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of B. coli infection is established by detection of trophozoites or cysts in stool examinations or mucosal scrapings obtained at colonoscopy or sigmoidoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/12\">",
"     12",
"    </a>",
"    ]. The trophozoites are relatively large (40 to 200 microns) (",
"    <a class=\"graphic graphic_picture graphicRef77476 \" href=\"mobipreview.htm?16/14/16611\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to treatment of balantidiasis is uncertain. In general, it is reasonable to treat symptomatic patients; data are limited regarding treatment of asymptomatic cyst excretion; but we favor a course of therapy. Treatment consisting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg orally four times daily for 10 days) is effective therapy for B. coli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32834/abstract/13\">",
"     13",
"    </a>",
"    ]. An alternative is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (750 mg orally three times daily for 5 days). Follow-up stool examination is warranted if symptoms persist.",
"   </p>",
"   <p>",
"    For prevention of infection travelers should adhere to routine precautions about consumption of food and water. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=see_link&amp;anchor=H22624029#H22624029\">",
"     \"Travel advice\", section on 'Food and water'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10030599\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balantidium coli is a protozoa that can cause colitis. Human balantidiasis is most prevalent in tropical and subtropical regions and developing countries. The principal means for acquisition of infection by humans consist of porcine fecal contamination of food or water. (See",
"      <a class=\"local\" href=\"#H10030159\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases are asymptomatic; patients with debilitating conditions or other infections are at increased risk for developing symptomatic infection. Symptoms of acute colitis include nausea, vomiting, weight loss, abdominal pain, and prominent diarrhea that may be bloody. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of B. coli infection is established by detection of trophozoites or cysts in stool examinations or mucosal scrapings obtained at colonoscopy or sigmoidoscopy (",
"      <a class=\"graphic graphic_picture graphicRef77476 \" href=\"mobipreview.htm?16/14/16611\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      for treatment of B. coli (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      );",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      is an alternative agent. For prevention of infection travelers should adhere to routine precautions about consumption of food and water. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/1\">",
"      Schuster FL, Ramirez-Avila L. Current world status of Balantidium coli. Clin Microbiol Rev 2008; 21:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/2\">",
"      Weiss LM, Keohane EM. The uncommon gastrointestinal Protozoa: Microsporidia, Blastocystis, Isospora, Dientamoeba, and Balantidium. Curr Clin Top Infect Dis 1997; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/3\">",
"      Walzer PD, Judson FN, Murphy KB, et al. Balantidiasis outbreak in Truk. Am J Trop Med Hyg 1973; 22:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/4\">",
"      Hindsbo O, Nielsen CV, Andreassen J, et al. Age-dependent occurrence of the intestinal ciliate Balantidium coli in pigs at a Danish research farm. Acta Vet Scand 2000; 41:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/5\">",
"      SWARTZWELDER JC. Balantidiasis. Am J Dig Dis 1950; 17:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/6\">",
"      Esteban JG, Aguirre C, Angles R, et al. Balantidiasis in Aymara children from the northern Bolivian Altiplano. Am J Trop Med Hyg 1998; 59:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/7\">",
"      Ferry T, Bouhour D, De Monbrison F, et al. Severe peritonitis due to Balantidium coli acquired in France. Eur J Clin Microbiol Infect Dis 2004; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/8\">",
"      Ladas SD, Savva S, Frydas A, et al. Invasive balantidiasis presented as chronic colitis and lung involvement. Dig Dis Sci 1989; 34:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/9\">",
"      Cerme&ntilde;o JR, Hern&aacute;ndez De Cuesta I, Uzc&aacute;tegui O, et al. Balantidium coli in an HIV-infected patient with chronic diarrhoea. AIDS 2003; 17:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/10\">",
"      Vasilakopoulou A, Dimarongona K, Samakovli A, et al. Balantidium coli pneumonia in an immunocompromised patient. Scand J Infect Dis 2003; 35:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/11\">",
"      Yazar S, Altuntas F, Sahin I, Atambay M. Dysentery caused by Balantidium coli in a patient with non-Hodgkin's lymphoma from Turkey. World J Gastroenterol 2004; 10:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/12\">",
"      Castro J, Vazquez-Iglesias JL, Arnal-Monreal F. Dysentery caused by Balantidium coli--report of two cases. Endoscopy 1983; 15:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32834/abstract/13\">",
"      Drugs for Parasitic Infections. The Medical Letter 2010.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5726 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32834=[""].join("\n");
var outline_f32_4_32834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10030599\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10030159\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10030599\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5726|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/32/14855\" title=\"figure 1\">",
"      Balantidium coli life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5726|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/14/16611\" title=\"picture 1\">",
"      Balantidium microscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_4_32835="Postmenopausal hormone therapy";
var content_f32_4_32835=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/4/32835/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32835/contributors\" id=\"au4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/4/32835/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32835/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32835/contributors\" id=\"se3550\">",
"       William F Crowley, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/4/32835/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32835/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/4/32835?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Menopause is defined as the time in a woman's life, usually between 45 and 55 years, when the ovaries stop producing eggs and menstrual periods end. For several years before menopause, menstrual periods become irregular, and many women develop hot flashes, night sweats, difficulty falling and staying asleep, and vaginal dryness. This stage is called perimenopause or the menopausal transition. A woman is said to be postmenopausal when she has not had menstrual bleeding for at least 12 months.",
"    </p>",
"    <p>",
"     The",
"     <strong>",
"      average",
"     </strong>",
"     age of menopause is approximately 51 years, but 5 percent of women become postmenopausal before age 45 years and 5 percent become postmenopausal after age 55.",
"    </p>",
"    <p>",
"     During the transition to menopause, the ovarian production of estrogen decreases by more than 90 percent. The decrease in ovarian estrogen production may cause symptoms such as hot flashes, also known as vasomotor symptoms, and a dry vagina. There are a number of options available to ease the symptoms of menopause, including estrogen. This article explains how estrogen works and discusses the risks and benefits of postmenopausal hormone use.",
"    </p>",
"    <p>",
"     Other articles about menopause are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=see_link\">",
"      \"Patient information: Menopause (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"      \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about postmenopausal hormone therapy is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"      \"Treatment of menopausal symptoms with hormone therapy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS POSTMENOPAUSAL HORMONE THERAPY?",
"     </span>",
"    </p>",
"    <p>",
"     Postmenopausal hormone therapy is the term used to describe the two hormones, estrogen and progestin, that are given to relieve bothersome symptoms of menopause. Estrogen is the hormone that relieves the symptoms. Women with a uterus must also take progestin (a progesterone-like hormone) to prevent uterine cancer. This is because estrogen alone can cause the lining of the uterus to overgrow (potentially leading to uterine cancer).",
"    </p>",
"    <p>",
"     Women who have had a hysterectomy do not have a uterus and cannot develop uterine cancer. These women are treated with estrogen alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Types of estrogen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Estrogen is available in many different forms. For hot flashes, it can be taken as an oral pill, a transdermal patch (worn on the skin), or a \"ring\" or tablet that is inserted into the vagina. There are also creams and sprays that can be put on the skin.",
"    </p>",
"    <p>",
"     The \"standard\" dose of oral (by mouth) conjugated estrogen is 0.625 mg, although lower doses of 0.3 mg or 0.45 mg may relieve menopausal symptoms for many women. Experts recommend starting with a low dose. If the lowest dose does not improve your symptoms, your doctor or nurse might recommend a higher dose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Estrogen pill",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many types of estrogen pills. One of the most commonly used brands, called Premarin&reg;, is made from the urine of pregnant horses (mares). Other preparations are derived from plant sources. All types of estrogen can help to relieve menopausal symptoms.",
"    </p>",
"    <p>",
"     Combination pills that include both estrogen and progestin are available. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Types of progestin'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Low-dose birth control pill &mdash; Very-low-dose birth control pills are a good option for women in their 40s who have bothersome hot flashes, irregular bleeding, and who still need a reliable form of birth control. Birth control pills are generally NOT recommended for postmenopausal women because the dose of estrogen is higher than needed to relieve hot flashes. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Estrogen patch",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many brands of estrogen patches. A combination estrogen and progestin patch is also available. Some patches need to be replaced every few days, while others are only replaced once a week.",
"    </p>",
"    <p>",
"     Estrogen patches work as well as estrogen pills to increase bone density and treat menopausal symptoms. Women with a uterus who use an estrogen patch must also take a progestin to decrease the risk of uterine cancer (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Types of progestin'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Vaginal estrogen",
"     </span>",
"     &nbsp;&mdash;&nbsp;A vaginal ring that contains estrogen can be used to treat hot flashes. Women with a uterus would also need to take progestin pills.",
"    </p>",
"    <p>",
"     Women with vaginal dryness can also be treated with a vaginal ring containing estrogen. This ring contains a much lower dose of estrogen than the ring used to treat hot flashes. Vaginal estrogen used to treat dryness is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"      \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Types of progestin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postmenopausal women with a uterus who are treated with estrogen alone have an increased risk of developing uterine cancer and hyperplasia (a precursor to uterine cancer). Taking a second hormone, progestin, minimizes this risk. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/55/19314?source=see_link\">",
"      \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Oral progestins &mdash; The most commonly prescribed progestin pill is medroxyprogesterone acetate. Other types of progestin pills (norethindrone, norgestrel) are also available.",
"       <br/>",
"       <br/>",
"       A natural progesterone, called Prometrium&reg;, is another option. There is also a generic form of natural progesterone. Natural progesterone has no negative effect on lipids and may be a good choice for women with high cholesterol levels.",
"      </li>",
"      <li>",
"       Intrauterine progestin &mdash; An intrauterine device (IUD) is a device that releases progestin (called Mirena&reg;) to prevent pregnancy. This type of IUD has also been used in menopausal women to minimize the risk of developing uterine cancer. However, the IUD is not currently approved in the US for use in menopausal women.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      \"Natural\" or \"bioidentical\" products",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many postmenopausal women are turning to \"natural\" or \"bioidentical\" hormone therapy as an alternative to conventional hormones. The \"bioidentical\" approach uses an individualized dose of hormones that is made by a pharmacy as pills, creams, or vaginal suppositories. The quality of these products is not regulated. The dose of hormones can vary from batch to batch.",
"    </p>",
"    <p>",
"     The hormones most commonly included in bioidentical products are estradiol, estrone, estriol, progesterone, testosterone, and DHEA. You may be asked to provide a saliva or blood sample to measure your baseline hormone levels. Based upon the results, the prescriber selects the individual hormones and doses, which are then made by a compounding pharmacy.",
"    </p>",
"    <p>",
"     Supporters of this approach claim that bioidentical hormones are safer and have fewer side effects than commercially available preparations. However, there is no scientific proof that this is true [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/4/32835/abstract/1\">",
"      1",
"     </a>",
"     ]. Expert groups recommend that women should not adopt this approach because the hormone products do not have adequate quality control [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/4/32835/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      RISKS AND BENEFITS OF HORMONE THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     The Women's Health Initiative (WHI) was a large study designed to find out if hormone therapy would reduce the risk of heart attacks (coronary heart disease [CHD]) after menopause. The study found that taking estrogen-progestin in combination actually increases the risk of heart attacks, breast cancer, blood clots, and strokes in older postmenopausal women. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"      \"Postmenopausal hormone therapy: Benefits and risks\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The results of the estrogen-only study were different. Women who took estrogen alone had a small increase in the risk of stroke and blood clots, but there was no increased risk of heart attacks or breast cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Heart attacks",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of having a heart attack related to use of hormone therapy appears to depend on your age. There is NO increased risk of heart attacks related to hormone therapy in women who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Became menopausal less than 10 years before starting hormones",
"       <strong>",
"        or",
"       </strong>",
"      </li>",
"      <li>",
"       Were 50 to 59 years when they took hormone therapy [",
"       <a class=\"abstract\" href=\"mobipreview.htm?32/4/32835/abstract/3\">",
"        3",
"       </a>",
"       ]",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Women who become menopausal more than 10 years ago or over age 60 years were at increased risk of having a heart attack related to hormone therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is a small increased risk of breast cancer in women who took combined estrogen-progestin therapy, but not in women who took estrogen alone. Experts think that it takes about 10 years or more of estrogen use (alone) before the risk goes up, but only 5 to 6 years if you take both hormones. After that, the risk will continue to go higher if you keep taking estrogen. This is discussed in detail separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"      \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Osteoporotic fracture",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of breaking a bone at the hip or spine because of osteoporosis is lower in women who take estrogen-progestin or estrogen alone. However, hormone therapy is not recommended to prevent or treat osteoporosis because there are bone medicines (called bisphosphonates) that have fewer serious risks. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Dementia",
"     </span>",
"     &nbsp;&mdash;&nbsp;In women who took combined estrogen-progestin or estrogen alone, there was no significant improvement in memory or thinking, but there was an increase in the risk of developing dementia. But some experts think that estrogen treatment might be helpful for preventing dementia if you take it in the early years after menopause (although this is not proven); taking it many years after menopause seems to be harmful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women develop depression for the first time during the few years leading up to menopause. Some studies show that estrogen treatment helps to improve mood and decrease depression. However, some women need to be treated with both estrogen and an antidepressant to feel completely better. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"      \"Patient information: Depression in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H269700565\">",
"     <span class=\"h2\">",
"      Sleep problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many perimenopausal and postmenopausal women have sleep problems. Sometimes this is because they have hot flashes at night that interfere with sleep (night sweats). But women can have trouble sleeping even if they don&rsquo;t have hot flashes. This can be due to disorders like restless leg syndrome and sleep apnea. Estrogen treatment is very effective for improving sleep in women with night sweats.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHO SHOULD TAKE HORMONE THERAPY?",
"     </span>",
"    </p>",
"    <p>",
"     The most common reason for taking hormone therapy is to treat bothersome menopausal symptoms, such as hot flashes. Most experts agree that hormone therapy is safe for healthy women who have menopausal symptoms. If you decide to take hormones, you should take them for the shortest period of time possible. Short-term use of hormones (less than five years) does not seem to increase the risk of breast cancer.",
"    </p>",
"    <p>",
"     Most experts recommend that you eventually decrease and stop taking hormone therapy. If you are taking pills, one way to do this is to skip one pill per week. If you are using a patch, your doctor or nurse can give you a lower-dose patch.",
"    </p>",
"    <p>",
"     If menopausal symptoms return as you lower your dose of hormones, you can try hormone therapy alternatives. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"      \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Who should avoid hormones?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hormone therapy is not recommended for women with the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Current or past history of breast cancer",
"      </li>",
"      <li>",
"       Coronary heart disease",
"      </li>",
"      <li>",
"       A previous blood clot, heart attack, or stroke",
"      </li>",
"      <li>",
"       Women at high risk for these complications",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Women with breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with breast cancer often experience early menopause due to breast cancer treatments. In these women, estrogen or hormone therapy (by mouth or patch) is NOT recommended. The hormones could increase the chance of the cancer coming back.",
"    </p>",
"    <p>",
"     Alternatives to hormone therapy are available and are often effective in relieving bothersome menopausal symptoms. These alternatives are discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"      \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784794821\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12644614\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=see_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=see_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/2/13346?source=see_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12644622\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=see_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/55/19314?source=see_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link\">",
"      Androgen production and therapy in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=see_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40486?source=see_link\">",
"      Continuous postmenopausal hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"      Estrogen and cognitive function",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"      Menopausal hot flashes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/hormonereplacementtherapy.html\">",
"      www.nlm.nih.gov/medlineplus/hormonereplacementtherapy.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/menopause.cfm\">",
"      www.hormone.org/public/menopause.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/4/32835/abstract/1,3,4\">",
"      1,3,4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/4/32835?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32835/abstract/1\">",
"      Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004; 11:356.",
"     </a>",
"    </li>",
"    <li>",
"     The Endocrine Society Position Statement, 2006: file://www.endo-society.org/advocacy/policy/upload/BH_position_Statement_final_10_25_06_w_Header.pdf (Accessed on July 26, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32835/abstract/3\">",
"      Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32835/abstract/4\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f32_4_32835=[""].join("\n");
var outline_f32_4_32835=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS POSTMENOPAUSAL HORMONE THERAPY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           RISKS AND BENEFITS OF HORMONE THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHO SHOULD TAKE HORMONE THERAPY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f32_4_32836="Prostate adenocarcinoma4 light";
var content_f32_4_32836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prostate adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This low power photomicrograph of an hematoxylin and eosin stained section of the prostate gland demonstrates the characteristic blue-tinged mucin and amorphic secretion in the malignant glands (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32836=[""].join("\n");
var outline_f32_4_32836=null;
var title_f32_4_32837="Langers lines of the face";
var content_f32_4_32837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langer's lines of the face",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Blackbourne LH. Advanced Surgical Recall, 2nd ed, Lippincott Williams &amp; Wilkins, Baltimore 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32837=[""].join("\n");
var outline_f32_4_32837=null;
var title_f32_4_32838="Radial head and neck fractures in adults";
var content_f32_4_32838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radial head and neck fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32838/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32838/contributors\">",
"     Mark Slabaugh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32838/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32838/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32838/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32838/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/4/32838/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial head and neck fractures occur frequently, most often following a fall onto an outstretched hand. Nondisplaced fractures can be managed by knowledgeable, primary care physicians; orthopedic referral is needed for more complex fractures.",
"   </p>",
"   <p>",
"    The presentation, evaluation, and basic management of radial head and neck fractures are reviewed here. The management of pediatric elbow fractures and other upper extremity injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19607?source=see_link\">",
"     \"Elbow anatomy and radiographic diagnosis of elbow fracture in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14983?source=see_link\">",
"     \"Evaluation of elbow pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial head and neck fractures are common and are present in about 30 percent of all elbow fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They represent between 1.7 and 5.4 percent of all fractures in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies describe a male predominance with a ratio of 2:1, but others describe equal distribution between genders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. On average, fractures in men occur seven years earlier than in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/5\">",
"     5",
"    </a>",
"    ]. Radial head fractures occur throughout adulthood; the mean age at the time of injury is approximately 45 years. Fractures of the radial neck occur most often in children and are much less common in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FUNCTIONAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radial head and neck comprise the most proximal portion of the radius (",
"    <a class=\"graphic graphic_figure graphicRef68107 \" href=\"mobipreview.htm?15/25/15761\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"mobipreview.htm?22/52/23365\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66874 \" href=\"mobipreview.htm?36/29/37330\">",
"     figure 3",
"    </a>",
"    ). The radial head lies at the proximal end. It is disk-shaped with a flattened end that articulates with the capitellum of the humerus proximally. The radial head also articulates with the lesser sigmoid notch of the ulna medially. Just distal to the head but proximal to the tuberosity is the radial neck, which is narrower than the head and slightly concave.",
"   </p>",
"   <p>",
"    Articular cartilage covers nearly the entire circumference of the radial head. The radial head derives its blood supply from both intraarticular and intraosseous sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/6\">",
"     6",
"    </a>",
"    ]. This dual blood supply likely contributes to its resistance to osteonecrosis even following displaced fractures.",
"   </p>",
"   <p>",
"    The elbow consists of three separate bony articulations: the radiocapitellar, ulnotrochlear, and proximal radioulnar joints. All three are located within a single joint capsule. Together they form a modified hinge joint. The ulnotrochlear and radiocapitellar joints enable flexion and extension of the elbow, and allow for the transmission of forces from the forearm to the humerus. The radiocapitellar joint, along with the medial collateral ligament or ulnar collateral ligament, provides a significant degree of valgus stability, especially with the elbow in extension.",
"   </p>",
"   <p>",
"    In conjunction with the distal radioulnar joint, the proximal radioulnar joint allows for pronation and supination. The strong annular ligament of the radius holds the radial head in the lesser trochlear (radial) notch of the ulna to allow for smooth rotation throughout pronation and supination.",
"   </p>",
"   <p>",
"    Although the posterior interosseous nerve (a branch of the radial nerve) runs through the supinator muscle just distal to the radial neck and is anatomically at risk of injury with radial head and neck fractures, in fact the nerve is rarely injured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No ideal fracture classification system exists for radial head fractures, but a modified Mason classification is used most often. The system was originally based upon radiographic appearance alone but was modified to include a fourth category of fractures with associated elbow dislocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Approximately two-thirds of radial head fractures are Mason Type I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Mason classification is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mason Type I &ndash; Nondisplaced fractures (displacement &le;2 mm) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58327 \" href=\"mobipreview.htm?2/16/2319\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mason Type II &ndash; Displaced fractures &gt;2 mm",
"     </li>",
"     <li>",
"      Mason Type III &ndash; Comminuted fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61080 \" href=\"mobipreview.htm?8/48/8974\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mason Type IV &ndash; Radial head fracture with associated elbow dislocation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73891 \" href=\"mobipreview.htm?38/38/39535\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanism for radial head and neck fractures is a fall onto an outstretched hand leading to axial impaction of the radius on the capitellum (",
"    <a class=\"graphic graphic_figure graphicRef81169 \" href=\"mobipreview.htm?0/7/126\">",
"     figure 4",
"    </a>",
"    ). The severity of the fracture is generally proportional to the force applied to the arm. Injuries suffered as a result of sports and falls from a height often entail more severe fracture patterns. Fractures can also occur due to direct trauma or from a radial head dislocation in association with a Monteggia fracture (ulnar fracture with radial head fracture) or elbow dislocation.",
"   </p>",
"   <p>",
"    Concomitant fractures, dislocations, and soft tissue injuries are common with more severe fractures (Mason Types II and III) but uncommon with Mason Type I fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. Detecting associated injuries is important for proper management. Injuries to structures about the elbow, including the medial collateral ligament, interosseous ligament, coronoid process, and distal radioulnar joint, are particularly important and likely to affect treatment. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Functional anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with radial head or neck fractures typically present within 48 hours following a fall onto an outstretched hand or direct elbow trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/5\">",
"     5",
"    </a>",
"    ]. Nevertheless, subacute and chronic injuries do occur. A history of a dislocation with spontaneous relocation increases the likelihood of a medial collateral ligament (MCL) or coronoid process injury.",
"   </p>",
"   <p>",
"    A screening neurovascular examination should be performed. Although rarely injured, the posterior interosseous nerve can be tested by having the patient extend their thumb. Techniques for performing a screening neurologic examination of the upper extremity are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27510?source=see_link&amp;anchor=H5#H5\">",
"     \"Midshaft humeral fractures in adults\", section on 'Symptoms and examination findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fracture of the proximal radius should be considered in any patient with pain, tenderness, or swelling over the lateral elbow, or with decreased elbow motion, following any type of trauma. Ipsilateral wrist or forearm pain may be a sign of concomitant injury and warrants radiographic investigation.",
"   </p>",
"   <p>",
"    Inspect the elbow and wrist for obvious deformity or bruising. Significant ecchymosis is most often a sign of soft tissue damage.",
"   </p>",
"   <p>",
"    Palpate the radial head for crepitus and tenderness while the forearm is gently pronated and supinated. Based upon clinical experience, joint tenderness over the radial head is a sensitive sign of injury. Carefully palpate the forearm and elbow for tenderness along the interosseous membrane and MCL. Examine the wrist and forearm for focal tenderness suggesting other injuries.",
"   </p>",
"   <p>",
"    Assess the elbow's range of motion (both flexion-extension and supination-pronation) as permitted by the patient's pain (",
"    <a class=\"graphic graphic_table graphicRef70587 \" href=\"mobipreview.htm?42/6/43115\">",
"     table 1",
"    </a>",
"    ). Fracture fragments may sometimes block forearm rotation, but in the acute setting motion is usually limited by a painful hemarthrosis, not a true mechanical block. Management of the elbow with reduced motion is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Limited joint motion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtain standard anterior-posterior (AP) and lateral x-rays of the elbow in all patients with a suspected radial head or neck fracture. Inspect these x-rays for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture line (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83475 \" href=\"mobipreview.htm?34/18/35108\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abnormal bony alignment (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62567 \" href=\"mobipreview.htm?12/57/13200\">",
"       image 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Angulation, depression, comminution, or displacement of the radial head or neck",
"     </li>",
"     <li>",
"      Fat pads (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50782 \" href=\"mobipreview.htm?30/60/31680\">",
"       image 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70692 \" href=\"mobipreview.htm?20/7/20595\">",
"       figure 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Small bone fragments within the joint",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated anterior and posterior fat pads (so-called \"sail sign\") due to blood distending the joint capsule may be the only sign of an occult, nondisplaced radial head fracture. Fractures of the radial neck are less likely to produce elevated fat pads as the fracture may be entirely extraarticular. A posterior fat pad sign is abnormal and more specific for fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A small oval anterior fat pad may be a normal finding, but displacement of the fat pad away from the bone in the setting of acute trauma suggests a joint effusion. Bone fragments within the joint suggest a chip fracture of the capitellum.",
"   </p>",
"   <p>",
"    Clinicians can perform a radiocapitellar, or Greenspan, view to better characterize a fracture or when a fracture is suspected clinically but not apparent on standard views. The Greenspan view is obtained by angling the beam 45 degrees cephalad with the elbow in neutral position (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71172 \" href=\"mobipreview.htm?4/51/4914\">",
"     image 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scanning is most useful in preoperative planning and is not indicated in the acute setting. The role of MRI for detecting occult fractures remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures, fracture dislocations, and all fractures associated with a neurologic deficit (eg, median, radial, or ulnar nerve injury) or circulatory compromise (brachial artery injury) require emergent surgical consultation.",
"   </p>",
"   <p>",
"    Orthopedic consultation should be obtained within several days of the injury for all displaced radial head and neck fractures, including Mason Types II and III. Elbow",
"    <span class=\"nowrap\">",
"     fracture/dislocations",
"    </span>",
"    (Mason type IV) require urgent orthopedic consultation. The Mason classification is described above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nondisplaced (Mason Type I) fractures involving the radial head or both the radial head and neck can generally be treated by a primary care physician once it has been determined that no mechanical block to elbow flexion exists. A mechanical block suggests a displaced bone fragment, which requires orthopedic intervention. Assessment for a mechanical block is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Limited joint motion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Goals of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment for a radial head fracture are to promote fracture healing while maintaining elbow range of motion and hand and arm strength. Although randomized trials to support this approach are lacking, many experts believe that early mobilization is the most important factor for maintaining normal elbow motion in patients with nondisplaced or minimally displaced radial head fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Basic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment depends upon the fracture type and the patient's symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/14\">",
"     14",
"    </a>",
"    ]. Nondisplaced (Mason Type I) radial head fractures with full motion can be treated with a sling for comfort for 24 to 48 hours. A posterior splint may be applied in the acute setting but should not be used for more than a day or two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/16\">",
"     16",
"    </a>",
"    ]. Range of motion exercises should be started as early as possible. Ice is applied during the first 24 hours.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs (NSAIDs) are generally adequate for acute pain control; opioids are usually unnecessary.",
"   </p>",
"   <p>",
"    Range of motion exercises consist primarily of extension and flexion of the elbow with the emphasis on fully straightening and flexing the joint. Additionally, the patient performs pronation and supination with their arm at their side and their elbow held at 90 degrees. In this position, the patient simply rotates the forearm so the palm faces up and then down.",
"   </p>",
"   <p>",
"    In the acute setting, clinicians can treat patients with displaced or complex fractures (Mason Types II or III) with a sling or posterior splint for comfort, ice, analgesics, and orthopedic referral within several days for further care. The treatment of Mason Type II radial head fractures remains controversial and should be determined by an orthopedist. The majority of Mason Types III and IV radial head fractures require operative intervention, often with radial head resection and prosthetic replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Limited joint motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial head fractures associated with restricted elbow flexion-extension on presentation need further evaluation. Most often, limited mobility is due to the pain of a distended joint capsule from hemarthrosis, but occasionally a fracture fragment in the joint mechanically blocks motion.",
"   </p>",
"   <p>",
"    Aspiration of the hemarthrosis and injection of local anesthetic into the joint provide substantial pain relief and enable the clinician to perform a better evaluation of joint motion (",
"    <a class=\"graphic graphic_figure graphicRef59213 \" href=\"mobipreview.htm?3/46/3809\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A persistent mechanical block requires orthopedic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate reduction is critical in patients who present with a radial head or neck fracture associated with an elbow dislocation. The longer the elbow is allowed to remain dislocated, the more difficult the reduction and the greater the risk of avascular necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/20\">",
"     20",
"    </a>",
"    ]. If an orthopedic surgeon is not immediately available, the treating physician must reduce a posterior elbow dislocation, even when associated fractures are present.",
"   </p>",
"   <p>",
"    Ideally, reduction is performed in a monitored environment with the ability to give intravenous sedation and analgesia. The performance of procedural sedation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One traditional way to reduce a posterior elbow dislocation consists of applying longitudinal traction to the supinated forearm, while an assistant provides counter traction to the humerus. The elbow is held in slight flexion. The clinician then applies moderate steady force to the posterior tip of the olecranon using the thumb while the opposite hand continues to apply steady traction to the forearm. If this approach is unsuccessful, the clinician can use the hand applying traction to gently flex the patient's elbow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the reduction must be performed without assistance, a gurney or chair can be used to brace the humerus, while the clinician applies traction to the forearm with one hand and presses on the olecranon with the thumb of the opposite hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the joint is reduced (often with a satisfying clunk), the elbow is taken through its full range of motion (including full extension, flexion, pronation, and supination) to assess stability. Stability against valgus and varus stress should also be assessed with the elbow in near full extension.",
"   </p>",
"   <p>",
"    If the elbow loses reduction during this evaluation, note the position in which this occurred. Repeat the reduction maneuver and splint the elbow in 90 degrees of flexion with the forearm in neutral. Once the elbow is reduced, obtain repeat radiographs with the elbow splinted to confirm that the elbow is in fact reduced. Orthopedic consultation within 24 hours is necessary for cases in which the elbow is successfully reduced. If the elbow cannot be reduced, emergent orthopedic consultation is mandatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nondisplaced radial head or neck fractures are reassessed weekly for three weeks to confirm continued improvement. Encourage patients to perform active flexion-extension and pronation-supination exercises, as early motion is the most important factor in speeding recovery and maximizing long-term joint mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32838/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient has increasing pain or does not show improvement in range of motion, take repeat radiographs to asses fracture stability and look for other injuries. Immediate referral to an orthopedist is necessary if a displaced fracture or concomitant injury is detected. If such conditions are absent, the patient may need closely supervised physical therapy. Despite these cautions, conservative treatment is successful in the great majority of cases.",
"   </p>",
"   <p>",
"    Follow-up care for patients with displaced (ie, Mason II to IV) fractures is determined by the orthopedic surgeon and the timing of operative intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication from radial head and neck fractures is decreased elbow range of motion, particularly loss of full extension. Early, active range of motion exercise is the most important factor in mitigating this complication.",
"   </p>",
"   <p>",
"    Elbow instability is infrequent but can occur with concomitant injuries to the lateral or medial collateral ligaments or the coronoid process. These inevitably require reconstruction, and specialized orthopedic care should be sought. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients reporting continued pain at the elbow may have occult soft tissue injuries, a capitellar fracture, or an osteochondral lesion. Traumatic osteoarthritis is another cause of elbow pain following fracture of the radial head; the likelihood of osteoarthritis increases with the severity of fracture.",
"   </p>",
"   <p>",
"    Wrist pain is not uncommon and may be due to unrecognized injuries to the carpal bones, interosseous membrane, distal radioulnar joint, triangular fibrocartilage complex, or other structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may return to sports or heavy physical labor once the injured elbow has recovered painless full range of motion and the arm has regained normal strength, which typically requires about 8 to 12 weeks with nonoperative treatment. Return to sports and work is generally delayed by two to four additional weeks in patients who undergo operative fixation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radial head and neck fractures are common in adults of all ages. More severe fracture types are often associated with other injuries; isolated nondisplaced fractures can be managed by primary care physicians. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suspect fracture of the proximal radius in all patients presenting with lateral elbow pain and a history of a fall onto an outstretched hand. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate orthopedic evaluation is needed for any patient with an open fracture, neurovascular compromise, or fracture dislocation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate reduction is critical in patients who present with a radial head or neck fracture and an elbow dislocation. The longer the joint is allowed to remain dislocated, the more difficult the reduction and the greater the risk of avascular necrosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain AP and lateral radiographs in all patients where a fracture about the elbow is suspected. If no fracture is evident, a radiocapitellar (Greenspan) view may better characterize the radiocapitellar joint. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated anterior or posterior fat pads may be the only indication of a radial head fracture; such patients can be treated in the acute setting with either a posterior splint or sling, as if a Mason Type I fracture were present.",
"     </li>",
"     <li>",
"      Assessing range of motion of both flexion-extension and pronation-supination is vital in patients with Mason Type I radial head fractures. If deficits are identified, further evaluation is needed following hemarthrosis aspiration and local anesthetic injection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Limited joint motion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early mobilization is paramount in obtaining good short-term and long-term results. Patients that are slow to progress may need closely supervised physical therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/1\">",
"      Conn, J, Wade, PA. Injuries of the elbow: A ten-year review. J Trauma 1961; 1:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/2\">",
"      MASON ML. Some observations on fractures of the head of the radius with a review of one hundred cases. Br J Surg 1954; 42:123.",
"     </a>",
"    </li>",
"    <li>",
"     Morey B. The Elbow and Its Disorders, 3rd, Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/4\">",
"      ARNER O, EKENGREN K, VON SCHREEB T. Fractures of the head and neck of the radius; a clinical and roentgenographic study of 310 cases. Acta Chir Scand 1957; 112:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/5\">",
"      van Riet RP, Morrey BF, O'Driscoll SW, Van Glabbeek F. Associated injuries complicating radial head fractures: a demographic study. Clin Orthop Relat Res 2005; 441:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/6\">",
"      Yamaguchi K, Sweet FA, Bindra R, et al. The extraosseous and intraosseous arterial anatomy of the adult elbow. J Bone Joint Surg Am 1997; 79:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/7\">",
"      JOHNSTON GW. A follow-up of one hundred cases of fracture of the head of the radius with a review of the literature. Ulster Med J 1962; 31:51.",
"     </a>",
"    </li>",
"    <li>",
"     McKee MD, Jupiter J. Trauma to the adult elbow and fractures of the distal humerus. In: Skeletal Trauma: Basic Science, Management, and Reconstructions, 3rd, Browner B, Jupiter J, Levine A, Trafton P.  (Eds), Saunders, Philadelphia 2002. p.1404.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/9\">",
"      van Riet RP, Morrey BF. Documentation of associated injuries occurring with radial head fracture. Clin Orthop Relat Res 2008; 466:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/10\">",
"      Itamura J, Roidis N, Mirzayan R, et al. Radial head fractures: MRI evaluation of associated injuries. J Shoulder Elbow Surg 2005; 14:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/11\">",
"      Skaggs DL, Mirzayan R. The posterior fat pad sign in association with occult fracture of the elbow in children. J Bone Joint Surg Am 1999; 81:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/12\">",
"      O'Dwyer H, O'Sullivan P, Fitzgerald D, et al. The fat pad sign following elbow trauma in adults: its usefulness and reliability in suspecting occult fracture. J Comput Assist Tomogr 2004; 28:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/13\">",
"      Greenspan A, Norman A. The radial head, capitellum view: useful technique in elbow trauma. AJR Am J Roentgenol 1982; 138:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/14\">",
"      Weseley MS, Barenfeld PA, Eisenstein AL. Closed treatment of isolated radial head fractures. J Trauma 1983; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/15\">",
"      Liow RY, Cregan A, Nanda R, Montgomery RJ. Early mobilisation for minimally displaced radial head fractures is desirable. A prospective randomised study of two protocols. Injury 2002; 33:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/16\">",
"      Unsworth-White J, Koka R, Churchill M, et al. The non-operative management of radial head fractures: a randomized trial of three treatments. Injury 1994; 25:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/17\">",
"      Radin EL, Riseborough EJ. Fractures of the radial head. A review of eighty-eight cases and analysis of the indications for excision of the radial head and non-operative treatment. J Bone Joint Surg Am 1966; 48:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/18\">",
"      Dooley JF, Angus PD. The importance of elbow aspiration when treating radial head fractures. Arch Emerg Med 1991; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/19\">",
"      Holdsworth BJ, Clement DA, Rothwell PN. Fractures of the radial head--the benefit of aspiration: a prospective controlled trial. Injury 1987; 18:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/20\">",
"      Mehta JA, Bain GI. Elbow dislocations in adults and children. Clin Sports Med 2004; 23:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/21\">",
"      PARVIN RW. Closed reduction of common shoulder and elbow dislocations without anesthesia. AMA Arch Surg 1957; 75:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/22\">",
"      Meyn MA Jr, Quigley TB. Reduction of posterior dislocation of the elbow by traction on the dangling arm. Clin Orthop Relat Res 1974; :106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32838/abstract/23\">",
"      Minford EJ, Beattie TF. Hanging arm method for reduction of dislocated elbow. J Emerg Med 1993; 11:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 210 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32838=[""].join("\n");
var outline_f32_4_32838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FUNCTIONAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Goals of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Basic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Limited joint motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/210|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/16/2319\" title=\"diagnostic image 1\">",
"      Nondisplaced radial head fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/48/8974\" title=\"diagnostic image 2\">",
"      Radial head fracture complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/38/39535\" title=\"diagnostic image 3\">",
"      Radial head fracture dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/18/35108\" title=\"diagnostic image 4\">",
"      X-ray fracture of the coronoid process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/57/13200\" title=\"diagnostic image 5\">",
"      Elbow x-ray lateral anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/60/31680\" title=\"diagnostic image 6\">",
"      Elbow x-ray adult fat pad",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/51/4914\" title=\"diagnostic image 7\">",
"      Radiocapitellar x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/210|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/25/15761\" title=\"figure 1\">",
"      Posterolateral view right elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/52/23365\" title=\"figure 2\">",
"      Major arteries and nerves of the anterior elbow region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/29/37330\" title=\"figure 3\">",
"      Elbow joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/7/126\" title=\"figure 4\">",
"      Radial head fracture mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/7/20595\" title=\"figure 5\">",
"      Fat pad sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/46/3809\" title=\"figure 6\">",
"      Elbow injection site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/210|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/6/43115\" title=\"table 1\">",
"      Range of motion elbow",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19607?source=related_link\">",
"      Elbow anatomy and radiographic diagnosis of elbow fracture in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14983?source=related_link\">",
"      Evaluation of elbow pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27510?source=related_link\">",
"      Midshaft humeral fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_4_32839="Clobazam: Pediatric drug information";
var content_f32_4_32839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clobazam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?39/49/40727?source=see_link\">",
"    see \"Clobazam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/60/41924?source=see_link\">",
"    see \"Clobazam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13688779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Onfi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clobazam&reg;;",
"     </li>",
"     <li>",
"      Clobazam-10;",
"     </li>",
"     <li>",
"      Dom-Clobazam;",
"     </li>",
"     <li>",
"      Frisium&reg;;",
"     </li>",
"     <li>",
"      Novo-Clobazam;",
"     </li>",
"     <li>",
"      PMS-Clobazam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1006224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1006259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/49/40727?source=see_link\">",
"      see \"Clobazam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be titrated according to patient tolerability and response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lennox-Gastaut syndrome:",
"     </b>",
"     Children  &ge;2 years and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;30 kg: Initial: 5 mg once daily for &ge;1 week, may then increase to 5 mg twice daily for &ge;1 week, then increase to 10 mg twice daily thereafter (maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;30 kg: Initial: 5 mg twice daily for &ge;1 week, may then increase to 10 mg twice daily for &ge;1 week, then increase to 20 mg twice daily thereafter (maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Seizures, generalized or partial, monotherapy or adjunctive therapy:",
"     </b>",
"     Oral: Limited data available [Frisium&reg; prescribing information (U.K.; Canada), 2011; Canadian Study Group, 1998; Ng, 2007]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Initial: 0.5-1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     usually in divided doses twice daily; maximum initial daily dose: 5 mg/",
"     <b>",
"      day",
"     </b>",
"     ; may increase dosage slowly (not more often than every 5-7 days); maximum daily dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-16 years: Initial: 5 mg once daily; may increase dosage slowly (not more often than every 5 days), usual range: 10-20 mg/",
"     <b>",
"      day",
"     </b>",
"     or 0.3-1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses twice daily; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lennox-Gastaut, adjunctive:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &le;30 kg: Initial: 5 mg once daily for &ge;1 week, then increase to 5 mg twice daily for &ge;1 week, then increase to 10 mg twice daily thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;30 kg: Initial: 5 mg twice daily for &ge;1 week, then increase to 10 mg twice daily for &ge;1 week, then increase to 20 mg twice daily thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use with caution, has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild to moderate impairment (Child-Pugh Score 5-9):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &le;30 kg: Initial: 5 mg once daily for &ge;2 weeks, then increase to 5 mg twice daily for &ge;1 week, may then increase to 10 mg twice daily based on patient tolerability and response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;30 kg: Initial: 5 mg once daily for &ge;1 week, then increase to 5 mg twice daily for &ge;1 week, then increase to 10 mg twice daily for &ge;1 week, may then increase to 20 mg twice daily based on patient tolerability and response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe impairment: Use with extreme caution; has not been studied; undergoes extensive hepatic metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for CYP2C19 poor metabolizers:",
"     </b>",
"     Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &le;30 kg: Initial: 5 mg once daily for &ge;2 weeks, then increase to 5 mg twice daily for &ge;1 week, may then increase to 10 mg twice daily based on patient tolerability and response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;30 kg: Initial: 5 mg once daily for &ge;1 week, then increase to 5 mg twice daily for &ge;1 week, then increase to 10 mg twice daily for &ge;1 week, may then increase to 20 mg twice daily based on patient tolerability and response",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13688780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onfi&trade;: 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15859539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onfi&trade; oral suspension: FDA approved December 2012; anticipated availability is midyear to third quarter 2013.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F13689303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13362239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM277791.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM277791.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1006265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Tablets can be crushed and mixed in applesauce.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1006247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1006225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (FDA approved in ages &ge;2 years and adults); has also been used as monotherapy and adjunctive treatment for other forms of epilepsy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13689302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CloBAZam may be confused with clonazePAM",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Aggressiveness, ataxia, fatigue, fever, insomnia, irritability, lethargy, psychomotor hyperactivity, sedation, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Appetite increased, constipation, dysphagia, salivation increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Dysarthria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchitis, cough, pneumonia, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Aspiration, behavior changes, blurred vision, confusion, delirium, delusions, depression, diplopia, eosinophilia, hallucinations, leukopenia, mood changes, respiratory depression, Stevens-Johnson syndrome, suicidal ideation, suicide attempts, thrombocytopenia, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1006232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clobazam or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7689404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dose in patients with hepatic impairment; consider avoiding with severe hepatic impairment; no dosage recommendations exist. Use with caution and adjust dose in patients who are CYP2C19 poor metabolizers. Use with caution in patients at risk for falls, including elderly. May cause muscle weakness, use with caution in patients with pre-existing muscle weakness, spinal or cerebellar ataxia, or myasthenia gravis. Use with caution in patients with impaired gag reflex; benzodiazepines may decrease the ability to manage secretions increasing risk for postictal aspiration pneumonia. Use with caution in patients with narrow-angle glaucoma. Tolerance and loss of seizure control have been reported with chronic administration. May decrease efficacy of hormonal contraceptives; female patients of childbearing potential should be counseled to use alternative nonhormonal contraception during therapy and for 28 days following clobazam discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Decreased bone density and bone length and alterations in behavior  have been reported in juvenile animal studies at levels of exposure greater than therapeutic doses; adverse bone effects were reversible upon discontinuation. Administration of high doses to rats for 2 years was associated with an increase in thyroid follicular cell adenomas; implications for human use are uncertain.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1006233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause CNS depression and dose-related somnolence and sedation (incidence: 32% with high doses); onset of somnolence and sedation occurs within first month of therapy and may lessen with continued treatment; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving); use with caution in patients with severe respiratory insufficiency, sleep apnea, or who are  receiving other CNS depressants, psychoactive agents, or ethanol as additive CNS depressant effects can occur; concomitant ethanol use can increase clobazam serum concentrations by 50%. May cause physical and psychological dependence with prolonged use; do not abruptly discontinue; rebound or withdrawal symptoms (including seizures) may occur following abrupt discontinuation or large decreases in dose; use caution when reducing dose or withdrawing therapy; decrease slowly (5-10 mg/day on a weekly basis) and monitor for withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Does not have antidepressant, antipsychotic, or analgesic properties; benzodiazepines have been associated with anterograde amnesia. Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients. Hypotonia, hypothermia, withdrawal symptoms, and respiratory and feeding difficulties have been reported in the infant following maternal use of benzodiazepines near time of delivery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F152626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (major), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (moderate), UGT1A4, UGT1A6, UGT2B4;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of CloBAZam. Alcohol (Ethyl) may increase the serum concentration of CloBAZam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): CloBAZam may decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): CloBAZam may decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clobazam was shown to be teratogenic in some animal studies. Clobazam crosses the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. Epilepsy itself, the number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines. An increased risk of fetal malformations may be associated with first trimester exposure. The Canadian labeling contraindicates use  in the first trimester.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to clobazam during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13761521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and mental status/suicidality (eg, suicidal thoughts, depression, behavioral changes); CBC, liver function, and renal function; some recommend periodic thyroid function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1006249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA. GABA is a major inhibitory neurotransmitter in the brain and suppresses the spike-and-wave discharge seizures by depressing nerve transmission in the motor cortex.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13760898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect:  5-9 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1006251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive; not affected by food or crushing tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 100 L; Protein binding: Clobazam: 80% to 90%; N-desmethylclobazam (NCLB): 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and to a lesser extent via CYP2C19 and 2B6; N-demethylation to active metabolite (N-desmethyl) with ~20% activity of clobazam. CYP2C19 primarily mediates subsequent hydroxylation of the N-desmethyl metabolite; metabolic rate increased in children (53% to 69%) (Ng, 2007). Plasma concentrations of NCLB are 5 times higher in CYP2C19 poor metabolizers versus extensive metabolizers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Bioavailability: 87% (Ng, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Clobazam: 16 hours (Ng, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Clobazam: 36-42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NCLB: 71-82 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Time to peak serum concentration: 0.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Elimination: Urine: 82% of dose; unchanged drug: 2%, NCLB and other metabolites: ~94%. Feces: 11% of dose; unchanged drug: 1%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1006269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/60/41924?source=see_link\">",
"      see \"Clobazam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; avoid other medications that can cause drowsiness. May be habit-forming; avoid abrupt discontinuation after prolonged use (withdrawal symptoms or an increase in seizure activity may occur). May cause dry mouth. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you have feelings of depression or thoughts of suicide or self harm. Report excessive drowsiness, CNS changes (eg, confusion, depression, headache) or changes in cognition; respiratory difficulty or shortness of breath; muscle tremors; visual disturbances; excessive GI symptoms (constipation, vomiting, anorexia); worsening of seizure activity, or loss of seizure control. Female patients of childbearing potential should be counseled to use alternative nonhormonal contraception during therapy and for 28 days following clobazam discontinuation.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Study Group for Childhood Epilepsy, \"Clobazam Has Equivalent Efficacy to Carbamazepine and Phenytoin as Monotherapy for Childhood Epilepsy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1998, 39(9):952-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/4/32839/abstract-text/9738674/pubmed\" id=\"9738674\" target=\"_blank\">",
"        9738674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montenegro MA, Arif H, Nahm EA, et al, \"Efficacy of Clobazam as Add-On Therapy for Refractory Epilepsy: Experience at a U.S. Epilepsy Center,\"",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 2008, 31(6):333-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/4/32839/abstract-text/19050410/pubmed\" id=\"19050410\" target=\"_blank\">",
"        19050410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng YT and Collins SD, \"Clobazam,\"",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2007, 4(1):138-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/4/32839/abstract-text/17199029/pubmed\" id=\"17199029\" target=\"_blank\">",
"        17199029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng YT, Conry JA, Drummond R, et al, \"Ranodmized, Phase III Study Results of Clobazam in Lennox-Gastaut Syndrome,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 77(15):1473-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/4/32839/abstract-text/21956725/pubmed\" id=\"21956725\" target=\"_blank\">",
"        21956725",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riss J, Cloyd J, Gates J, et al, \"Benzodiazepines in Epilepsy: Pharmacology and Pharmacokinetics,\"",
"      <i>",
"       Acta Neurol Scand",
"      </i>",
"      , 2008, 118(2):69-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/4/32839/abstract-text/18384456/pubmed\" id=\"18384456\" target=\"_blank\">",
"        18384456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83321 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32839=[""].join("\n");
var outline_f32_4_32839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13688779\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152592\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006224\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006259\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13688780\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15859539\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13689303\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13362239\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006265\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006247\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13689302\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152637\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006232\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7689404\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006233\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152626\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152562\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152576\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13761521\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006249\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13760898\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006251\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006269\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83321|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/49/40727?source=related_link\">",
"      Clobazam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/60/41924?source=related_link\">",
"      Clobazam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_4_32840="Hand and wrist anatomy palmar view";
var content_f32_4_32840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Hand and wrist anatomy palmar view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arterial anastomoses of the hand. The radial and ulnar arteries connect to each other through two loops: a superficial palmar arch and a deep palmar arch. This ensures adequate perfusion in the event of lacerations, which are common injuries to the fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Agur AM. Essential Clinical Anatomy, 3rd Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy;2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32840=[""].join("\n");
var outline_f32_4_32840=null;
var title_f32_4_32841="Natural history of hypertrophic cardiomyopathy";
var content_f32_4_32841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history of hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     Perry M Elliott, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32841/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/4/32841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"mobipreview.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the majority of patients with HCM, LVH is not progressive, and the clinical course is relatively benign. A small subset of patients, however, will progress to an end-stage form of the disease that is characterized by LV dilation, wall thinning, and systolic dysfunction. Such patients are managed according to the standard approach to patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of HCM will be reviewed here. Other issues such as the clinical manifestations, diagnosis and evaluation, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF HYPERTROPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36997658\">",
"    <span class=\"h2\">",
"     Hypertrophy and fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial HCM can present with cardiac hypertrophy in infancy and childhood, but this more typically develops during the pubertal growth spurt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/1\">",
"     1",
"    </a>",
"    ]. A pathologic study in asymptomatic children and young adults with HCM who died suddenly found that increased thickness of the septum was due both to hypertrophy and to an abnormal, disorganized, and thickened collagen matrix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/2\">",
"     2",
"    </a>",
"    ]. The increase in collagen may be mediated by angiotensin II, which is supported by an animal study of HCM in which increased interstitial fibrosis was attenuated by an angiotensin II receptor blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'Renin-angiotensin system polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early evidence of a profibrotic state was identified in a study of 38 subjects with pathogenic sarcomere mutations and overt HCM, 39 subjects with mutations but no left ventricular hypertrophy, and 30 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/4\">",
"     4",
"    </a>",
"    ]. The subjects were evaluated using echocardiography, cardiovascular magnetic resonance (CMR), and serum biomarkers of collagen metabolism. Levels of serum C-terminal propeptide of type I procollagen (PICP) were significantly higher in mutation carriers with and without left ventricular hypertrophy as compared to controls (69 and 31 percent higher, respectively). An elevated ratio of PICP to C-terminal telopeptide of type I collagen (reflecting collagen synthesis exceeding degradation) was observed only in subjects with overt hypertrophy. CMR demonstrated late gadolinium enhancement indicating focal fibrosis in 71 percent of subjects with overt hypertrophy but none in mutation carriers without left ventricular hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Cardiovascular magnetic resonance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Late onset disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most HCM disease expression develops during childhood and adolescence, late-onset disease is recognized and was first noted in patients with mutation in cardiac myosin binding protein-C. Most cross-sectional studies of families with mutations in the cardiac myosin binding protein-C gene, which account for approximately 15 percent of cases of familial HCM, have shown that the proportion of proven carriers of the mutation who have hypertrophy increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one cross-sectional study of 16 probands and 574 family members at risk, 58 percent of patients aged less than fifty years with a mutation in the cardiac myosin binding protein C gene had hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a later age at onset with cardiac myosin binding protein-C gene mutations has not been noted in all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H8#H8\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'Cardiac myosin binding protein-C gene'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H21#H21\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'HCM in the elderly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related disorder, idiopathic or \"inappropriate\" left ventricular hypertrophy in patients over age 60, is well described, but its etiology is not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. In a community-based cohort from the Framingham Heart Study, three percent had increased unexplained left ventricular wall thickness, 18 percent of whom had a sarcomeric contractile protein gene mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link&amp;anchor=H7#H7\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Obstructive HCM in elderly adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to familial early-onset HCM (which results from defects in the beta myosin heavy chain, cardiac troponin T, and alpha tropomyosin genes in more than 45 percent of cases), elderly-onset HCM is in some series associated with mutations in the cardiac myosin binding protein-C, troponin I, and alpha myosin heavy chain genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, the likelihood of identifying any mutation may be lower in late onset HCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sigmoid septal morphology is common particularly among older adults diagnosed with HCM (as well as in older adults without HCM). Among HCM patients, this morphologic subtype appears to be less commonly associated with a mutation than other morphologic variants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H21#H21\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'HCM in the elderly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with HCM, the excess death rate appears to vary with the age of the patient at diagnosis, with late onset disease being associated with a better overall prognosis. However, some mutations associated with late onset disease do not have a benign course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Relation to restrictive cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restrictive cardiomyopathy is characterized by restrictive filling and reduced diastolic volume of the left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricle despite normal or near-normal systolic function and wall thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/21\">",
"     21",
"    </a>",
"    ]. Primary forms are uncommon, while secondary forms usually present at the advanced stage of an infiltrative disease (sarcoidosis, amyloidosis) or a systemic storage disease (eg, hemochromatosis). Idiopathic restrictive cardiomyopathy is uncommon, and may be familial and present in children and young adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several observations suggest that idiopathic restrictive cardiomyopathy may be part of the spectrum of familial hypertrophic cardiomyopathy (HCM):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some cases of restrictive cardiomyopathy have extensive myocyte and myofibrillar disarray at explant or postmortem, findings similar to those seen in HCM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with primary restrictive cardiomyopathy have a family history of HCM, and mutations in sarcomeric contractile protein genes can lead to restrictive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertrophic cardiomyopathy within the same family [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency and clinical significance of this relationship was illustrated in 1226 patients from 688 consecutive HCM families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/22\">",
"     22",
"    </a>",
"    ]. A restrictive phenotype was seen in 19 patients (1.5 percent) and was associated with a relatively poor prognosis, with a 44 percent rate of death, heart transplantation, or implantable cardioverter-defibrillator discharge. Genotyping was feasible in 15 of 16 probands: mutations were found in eight, four in the beta-myosin heavy chain gene and four in the cardiac troponin I gene. A troponin I mutation has also been identified in six of nine unrelated individuals transplanted for idiopathic restrictive cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     End-stage HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients with HCM eventually progress to a stage with reduced systolic performance and left ventricular remodeling. In severe cases, there is relative left ventricular dilation and wall thinning, with extensive late enhancement on cardiac magnetic resonance imaging and an overall greater resemblance to the morphologic and functional features of dilated cardiomyopathy (",
"    <a class=\"graphic graphic_figure graphicRef81390 \" href=\"mobipreview.htm?7/27/7614\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/19,25-29\">",
"     19,25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This phase has been termed \"end-stage\" or \"burned out\" HCM. The mechanism is uncertain but diffuse myocardial ischemia due to microvascular dysfunction may be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/30\">",
"     30",
"    </a>",
"    ]. The degree of microvascular dysfunction is also an independent predictor of clinical deterioration and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of progression to a dilated, hypokinetic phenotype was evaluated in a series of 222 patients with HCM who were prospectively followed for a mean of 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eleven patients (5 percent) had a dilated, hypokinetic phenotype at initial evaluation. These patients had a left ventricular ejection fraction (LVEF) of 32 percent compared to 66 percent in those with classic HCM.",
"     </li>",
"     <li>",
"      Among the 210 patients with classic HCM at initial evaluation, 12 (5.7 percent) underwent a dilated, hypokinetic evolution, characterized in part by a fall in LVEF from 67 percent at initial evaluation to 35 percent at last evaluation. The rate of deterioration was about 0.5 percent per year. These patients, compared to those with HCM and preserved left ventricular function, were younger and more likely to have had a family history of HCM (61 versus 26 percent) or sudden death (43 versus 19 percent) and had a greater wall thickness at presentation. During follow-up, they had a significantly lower rate of cardiovascular death-free survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progressive wall thinning may be more common in patients with initially severe hypertrophy. In a series of 106 patients with initial wall thickness &ge;30 mm, more than 5 mm of wall thinning was seen in 41 of the 71 patients who underwent serial assessment (58 percent); the duration of follow-up was a significant predictor of thinning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/28\">",
"     28",
"    </a>",
"    ]. Development of left ventricular dilatation and impaired systolic function resembling dilated cardiomyopathy with progressive wall thinning also may be more common with certain gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of end-stage HCM were further evaluated in a retrospective analysis combining three cohorts that included a total of 1259 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/29\">",
"     29",
"    </a>",
"    ]. End-stage HCM was defined as an LVEF &lt;50 percent. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      44 patients (3.5 percent) were classified as end-stage. Of these, 11 were diagnosed at study entry and 33 during follow-up, with an annual incidence of 1.1 cases per 100 person-years. The mean age at diagnosis of end-stage was 45 years, but there was a very wide range (14 to 74 years).",
"     </li>",
"     <li>",
"      In patients with LVEF &lt;50 percent, left ventricular remodeling and cavity dilation were common (52 percent).",
"     </li>",
"     <li>",
"      The average duration from the onset of HCM symptoms to end-stage HCM was 14 years.",
"     </li>",
"     <li>",
"      Once end-stage HCM developed, further deterioration was rapid, and 66 percent of patients progressed to death from progressive heart failure, sudden cardiac death, or transplantation over a mean of 2.7 years. Sudden cardiac death occurred at a rate of 11 percent per year and, among patients awaiting transplant, the incidence of appropriate ICD shocks was 10 percent per year.",
"     </li>",
"     <li>",
"      At the time of initial evaluation, predictors of eventual development of end-stage HCM included younger age, more severe symptoms, larger LV cavities, and a family history of end-stage HCM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors suggested that although uncommon, the transition to end-stage HCM represents an ominous change. Early detection of LV dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dilation should prompt consideration of more aggressive interventions, including standard drug treatment for systolic heart failure (eg, ACE inhibitors). Heart transplantation is appropriate in patients with severe drug refractory symptoms. The efficacy and most appropriate timing of prophylactic ICD implantation remains to be determined in those with advanced LV dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Related disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of familial HCM that have been described involve mutations in proteins that encode components of the contractile apparatus. However, HCM has also been described in association with mutations in genes related to carbohydrate metabolism, PRKAG2 and LAMP2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Although these disorders share some of the clinical characteristics of classical HCM, they also have some unique features. Progressive conduction system disease requiring pacemaker implantation is common with PRKAG2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/32\">",
"     32",
"    </a>",
"    ], while progression to end-stage HF in early adulthood is common in males (X-linked) with LAMP2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of these disorders are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'PRKAG2 and LAMP2 genes and WPW syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43315?source=see_link\">",
"     \"Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 25 percent of Noonan patients have HCM, while Fabry disease may also mimic HCM. Screening for Fabry disease among patients with suspected HCM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with HCM have no or only minor symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, affected children and adolescents are often diagnosed during family screening. Patients who are asymptomatic, or have only minor symptoms, have a better prognosis than those with more severe symptoms. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with mild to moderate limitation usually experience slow progression of symptoms with advancing age, in association with a modest deterioration in left ventricular function. Typical symptoms include dyspnea, chest pain, syncope, and palpitations. An in-depth discussion of the clinical manifestations of HCM is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small group of patients with HCM has severe \"restrictive\" physiology. In these patients, signs of right heart failure may be prominent with elevated jugular venous pressure, liver congestion, ascites, and peripheral edema. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Relation to restrictive cardiomyopathy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DISEASE-RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major disease-related complications of HCM are death, heart failure, arrhythmias, stroke, heart block, and infective endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In series published in the 1980s, the annual mortality of HCM in referral center populations, which usually included symptomatic patients, was approximately 2 percent in adults, and 4 to 6 percent during childhood and adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. However, lower annual mortality rates (approximately 1 to 1.3 percent) and sudden death rates (0.7 percent) have been observed in more recent series and in outpatient-based adult populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/34,41-45\">",
"     34,41-45",
"    </a>",
"    ]. In a report from a referral population of 312 patients, 73 (23 percent) lived at least 75 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most comprehensive contemporary data comes from a review of 956 adults (mean age 42) seen between 1988 and 2002; the outcomes were compared with those in natural history studies published between 1960 and 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/47\">",
"     47",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual rates of heart failure death or transplantation and stroke-related deaths were 0.55 and 0.07 percent, respectively.",
"     </li>",
"     <li>",
"      Published sudden death rates over the last 10 years of the study were lower than in previously published reports (median 1 versus 2 percent).",
"     </li>",
"     <li>",
"      The more recent studies were larger and included less severely affected patients as manifested by fewer patients with NYHA class III or IV heart failure (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) and fewer patients who underwent septal myectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major causes of death in HCM are sudden cardiac death (SCD), heart failure, and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. In a review of 744 consecutive and largely unselected patients, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCM-related death occurred in 12 percent over a mean follow-up of eight years; 51 percent of deaths were sudden, 36 percent were due to progressive heart failure, and 13 percent were due to stroke associated with atrial fibrillation.",
"     </li>",
"     <li>",
"      Sudden death was most common in young patients, while death from heart failure or stroke occurred more frequently in midlife and beyond. However, neither sudden death nor heart failure-related death had any clear predilection for any particular age group. Stroke occurred primarily in older patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients who died suddenly, 71 percent had no or mild symptoms, and only 16 percent were engaged in moderate to vigorous physical activity at the time of death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, patients with HCM have an increased risk of death from several causes (SCD, heart failure, and stroke). The following discussion will review factors associated with overall mortality in HCM patients. Because of their potential impact on the decision to implant a cardioverter-defibrillator, risk factors have also been evaluated for their specific association with SCD. This issue discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link&amp;anchor=H11#H11\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Identifying high-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14438794\">",
"    <span class=\"h4\">",
"     Age at diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excess death rate appears to vary with the age of the patient at diagnosis. This was illustrated in a review of 277 outpatients who were followed for eight years; the mean age of death from HCM was 56 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/34\">",
"     34",
"    </a>",
"    ]. The annual mortality compared to the general population was substantially increased in those identified during childhood (1.3 versus 0.08 percent) but not in those identified in adulthood (2.2 versus 1.9 percent).",
"   </p>",
"   <p>",
"    Similar data on survival in adults were noted in a series from the Mayo Clinic in which 37 patients with HCM and a mean age of 59 years had one and five year survival rates (95 and 92 percent) that did not differ from an age and sex matched population without HCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/43\">",
"     43",
"    </a>",
"    ]. However, some mutations associated with late onset disease do not have a benign course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Late onset disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14438801\">",
"    <span class=\"h4\">",
"     Symptom status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of symptoms in patients with HCM is associated with worse outcomes compared to asymptomatic patients with HCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/34,46,48-50\">",
"     34,46,48-50",
"    </a>",
"    ]. In the above report of 277 outpatients, 90 percent were asymptomatic at presentation; during the eight year follow-up, 69 percent remained asymptomatic or had only mild symptoms, while 25 percent had incapacitating symptoms or died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/34\">",
"     34",
"    </a>",
"    ]. Factors that increased the likelihood of HCM-related death included advanced symptoms at diagnosis; other adverse risk factors were atrial fibrillation associated with an embolic stroke, basal outflow obstruction &ge;30 mmHg, and marked left ventricular hypertrophy &gt;25 mm.",
"   </p>",
"   <p>",
"    Similar findings were noted in a series of 128 adults with HCM who were followed for 9 to 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/48\">",
"     48",
"    </a>",
"    ]. The 58 patients who were asymptomatic at presentation had a lower annual cardiac mortality than those with symptoms (0.9 versus 1.9 percent) that was entirely due to a lower annual rate of sudden death (0.1 versus 1.4 percent) (",
"    <a class=\"graphic graphic_figure graphicRef66790 \" href=\"mobipreview.htm?6/38/6766\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Not surprisingly, the mortality risk is markedly increased in patients who develop severe symptoms (NYHA class III or IV), (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Heart failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14438808\">",
"    <span class=\"h4\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the presence of symptoms, significant left ventricular outflow tract (LVOT) obstruction at rest is an independent predictor of poor prognosis in patients with HCM. In a multicenter study of 1101 patients with HCM, 273 (25 percent) had LVOT obstruction at rest with a peak gradient &ge;30 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/49\">",
"     49",
"    </a>",
"    ]. At a mean follow-up of six years, 127 patients (12 percent) died, and 216 surviving patients (20 percent) had progression to NYHA class III or IV heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). After adjusting for age, gender, heart failure at entry, presence of atrial fibrillation, and LV wall thickness &ge;30 mm, patients with LVOT obstruction had a higher rate of HCM-related mortality (relative risk 1.6, 95% CI 1.1-2.4).",
"   </p>",
"   <p>",
"    A subsequent report of 526 consecutive patients with HCM, 141 of whom (27 percent) had LVOT obstruction, noted that the prognostic value of LVOT obstruction varied with the severity of symptoms during mean follow-up of 4.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/50\">",
"     50",
"    </a>",
"    ]. At initial evaluation, LVOT obstruction was a significant predictor of mortality among patients with no or mild symptoms at presentation (adjusted hazard ratio 2.4). However, after the onset of severe symptoms, NYHA functional class becomes the dominant marker of prognosis, independent of the LVOT gradient.",
"   </p>",
"   <p>",
"    Pharmacologic therapy (eg, beta blockers) can improve symptoms due to LVOT obstruction. Nonpharmacologic approaches (eg, surgical myectomy and nonsurgical septal ablation) are warranted in patients with moderate to severe symptoms or exercise limitation despite maximum tolerated drug therapy. Interpretation of the impact of the LVOT gradient on mortality is confounded by variable approaches to treatment and the absence of efficacy data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14438817\">",
"    <span class=\"h4\">",
"     Coronary disease and stress-induced ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effect of coronary artery disease (CAD) on prognosis in HCM was illustrated in a study of 433 adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/51\">",
"     51",
"    </a>",
"    ]. Severe CAD was defined as the presence of a single luminal stenosis of &ge;50 percent in the left main coronary artery, &ge;70 percent in other major epicardial branches, or two stenoses of &ge;50 percent. Ten-year overall survival was 46 percent, 71 percent, and 77 percent for patients with severe, mild-to-moderate, and no coronary artery disease, respectively. The risk of death with severe CAD and HCM far exceeds historical death rates of CAD patients with normal left ventricular function (e.g. 12 year survival of 73 percent in the CASS registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/52\">",
"     52",
"    </a>",
"    ]). In addition, the presence of coexistent CAD in patients who died suddenly without HCM risk factors suggests that this particular comorbidity is prognostically important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In HCM, exercise testing provides an objective measure of the patient's physical limitations and exercise stress testing can detect important abnormalities such as arrhythmia, exercise-induced hypotension, or ischemia. Marked (&gt;5mm) ST segment depression may reflect obstructive epicardial CAD or microvascular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Exercise testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress-induced ischemia is associated with an increased risk of cardiac events and perhaps reduced survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. If often occurs in the absence of significant angiographic CAD in patients with HCM and may reflect coronary microvascular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/30,31,57\">",
"     30,31,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 158 older HCM patients (age 18 to 88) who were referred for stress testing with nuclear imaging, the nuclear images were abnormal (with fixed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reversible defects) in 62 percent of patients and, of 47 patients who underwent coronary angiography after rMPI, only 10 had significant CAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/54\">",
"     54",
"    </a>",
"    ]. Ten-year survival was significantly lower in those with abnormal (with fixed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reversible defects) SPECT images (67 versus 90 percent with a normal test) and in those with reversible defects (64 versus 90 percent without reversible defects).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression to NYHA class III or IV heart failure (HF) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) occurs in a minority of patients with HCM. Such progression is more common in patients with significant outflow tract obstruction and perhaps with certain gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/19,49,50\">",
"     19,49,50",
"    </a>",
"    ]. Treatment of patients with HF and obstruction with surgical myectomy, but not medical therapy, appears to be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that mortality in HCM is due to progressive HF in approximately one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/44\">",
"     44",
"    </a>",
"    ]. Some patients develop a clinical picture similar to a dilated cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Mortality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'End-stage HCM'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Alternative diagnoses should always be considered when left ventricular systolic dysfunction is seen together with significant hypertrophy. Amyloid cardiomyopathy and primary metabolic disorders such as Fabry disease, glycogen storage disease, and mitochondrial disease may present with these findings. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Related disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progression to severe HF symptoms is associated with a marked increase in cardiovascular mortality. In different observational studies, patients with obstruction had a higher rate of progression to NYHA class III or IV or death from HF or stroke (relative risk 2.7, 95% CI 2.0-3.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/49\">",
"     49",
"    </a>",
"    ] and patients who had progressed to NYHA class III or IV had an eight-fold increase in cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment in these patients is the same as for any patient with systolic dysfunction, although there are no long-term data on the efficacy of angiotensin converting enzyme inhibitors or other vasodilators in heart failure associated with HCM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCM is associated with an age-related increase in the prevalence of all arrhythmias, except for arrhythmic sudden cardiac death which is more common in younger subjects (",
"    <a class=\"graphic graphic_figure graphicRef56594 \" href=\"mobipreview.htm?27/46/28397\">",
"     figure 4",
"    </a>",
"    ). This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke and systemic embolic events are known complications of HCM, but there are few data about frequency and predictors of occurrence. These issues were examined in a community-based cohort of 900 patients followed for 7.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/60\">",
"     60",
"    </a>",
"    ]. The prevalence rate of stroke or peripheral embolization was 6 percent (incidence 0.8 percent per year); 41 percent of patients with a stroke died or were permanently disabled. Most of the events (72 percent) occurred in patients over age 50 and, in those over age 60, the incidence was 1.9 percent per year. With a multivariate analysis, embolic events were also associated with atrial fibrillation, which was present in 88 percent of those who had a stroke, and congestive symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small number of families, HCM cosegregates with familial conduction system disease (eg, associated with PRKAG2 and LAMP2 mutations). Among patients with HCM who do not have familial heart block, abnormal atrioventricular nodal or His-Purkinje conduction is relatively common during electrophysiological testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/61\">",
"     61",
"    </a>",
"    ]. The incidence of clinically significant conduction block in HCM is unknown but appears to be low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'PRKAG2 and LAMP2 genes and WPW syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of patients with HCM have an outflow tract gradient at rest caused by anterior movement of the anterior or posterior leaflet of the mitral valve. The mitral valve itself is frequently abnormal with elongation of the anterior and sometimes the posterior leaflets. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis was recommended in the past in HCM patients with outflow gradients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral valve abnormalities. However, the 2007 AHA guideline for the prevention of infective endocarditis made major revisions, including the recommendation that prophylaxis is NOT indicated in patients with hypertrophic cardiomyopathy with latent or resting obstruction or mitral valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis may contribute to clinical deterioration in some patients with HCM. This was illustrated in a series of 119 HCM patients who underwent myocardial biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32841/abstract/63\">",
"     63",
"    </a>",
"    ]. Among these patients, 77 were clinically stable and 42 had experienced acute clinical deterioration, defined as either progressive heart failure or recurrent sustained ventricular arrhythmias.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphocyte infiltration and necrosis, consistent with myocarditis, were present in 28 of 42 unstable patients, but in none of the 77 stable patients.",
"     </li>",
"     <li>",
"      Biopsy specimens from all 119 patients were screened for viral genomes, which were found in 14 of the 28 unstable patients with evidence of myocarditis, and in none of the other 91.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings require confirmation and further investigation to clarify the potential significance of myocarditis as a contributing factor in the clinical deterioration of HCM patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/24/36226?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161839\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phenotypic expression of hypertrophic cardiomyopathy (HCM) usually occurs during childhood and adolescence, typically during the pubertal growth spurt. However, HCM sometimes manifests in infancy and early childhood, and late-onset disease has been recognized. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Development of hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small proportion of patients with HCM (5 to 10 percent) eventually progress to a stage with reduced systolic performance and left ventricular remodeling. In severe cases, there is relative left ventricular dilation and wall thinning, with greater resemblance to the morphologic and functional features of dilated cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'End-stage HCM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The annual mortality of patients with HCM in referral center populations is on the order of one percent, with the major causes of death being sudden cardiac death (SCD), heart failure, and stroke. SCD is more common in young patients, while death from heart failure or stroke is more common in older patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progression to NYHA class III or IV heart failure (HF) occurs in a minority of patients with HCM. Such progression is more common in patients with significant LVOT obstruction and perhaps with certain gene mutations. Progression to severe HF symptoms is associated with a marked increase in cardiovascular mortality. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCM is associated with an age-related increase in the prevalence of all arrhythmias, except for arrhythmic sudden cardiac death, which is more common in younger subjects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=see_link\">",
"       \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strokes due to systemic embolization, heart block, infective endocarditis, and myocarditis are all potential complications of HCM. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Disease-related complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/1\">",
"      Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/2\">",
"      Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/3\">",
"      Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/4\">",
"      Ho CY, L&oacute;pez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010; 363:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/5\">",
"      Charron P, Dubourg O, Desnos M, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998; 97:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/6\">",
"      Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/7\">",
"      Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/8\">",
"      Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/9\">",
"      Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/10\">",
"      Van Driest SL, Ommen SR, Tajik AJ, et al. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/11\">",
"      Whiting RB, Powell WJ Jr, Dinsmore RE, Sanders CA. Idiopathic hypertrophic subaortic stenosis in the elderly. N Engl J Med 1971; 285:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/12\">",
"      Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985; 312:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/13\">",
"      Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 1989; 79:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/14\">",
"      Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/15\">",
"      Lewis JF, Maron BJ. Clinical and morphologic expression of hypertrophic cardiomyopathy in patients &gt; or = 65 years of age. Am J Cardiol 1994; 73:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/16\">",
"      Chikamori T, Doi YL, Yonezawa Y, et al. Comparison of clinical features in patients greater than or equal to 60 years of age to those less than or equal to 40 years of age with hypertrophic cardiomyopathy. Am J Cardiol 1990; 66:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/17\">",
"      Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/18\">",
"      Van Driest SL, Ommen SR, Tajik AJ, et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/19\">",
"      Kubo T, Kitaoka H, Okawa M, et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese. J Am Coll Cardiol 2005; 46:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/20\">",
"      Moolman JA, Reith S, Uhl K, et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000; 101:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/21\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/22\">",
"      Kubo T, Gimeno JR, Bahl A, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007; 49:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/23\">",
"      Angelini A, Calzolari V, Thiene G, et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am J Cardiol 1997; 80:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/24\">",
"      Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003; 111:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/25\">",
"      Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/26\">",
"      Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/27\">",
"      Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005; 46:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/28\">",
"      Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 2004; 44:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/29\">",
"      Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/30\">",
"      Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006; 47:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/31\">",
"      Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/32\">",
"      Murphy RT, Mogensen J, McGarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005; 45:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/33\">",
"      Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/34\">",
"      Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/35\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/36\">",
"      McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/37\">",
"      McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/38\">",
"      McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984; 59:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/39\">",
"      Romeo F, Pelliccia F, Cristofani R, et al. Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant? Eur Heart J 1990; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/40\">",
"      Loogen F, Kuhn H, Gietzen F, et al. Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983; 4 Suppl F:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/41\">",
"      Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/42\">",
"      Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/43\">",
"      Cannan CR, Reeder GS, Bailey KR, et al. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995; 92:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/44\">",
"      Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/45\">",
"      Ho HH, Lee KL, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med 2004; 116:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/46\">",
"      Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003; 42:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/47\">",
"      Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/48\">",
"      Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/49\">",
"      Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/50\">",
"      Autore C, Bernab&ograve; P, Barill&agrave; CS, et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/51\">",
"      Sorajja P, Ommen SR, Nishimura RA, et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003; 108:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/52\">",
"      Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994; 90:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/53\">",
"      Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/54\">",
"      Sorajja P, Chareonthaitawee P, Ommen SR, et al. Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. Am Heart J 2006; 151:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/55\">",
"      Lazzeroni E, Picano E, Morozzi L, et al. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Circulation 1997; 96:4268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/56\">",
"      Yamada M, Elliott PM, Kaski JC, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur Heart J 1998; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/57\">",
"      Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (\"small vessel\") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/58\">",
"      Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/59\">",
"      Watkins H, McKenna WJ. The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/60\">",
"      Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/61\">",
"      Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80:1259.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32841/abstract/63\">",
"      Frustaci A, Verardo R, Caldarulo M, et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J 2007; 28:733.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4916 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32841=[""].join("\n");
var outline_f32_4_32841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1161839\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEVELOPMENT OF HYPERTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36997658\">",
"      Hypertrophy and fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Late onset disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Relation to restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      End-stage HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DISEASE-RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14438794\">",
"      Age at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14438801\">",
"      Symptom status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14438808\">",
"      Obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14438817\">",
"      Coronary disease and stress-induced ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1161839\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4916|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/27/7614\" title=\"figure 2\">",
"      Pathogenesis end stage HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/38/6766\" title=\"figure 3\">",
"      Relationship between symptom status and survival in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/46/28397\" title=\"figure 4\">",
"      Relationship between age and arrhythmias in HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43315?source=related_link\">",
"      Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/24/36226?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_4_32842="Treatment of urinary incontinence";
var content_f32_4_32842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of urinary incontinence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Catherine E DuBeau, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/4/32842/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/4/32842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence, the involuntary leakage of urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/1\">",
"     1",
"    </a>",
"    ], often goes undetected by clinicians. Even when aware of incontinence, clinicians often undertreat. In one survey, only 60 percent of patients seeking care for leakage (at least once weekly) recalled receiving any treatment for their incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/2\">",
"     2",
"    </a>",
"    ]. Additionally, nearly 50 percent of those who did receive treatment reported moderate to great frustration with ongoing urinary leakage.",
"   </p>",
"   <p>",
"    A multicomponent stepped approach focused on the patient's most bothersome aspects of urinary incontinence is the key to successful therapy. Treatment aimed at simply decreasing the number of incontinent episodes (the focus of the majority of treatment trials) may not be sufficient to improve the quality of life for patients most bothered by the timing or inconvenience of urinary incontinence, nocturia, or leakage with exercise.",
"   </p>",
"   <p>",
"    Stepwise treatment strategies should be discussed with the patient. In general, treatment should advance from least invasive (lifestyle changes, behavioral therapies, medications) to more invasive therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/3\">",
"     3",
"    </a>",
"    ]. In older patients, correcting contributory factors such as comorbid conditions, functional impairment, and medications should be the initial focus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various therapies, most notably bladder training and pelvic muscle exercise, are effective for several types of urinary incontinence, including urge incontinence, stress incontinence, and mixed incontinence (coexistence of urge and stress incontinence), as well as overactive bladder.",
"   </p>",
"   <p>",
"    This topic will discuss the treatment of urinary incontinence, primarily in women. Urinary incontinence in men, as well as the epidemiology, pathogenesis, and diagnosis of urinary incontinence in women, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41737?source=see_link\">",
"     \"Urinary incontinence in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7192?source=see_link\">",
"     \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used measure of urinary incontinence (UI) treatment efficacy is a reduction in urinary incontinence episodes, variably measured as the reduction in mean number of daily episodes, percent reduction from baseline, or reduction in leakage volume. Cure is usually defined as complete absence of urinary incontinence; most drug trials have defined \"cure\" as an absence of incontinence over a limited number of days (eg, 3 to 7 days). Other outcome measures frequently used are urinary frequency (total number of daytime and nighttime voids), bladder capacity (or mean voided volume), and, for urge incontinence, frequency of urgency symptoms (with or without leakage).",
"   </p>",
"   <p>",
"    However, these measures may not reflect the patient's perception of improvement or the effect of treatment on the patients' quality of life. Patient-based outcomes used in most clinical trials include general satisfaction questions, patient perception of improvement of their bladder condition, and urinary incontinence-specific quality of life measures (",
"    <a class=\"graphic graphic_table graphicRef71639 \" href=\"mobipreview.htm?13/46/14060\">",
"     table 1",
"    </a>",
"    ). General health-related quality of life measures (such as the Medical Outcomes Study Short Form-36) largely have proved insensitive to changes in urinary incontinence after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment efficacy reported in clinical trials should be considered in light of the natural history of urinary incontinence symptoms and placebo response rates. Remission rates for urine leakage in women range from 0 to 13 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/6\">",
"     6",
"    </a>",
"    ]. Remission may be due to the changes in fluid intake, voiding habits and activity levels, treatment of comorbid conditions, and changes in medications. Control arms in randomized trials of urinary incontinence treatment consistently demonstrate high placebo response rates of 30 to 40 percent or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cost-effectiveness analyses of urge incontinence therapy have overwhelmingly focused on pharmacological treatment (mainly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    ). Overall, medical therapy appears cost-effective although results vary due to different cost assumptions and heterogeneity of the analytic methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/8\">",
"     8",
"    </a>",
"    ]. There are too few cost effectiveness analyses of incontinence treatment in nursing homes to draw conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIFESTYLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addressing lifestyle factors may be helpful in managing incontinence. However, except for weight loss, most recommendations have not been well-studied. Common sense strategies include: adequate, but not excessive fluid intake (up to two liters per day); avoidance of caffeinated beverages and alcohol; minimizing evening fluid intake for nocturnal incontinence; weight reduction for overweight individuals; and smoking cessation (in persons with stress or stress-predominant mixed incontinence).",
"   </p>",
"   <p>",
"    In one randomized trial of 112 nursing home residents, those randomly assigned to a multicomponent intervention were found to have lower rates of urinary incontinence compared to those randomly assigned to usual care over three month follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/9\">",
"     9",
"    </a>",
"    ]. The multicomponent intervention was comprised of trained research staff offering toileting assistance, food and fluid snacks every two hours for eight hours, and prompted exercise. Data suggest that there may have been differences in baseline characteristics of the control and intervention groups that could affect the study results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that weight loss can decrease episodes of stress urinary incontinence in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 338 overweight and obese women (average age 53 years, mean BMI 36",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      with urinary incontinence compared an intensive 6 month weight loss program (intervention group) with a structured education program (control group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/10\">",
"       10",
"      </a>",
"      ]. Incontinence was measured by self-recorded 7 day voiding diaries. Mean weight loss was 8 percent (7.8 kg) and 1.6 percent (1.5 kg) in the intervention and control groups, respectively. Weekly incontinence episodes decreased by 47 and 28 percent in the intervention and control groups respectively, driven by a significant decrease in stress, but not urge, incontinence in the intervention compared to control group.",
"     </li>",
"     <li>",
"      Lifestyle changes involving weight loss and increased physical activity lowered the prevalence of weekly urinary incontinence for women in the Diabetes Prevention Program trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/11\">",
"       11",
"      </a>",
"      ]. Women (n = 1957, average age 50 years, BMI 35",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      and waist circumference 104 cm) were randomly assigned to lifestyle intervention, metformin therapy, or placebo. Weight loss at three year follow-up was -3.4 kg, -1.5 kg, and +0.5 kg, respectively. The women in the lifestyle group had significantly lower odds of weekly urinary incontinence compared to women in the placebo group (OR 0.76, 95% CI 0.61-0.95), attributable to a decrease in stress incontinence, which was, in turn, almost entirely attributable to weight loss. A limitation of this study is that baseline incontinence status was not determined.",
"     </li>",
"     <li>",
"      In another study of women with diabetes and incontinence, moderate weight loss decreased the incidence of incontinence at one year follow-up but did not affect the resolution of weekly incontinence in women who were incontinent at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/13\">",
"       13",
"      </a>",
"      ]. There was a decrease in the prevalence of stress, but not urge, incontinence at one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dietary changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some foods and beverages are thought to contribute to bladder leakage. While this has not been rigorously evaluated, it is reasonable to see if eliminating one or all of these items is helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholic beverages",
"     </li>",
"     <li>",
"      Carbonated beverages (with or without caffeine)",
"     </li>",
"     <li>",
"      Coffee or tea (with or without caffeine)",
"     </li>",
"     <li>",
"      Other food groups mentioned in the literature but without supporting evidence include: citrus juice and fruits, tomatoes and tomato-based products, spicy foods, artificial sweetener, chocolate, corn syrup, sugar or honey",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BEHAVIORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral treatments are effective for urge, stress, and mixed urinary incontinence; should be the initial treatment for patients with mild to moderate leakage; and are an option for patients with more severe symptoms. Behavioral treatments include bladder training and pelvic muscle exercises (PME), which are often used in combination.",
"   </p>",
"   <p>",
"    Behavioral methods can be at least as effective as drug therapy for urge incontinence (",
"    <a class=\"graphic graphic_table graphicRef76810 \" href=\"mobipreview.htm?17/29/17885\">",
"     table 2",
"    </a>",
"    ). In one trial of older women with urge and mixed urinary incontinence, behavioral therapy with biofeedback reduced accidents by 81 percent, compared with 69 percent for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bladder training",
"    </span>",
"    &nbsp;&mdash;&nbsp;This method is used for urge and mixed incontinence and is based upon two general principles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent voluntary voiding to keep the bladder volume low",
"     </li>",
"     <li>",
"      Training of central nervous system and pelvic mechanisms to inhibit urgency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial frequency of the timed voluntary voiding is based upon the smallest time interval between voids, as obtained from a bladder diary, or can be started empirically at every two hours. Timed voiding is done only while the patient is awake.",
"   </p>",
"   <p>",
"    Intervening urgency is suppressed using relaxation techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients are instructed to stand still or sit down when urgency occurs, concentrate on making urgency decrease by taking a deep breath and letting it out slowly, contracting their pelvic muscles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visualizing the urge as a \"wave\" that peaks and then falls. Once they feel in control of the urgency, they should walk slowly to a bathroom and void. When the patient can go two days without leakage, the time between scheduled voids is increased by 30 to 60 minutes, and this process is continued until the patient is voiding every three to four hours without urinary incontinence. A sample patient bladder training instruction sheet is shown (",
"    <a class=\"graphic graphic_table graphicRef71150 \" href=\"mobipreview.htm?40/19/41275\">",
"     table 3",
"    </a>",
"    ). Successful bladder training takes several weeks. Patients need reassurance to proceed despite initial lack of response.",
"   </p>",
"   <p>",
"    A systematic review concluded that while bladder training may be helpful for urge incontinence, it is not possible to be definitive about its benefits as sole or supplemental treatment compared with other approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/16\">",
"     16",
"    </a>",
"    ]. Most patients in the trials were women.",
"   </p>",
"   <p>",
"    Bladder retraining is unlikely to be effective in persons with cognitive impairment. Alternative behavioral methods for these patients are discussed separately. (See",
"    <a class=\"local\" href=\"#H5238194\">",
"     'Cognitive impairment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pelvic muscle exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic muscle (Kegel) exercises (PME) are used for urge, stress, and mixed incontinence. PME strengthen the muscular components of the urethral closure mechanism and are based on principles of strength training (eg, small numbers of isometric contractions at maximal exertion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/17\">",
"     17",
"    </a>",
"    ]. The basic recommended regimen is three sets of 8 to 12 slow velocity contractions sustained for six to eight seconds each, performed three or four times a week and continued for at least 15 to 20 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=see_link\">",
"     \"Patient information: Pelvic floor muscle exercises (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PME are effective for prevention of pregnancy-related urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/19\">",
"     19",
"    </a>",
"    ], as well as for treatment of urge, stress, and mixed urinary incontinence. There is considerable misinformation about how to perform these exercises, such as instructions to interrupt urination on a regular basis or to do exercises \"one hundred times per day.\" These approaches are unphysiologic and will likely fail. Patients who report no improvement with previous Kegel exercises may have used inadequate methods. PME are most effective with specific instruction and monitoring by health professionals and diligent performance by motivated patients. However, it remains unclear which approach to PME is most effective for alleviating symptoms of urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of controlled trials of PME have found that women treated with PME were more likely to report improvement or cure than control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], with approximately one less incontinence episode per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/22\">",
"     22",
"    </a>",
"    ]. In general, greater efficacy was seen in younger women (age 40 to 60) with stress incontinence treated for at least three months, although significant differences in trial design, populations, and methods preclude definitive conclusions",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Biofeedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback as supplement to bladder training or PME may be helpful for some patients. Although biofeedback is helpful in improving urinary incontinence in women, randomized studies have shown their effects comparable to self-help booklets and verbal feedback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biofeedback sessions may include vaginal or anorectal biofeedback to help patients identify and selectively contract pelvic muscles, and how to respond to the sensation of urgency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/14\">",
"     14",
"    </a>",
"    ]. Biofeedback is covered by Medicare for patients who fail an initial four week trial of behavioral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Weighted vaginal cones",
"    </span>",
"    &nbsp;&mdash;&nbsp;PME training can be supplemented by the use of weighted vaginal cones, which a patient inserts in her vagina and uses pelvic muscle contractions to hold in place during activity. Small trials in younger women show efficacy compared with no treatment, but it is unclear whether outcomes are comparable to other behavioral therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment is widely used for urge and mixed incontinence if behavioral therapy alone is unsuccessful. There are fewer agents available for stress incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antimuscarinics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic drugs with antimuscarinic effects are the most frequently prescribed medications for urge incontinence. These medications are thought to act primarily by increasing bladder capacity and decreasing urgency, and not decreasing involuntary detrusor contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/26\">",
"     26",
"    </a>",
"    ]. Systematic reviews found that treatment with these agents are superior to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/7,27\">",
"     7,27",
"    </a>",
"    ]. One systematic review found a 40 percent higher rate of cure or improvement and an absolute decrease of 0.6 in both incontinent episodes and voids per 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/27\">",
"     27",
"    </a>",
"    ]. Another systematic review of 94 randomized trials in women with urge incontinence found that continence was achieved in 8.5 to 13.0 percent of women treated with one of five antimuscarinic agents, with only slight variation in response between agents, but that rates of treatment discontinuation due to adverse effects were 1.3 to 6.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/28\">",
"     28",
"    </a>",
"    ]. The absolute risk difference in continence, comparing drug and placebo, was less than 20 percent for all drugs. However, the evidence regarding impact on quality of life was felt to be &ldquo;insufficient,&rdquo; and it is to be noted that even partial improvement in continence can impact quality of life. This review was performed in preparation for the development of a practice guideline by the American College of Physicians.",
"   </p>",
"   <p>",
"    Antimuscarinic agents may also be tried in elderly patients with detrusor hyperactivity with impaired contractility (DHIC, the combination of detrusor overactivity and impaired detrusor contractile function), with monitoring for an increase in postvoid residual. However, there are no data regarding the efficacy and safety of antimuscarinic drugs in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute benefit over placebo was small, in part because patients who received placebo also tended to do well. This may be due to concomitant bladder training in some of the studies, or training effects from completion of multiple bladder diaries during a trial.",
"   </p>",
"   <p>",
"    Multiple drug trials indicate that antimuscarinic efficacy increases for up to four weeks, suggesting that clinicians should avoid escalating the dose, or abandoning therapy, too soon.",
"   </p>",
"   <p>",
"    Several studies have found that the actual clinical duration of antimuscarinic therapy is short. As an example, in a study of 29,000 women who were prescribed anticholinergic therapy for urinary symptoms, 58 to 71 percent had discontinued medication by six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/29\">",
"     29",
"    </a>",
"    ]. Discontinuation rates for extended-release agents were slightly lower compared to short-acting agents. Reasons for discontinuation were not evaluated, but could include lack of efficacy, adverse effects, incorrect diagnosis, and intervening comorbidity.",
"   </p>",
"   <p>",
"    A systematic review of 86 randomized trials and meta-analysis of 70 trials in patients with overactive bladder symptoms compared differing doses and formulations of four anticholinergic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/30\">",
"     30",
"    </a>",
"    ]. Quality of many of these trials was only fair, 40 percent were industry-supported, and a relatively-low number of studies were available for specific comparison. Findings were that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    was better tolerated than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    , although efficacy was similar, and extended-release formulations of these agents were better tolerated than immediate release.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/53/28501?source=see_link\">",
"     Fesoterodine",
"    </a>",
"    had better efficacy than extended-release tolterodine but caused more dry mouth leading to drug withdrawal.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/33/39445?source=see_link\">",
"     Solifenacin",
"    </a>",
"    was more effective and better tolerated than immediate-release tolterodine. Data were not available for other comparisons. There were incomplete data to make conclusions about comparative costs, long-term outcomes, or the impact on quality of life.",
"   </p>",
"   <p>",
"    The choice of agent for an individual patient depends on cost, dosing frequency, drug-drug interactions, potential side effects, and comorbid conditions that may increase adverse drug effects. A lack of response to one agent does not preclude response to another. Especially in older patients, antimuscarinics should be started at the lowest possible dose and titrated as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant peripheral adverse effects, attributed to blockade of muscarinic receptors throughout the body, may limit drug tolerability and dose escalation.",
"   </p>",
"   <p>",
"    Adverse effects include inhibition of salivary secretion (dry mouth), blockade of the ciliary muscle of the lens to cholinergic stimulation (blurred vision for near objects), tachycardia, drowsiness, decreased cognitive function, and inhibition of gut motility (constipation). Constipation and compensatory fluid intake for dry mouth may exacerbate urinary incontinence. Dry mouth predisposes to caries; dentulous patients should have regular dental care if they are maintained on antimuscarinics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimuscarinic agents are contraindicated in patients with gastric retention and angle closure glaucoma. Drug interactions occur with drugs that are potent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ). In one case report,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    potentiated the action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , suggesting the need for close monitoring of the INR when tolterodine is initiated in anticoagulated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the risks of these drugs outweigh the benefits in older patients with dementia. There is no compelling evidence that one agent is safer than another. Furthermore, there is emerging evidence that patients with dementia are often treated concomitantly with an antimuscarinic and a cholinesterase inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients receiving this combination have greater functional decline than patients on cholinesterase inhibitors alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus whether to monitor the postvoid residual (PVR) in patients on antimuscarinics, especially older persons. Patients whose incontinence symptoms worsen while on antimuscarinic agents should have the PVR evaluated, because subclinical urinary retention can increase the frequency of incontinence. Patients who are at higher risk for retention (eg, large pelvic organ prolapse, taking anticholinergic medications) may also benefit from monitoring PVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Oxybutynin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     Oxybutynin",
"    </a>",
"    has direct antispasmodic effects and inhibits the action of acetylcholine on smooth muscle.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     Oxybutynin",
"    </a>",
"    is available in immediate release (IR), extended release (ER), and transdermal patch and topical gel formulations. Efficacy is similar for all formulations; cost, adverse effects, and time to onset of action are factors to consider in selecting a preparation. The initial dosage for IR is 2.5 mg two to three times daily, followed by titration as needed up to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses. The ER formulation is started at 5 mg once daily and titrated up to 20 to 30 mg once daily. The transdermal patch (equivalent to 3.9",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    applied to the abdomen, hip, or buttock is changed twice a week. The topical 10% gel is applied as 1 gm (approximately 1 mL) daily to the thigh, abdomen, upper arm, or shoulder. In the United States (US), oxybutynin IR and ER are available as generic formulations, offering a cost advantage over other agents.",
"   </p>",
"   <p>",
"    The quick onset of action of the IR preparation makes it useful when protection is wanted at specific times.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     Oxybutynin",
"    </a>",
"    IR is associated with high rates of anticholinergic adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/7\">",
"     7",
"    </a>",
"    ], these effects, especially dry mouth, that can limit therapy with oxybutynin. Dry mouth is less frequent with the extended release and transdermal preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Adverse effects may be further minimized by slow titration of the drug. Irritation and pruritus at the application site has been reported in approximately 15 percent of patients using transdermal oxybutynin and 5 percent using the topical gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there has been concern raised about use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    in cognitively impaired patients, a short-term (4 week) randomized study conducted in 12 nursing homes found no difference in cognitive assessment for patients with mild to severe dementia receiving oxybutynin ER 5 mg daily or placebo; longer term studies should be undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tolterodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     Tolterodine",
"    </a>",
"    (1 to 2 mg twice a day IR, 2 to 4 mg per day ER) has similar efficacy to other antimuscarinics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/7\">",
"     7",
"    </a>",
"    ]. A meta-analysis found tolterodine is better tolerated than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    (dry mouth relative risk [RR] 0.54; 95% CI 0.48-0.61, study withdrawal because of adverse effects RR 0.63; 95% CI 0.46-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/39\">",
"     39",
"    </a>",
"    ]. There have been case reports of cognitive adverse effects mimicking dementia with tolterodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. A prescription event monitoring study found higher rate of hallucinations with tolterodine compared with 10 other non-anticholinergic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/42\">",
"     42",
"    </a>",
"    ], but there are no prospective studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fesoterodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/53/28501?source=see_link\">",
"     Fesoterodine",
"    </a>",
"    is a prodrug that is non-hepatically metabolized to 5-hydroxymethyl",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    , which is the active metabolite of tolterodine. Randomized trials have found that fesoterodine improves symptoms of overactive bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. As an example, in a 12-week titrated dose, randomized trial in 883 patients with overactive bladder symptoms, patients who were assigned fesoterodine 4 or 8 mg daily had small to moderate, but statistically significant, reductions in total micturations and incontinence episodes compared to patients who received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/43\">",
"     43",
"    </a>",
"    ]. The recommended starting dose is 4 mg once daily, which can be increased to 8 mg if needed. The most common adverse effects with fesoterodine were dry mouth (26 percent) and constipation (11 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Trospium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/9/26773?source=see_link\">",
"     Trospium",
"    </a>",
"    (immediate release 20 mg twice daily or extended release 60 mg daily) is the only antimuscarinic that is renally cleared. The initial dose of the immediate release formulation should be 20 mg once a day in the elderly and in persons with renal impairment, and the extended release formulation should not be used in patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute).",
"    </span>",
"    Because of poor bioavailability, trospium must be taken on an empty stomach.",
"   </p>",
"   <p>",
"    In a 12-week randomized trial in 658 patients with overactive bladder and urge incontinence, patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/9/26773?source=see_link\">",
"     trospium",
"    </a>",
"    had a greater decrease in the number of daily episodes of incontinence than patients who received placebo (from a mean of 2.9 to 1.0 with trospium and 1.6 with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients receiving trospium experienced dry mouth (20 percent) and constipation (11 percent).",
"   </p>",
"   <p>",
"    An extended release formulation (60 mg once daily) was studied in a 12-week randomized trial in 564 patients with severe urge incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/46\">",
"     46",
"    </a>",
"    ]. Incontinence episodes decreased significantly more with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/9/26773?source=see_link\">",
"     trospium",
"    </a>",
"    (-2.6) compared to placebo (-1.6). Adverse events were lower than reported for immediate-release trospium (dry mouth 13 percent, constipation 8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Solifenacin and darifenacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/33/39445?source=see_link\">",
"     Solifenacin",
"    </a>",
"    (5 to 10 mg daily) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43733?source=see_link\">",
"     darifenacin",
"    </a>",
"    (7.5 to 15 mg daily) are used for the treatment of overactive bladder with urge incontinence, urgency, and urinary frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/47\">",
"     47",
"    </a>",
"    ]. These agents are more selective for the M-3 muscarinic receptor found in the bladder and GI tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/48\">",
"     48",
"    </a>",
"    ], but whether this translates to better tolerability or clinical efficacy is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 12-week randomized trial in 1200 adults, mean urge incontinence episodes in 24 hours decreased more with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/33/39445?source=see_link\">",
"       solifenacin",
"      </a>",
"      (5 mg titrated to 10 mg) than with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"       tolterodine",
"      </a>",
"      (4 mg once daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/49\">",
"       49",
"      </a>",
"      ]. Dry mouth and constipation occurred somewhat more frequently with solifenacin than with tolterodine (30 versus 24 and 6 versus 3 percent respectively).",
"     </li>",
"     <li>",
"      In a 12-week randomized trial in 445 adults, median incontinence episodes per week decrease more with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43733?source=see_link\">",
"       darifenacin",
"      </a>",
"      15 mg than with placebo (-12.6 versus -9.8). Dry mouth occurred in 29 percent and constipation in 18 percent of patients receiving darifenacin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sub-analysis of pooled data from phase III trials of variable doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43733?source=see_link\">",
"     darifenacin",
"    </a>",
"    found superior efficacy to placebo in reducing incontinence in patients aged &ge;65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/51\">",
"     51",
"    </a>",
"    ]. In a prospective study in similarly aged patients, darifenacin was superior to placebo for patient-reported outcomes including quality of life, but not for decrease in incontinence, possibly due to a high placebo response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Alpha adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha adrenergic agonists stimulate urethral smooth muscle contraction and have been used for the treatment of stress incontinence. They are no longer recommended because they are only mildly efficacious compared with placebo and have a high rate of adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Imipramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     Imipramine",
"    </a>",
"    has dual alpha agonist and anticholinergic activity and can be used in women with mixed incontinence. However, stress leakage could be worsened if the postvoid residual increases, and efficacy data are lacking. It is not recommended for older patients in whom anticholinergic adverse effects and orthostatic hypotension may be significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H924545\">",
"    <span class=\"h2\">",
"     Beta-3 adrenergic receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-3 adrenergic receptor agonists are thought to facilitate urine storage through stimulation of beta-3 adrenoreceptors in the bladder wall that facilitate bladder relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/54\">",
"     54",
"    </a>",
"    ]. The first beta-3 adrenergic agonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/60/5061?source=see_link\">",
"     mirabegron",
"    </a>",
"    , was approved by the US Food and Drug Administration in June 2012 for the treatment of overactive bladder, on the basis of three randomized trials that demonstrated reduced urinary frequency and wetting episodes for patients assigned to medication compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/55\">",
"     55",
"    </a>",
"    ]. The most common side effects observed in the trials were increased blood pressure, nasopharyngitis, urinary tract infection, constipation, fatigue, tachycardia, and abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/55\">",
"     55",
"    </a>",
"    ]. Mirabegron is not recommended for use in those with severe uncontrolled high blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/55\">",
"     55",
"    </a>",
"    ].&nbsp;Evidence of cytochrome P450 (CYP)2D6 inhibition in clinical trials highlighted a concern for pharmacokinetic interaction with other drugs that are CYP2D6 substrates (eg, metoprolol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/54\">",
"     54",
"    </a>",
"    ]. Further trials are ongoing to evaluate long-term efficacy, safety, and tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    is a serotonin and norepinephrine reuptake inhibitor that is approved in the European Union for the treatment of stress incontinence. The US Food and Drug Administration has only approved duloxetine for the treatment of major depression and neuropathic pain. It stimulates pudendal motor neuron alpha adrenergic and 5-hydroxytryptamine-2 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/57\">",
"     57",
"    </a>",
"    ]. In large randomized controlled trials, treatment with duloxetine at a dose of 40 mg twice daily resulted in improved quality of life and moderate decreases in the frequency of incontinence compared with placebo (range of mean or median decrease 50 to 54 percent versus 27 to 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. However, two systematic reviews concluded that, despite improvement in symptoms, cure rates with duloxetine and placebo are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/21,60\">",
"     21,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea is common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    treatment (23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/21\">",
"     21",
"    </a>",
"    ]. Nausea may be attenuated by initiating therapy with 20 mg twice daily, and increasing to 40 mg twice daily after two weeks. It tends to improve or resolve over several weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/59\">",
"     59",
"    </a>",
"    ]. However, in randomized trials, approximately 20 percent of women stopped the drug due to adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/21\">",
"     21",
"    </a>",
"    ]. Duloxetine is contraindicated in patients with evidence of chronic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found that oral estrogen may worsen urinary incontinence, whereas local topical estrogen may improve symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/62\">",
"     62",
"    </a>",
"    ]. Estrogen receptors exist throughout the lower urinary tract and estrogen is trophic for urethral epithelial, vascular, and connective tissue. Estrogen may alleviate dyspareunia, recurrent cystitis, and",
"    <span class=\"nowrap\">",
"     vaginal/urethral",
"    </span>",
"    atrophy and inflammation in post-menopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, large randomized trials have found that oral estrogen replacement actually worsens incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Women's Health Initiative (WHI) included 23,296 women ages 50 to 79 for whom urinary incontinence rates were known at baseline and at one year; a subset of the women were also evaluated after three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/64\">",
"       64",
"      </a>",
"      ]. Women were treated with either conjugated estrogen (0.625 mg daily) or conjugated estrogen plus medroxyprogesterone acetate (2.5 mg daily) or with placebo. Women who were continent at baseline who were treated with estrogen or estrogen plus progesterone had an increased risk of all types of urinary incontinence at one year. This increased risk was greatest for stress incontinence (relative risk [RR] 2.2 for treatment with estrogen plus progesterone and RR 1.9 for treatment with estrogen alone); the risk of stress incontinence remained increased after three years of treatment. Women who were incontinent at baseline had worsening frequency and incontinence when treated with estrogen alone or estrogen plus progesterone.",
"     </li>",
"     <li>",
"      Data from the Nurses' Health Study found that hormonal therapy (both estrogen alone and estrogen plus progestin) for younger postmenopausal women (aged 37 to 54 years) also increased the risk of urinary incontinence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the available clinical trial data, and concerns about long-term",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    use raised by the WHI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/66\">",
"     66",
"    </a>",
"    ], oral estrogen should not be prescribed for the treatment of urinary incontinence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One meta-analysis of small randomized trials found that local estrogen (eg, vaginal creams, rings, dissolving tablets) may improve urinary incontinence episodes (RR 0.74, 95% CI 0.64-0.86), although some women experienced vaginal spotting, breast tenderness, or nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/62\">",
"     62",
"    </a>",
"    ]. Another meta-analysis found overall positive but inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear which is the optimal topical preparation of estrogen and which patients are likely to benefit from local estrogen treatment. Because there is no standardized regimen of topical estrogen for treatment of urinary incontinence, dosages for vaginal atrophy are often used (eg, estradiol vaginal cream 0.01%, 2 to 4 g daily for one to two weeks then gradually reduce to 1 to 2 g for one to two weeks, then 1 g three times weekly and re-evaluate at three months). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Alpha adrenergic antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial of 97 women with chronic voiding symptoms and low urinary flow treated with tamsulosin (0.2 mg daily for six weeks), a meaningful reduction in symptom score (&ge;50 percent) was seen in only 35 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/67\">",
"     67",
"    </a>",
"    ]. Alpha blockers may also have a role in patients with neurogenic voiding dysfunction from suprasacral spinal cord injury or multiple sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic complications of spinal cord injury\", section on 'Bladder dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Combining pharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of pharmacological agents that affect detrusor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sphincter contractions via different mechanisms, such as using antimuscarinics with alpha adrenergic antagonists, have been tested only in men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41737?source=see_link&amp;anchor=H9860254#H9860254\">",
"     \"Urinary incontinence in men\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488386438\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin A injected into the detrusor muscle may alleviate symptoms of urinary incontinence refractory to anti-cholinergic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral therapy. A major limitation to its use is post-treatment urinary retention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19336?source=see_link\">",
"     \"Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic complications of spinal cord injury\", section on 'Bladder dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents are used for urge incontinence, but lack consistent efficacy in randomized, controlled trials. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25476?source=see_link\">",
"       Bethanechol",
"      </a>",
"      chloride is a cholinergic agent that has been used to treat underactive detrusor function with elevated PVR. There is no compelling evidence to support this practice. Available trials involve heterogeneous groups of patients, are either small or lack control groups,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      combine bethanechol with other agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/68,69\">",
"       68,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/4/14404?source=see_link\">",
"       Propantheline",
"      </a>",
"      is an anticholinergic agent that is administered three to five times daily at a dose of 15 to 30 mg. Poor bioavailability requires that it be taken on an empty stomach.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/6/27749?source=see_link\">",
"       Dicyclomine",
"      </a>",
"      is an antispasmodic drug that may be given at a dose of 10 to 20 mg three times daily.",
"     </li>",
"     <li>",
"      Tricyclic antidepressants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      10 to 25 mg one to four times daily may be effective. However, they are not recommended for older patients in whom anticholinergic adverse effects and orthostatic hypotension may be significant.",
"     </li>",
"     <li>",
"      Vasopressin, while useful in children with enuresis, has significant side effects and lower efficacy in older individuals. Its expense and risks of congestive failure and hyponatremia argue against routine use of vasopressin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7178?source=see_link&amp;anchor=H602907610#H602907610\">",
"       \"Management of nocturnal enuresis in children\", section on 'Desmopressin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited efficacy data are available for several other drugs, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=see_link\">",
"       hyoscyamine",
"      </a>",
"      , calcium channel blockers, and nonsteroidal antiinflammatory agents. Randomized studies demonstrate that the antispasmodic agent flavoxate is ineffective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Investigational drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several novel classes of drugs are under investigation for the treatment of urge",
"    <span class=\"nowrap\">",
"     incontinence/overactive",
"    </span>",
"    bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachykinins may mediate",
"      <span class=\"nowrap\">",
"       bladder/spinal",
"      </span>",
"      reflex signaling and contribute to urgency and urge incontinence. &nbsp;Aprepitant and serlopitant are neurokinin-1 receptor antagonists that have been studied in randomized trials for overactive bladder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. Both aprepitant and serlopitant reduced the number of daily micturitions, but did not significantly reduce episodes of urinary incontinence, in comparison to placebo. In addition, aprepitant but not serlopitant was associated with adverse effects including pneumonia, palpitations, and exacerbation of asthma, whereas serlopitant was well-tolerated.",
"     </li>",
"     <li>",
"      Blockade of smooth muscle sodium channels may affect bladder contraction. An agent that both blocks sodium channels and muscarinic receptors is in phase II trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin D3 receptors in the bladder may affect bladder contractility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/74\">",
"       74",
"      </a>",
"      ]. A vitamin D3 analogue, elocalcitol, has completed phase II trials in Europe for treatment of LUTS associated with benign prostatic hypertrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     COMBINING BEHAVIORAL AND PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term adherence to antimuscarinic medications is generally low, and most patients with urge incontinence do not have total relief of symptoms. Combined behavioral and pharmacologic therapy has been proposed to improve urge incontinence symptoms. However, randomized trials have not found combined therapy to be more effective than pharmacologic therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. As an example, one multicenter randomized trial of 307 women with urge incontinence evaluated whether a 10 week course of treatment with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    plus behavioral training (bladder training and pelvic floor muscle exercises) or tolterodine alone would affect the need for medication and resolution of symptoms at follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/75\">",
"     75",
"    </a>",
"    ]. There was no significant difference between groups, six months after study intervention, in either of the primary study outcomes: the number of women remaining off drug therapy (41 percent for both groups) or the number who reported at least a 70 percent reduction in incontinence (69 percent for combination treatment versus 58 percent for drug only therapy, CI for difference -0.3 to 22.1). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     NEUROLOGIC STIMULATION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Electrical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical stimulation devices to treat urinary incontinence implement pelvic muscle contractions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    modulate detrusor contractions. Electrical stimulation therapies for UI include noninvasive stimulation, sacral nerve stimulation (SNS) via surgically implanted electrodes, percutaneous stimulation of peripheral tibial nerve, and intravesical stimulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive electrical stimulation is applied by a small removable device placed in either the vagina or anus. Its mechanism of action may include direct stimulation of periurethral striated muscle and reflex inhibition of the detrusor muscle secondary to afferent stimulation of the pudendal nerve. Some experts believe that there is some efficacy for urge, but not for stress, incontinence. However, estimates of its efficacy for urge UI are inconclusive because of variations in patient selection and stimulation parameters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sacral nerve stimulation (SNS) is used for refractory urge UI, refractory urgency-frequency, and idiopathic non-obstructive urinary retention. The exact mechanism of action is uncertain. In SNS, electrodes are placed percutaneously adjacent to the S3 dorsal roots. If &gt;50 percent improvement is seen with a one to four week trial, patients undergo permanent lead implantation with a pacemaker-like stimulator placed under the skin of a buttock. Several case series have reported long-term positive results women with refractory urge incontinence or urgency-frequency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/79-82\">",
"       79-82",
"      </a>",
"      ]. Adverse events that may occur during pre-implantation testing or permanent lead placement include lead migration, pain at the stimulator or lead site, infection, and transient electrical shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Percutaneous stimulation of the tibial nerve may have some benefit for women with overactive bladder symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/84\">",
"       84",
"      </a>",
"      ], detrusor overactivity, urge incontinence, and non-obstructive, non-neurogenic urinary retention who have failed other conservative care. Methods include needle electrodes placed medially above the ankle (1 to 3 sessions per week) or an implanted device in the same area. In a nonblinded, multicenter trial of 100 patients with overactive bladder symptoms randomly assigned to either percutaneous tibial nerve stimulation or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"       tolterodine",
"      </a>",
"      extended release 4 mg daily, after 12 weeks of therapy, there was no difference between the groups in the primary outcome, urinary frequency, or secondary outcomes including urge urinary incontinence episodes, urge severity, and nighttime voids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravesical stimulation is a controversial treatment of last resort for patients with a hypocontractile detrusor and impaired bladder sensation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Magnetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal magnetic stimulation devices for the treatment of incontinence include an electromagnetic chair to stimulate pelvic floor contractions and an externally applied magnet to stimulate sacral nerve roots. Trials of these devices have been uniformly small, included heterogeneous patient groups, and may have been incompletely blinded or had no control group. Positive benefits were variable and, when reported, appeared to be short-lived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/86\">",
"     86",
"    </a>",
"    ]. Some effectiveness was demonstrated for urge incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/87\">",
"     87",
"    </a>",
"    ]. Currently available data do not clarify the patients for whom this modality might be most effective, the optimal stimulation parameters for each condition, or whether magnetic stimulation is more beneficial than other conservative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Urge incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential surgical treatments for severe cases of intractable urge urinary incontinence are sacral nerve stimulation via surgically implanted electrodes and augmentation cystoplasty (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Electrical'",
"    </a>",
"    above). Augmentation cystoplasty is associated with high morbidity, which limits its use to individuals with profoundly severe incontinence, usually younger patients with poorly compliant bladders secondary to neurologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16094232\">",
"    <span class=\"h2\">",
"     Stress incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery offers the high cure rates for stress urinary incontinence, even in elderly women. However, it is invasive and potentially morbid. A vaginal or abdominal approach can be used for surgical treatment of SUI. Vaginal procedures include: midurethral sling, bladder neck sling, or injection of urethral bulking agents. Burch retropubic colposuspension is an abdominal procedure for SUI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss, fluid intake modification and some dietary measures may be helpful. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Lifestyle'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Pads and protective garments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients use pads and protective garments before, during, and after incontinence treatment. The choice of protection depends upon gender and the type and volume of urinary incontinence leakage. As examples, pads designed for menstrual use often are not sufficiently absorbent for sudden, larger volume leakage. Protective items are available at minimum to no cost in many European Union countries. However, in the US, these items are expensive and usually not covered by insurance, except by Medicaid. Information on pad varieties and other urinary incontinence supplies is available from medical supply companies and urinary incontinence patient advocacy groups such as The Simon Foundation (",
"    <a class=\"external\" href=\"file://www.simonfoundation.org/\">",
"     www.simonfoundation.org",
"    </a>",
"    ) and the National Association for Continence (",
"    <a class=\"external\" href=\"file://www.nafc.org/\">",
"     www.nafc.org",
"    </a>",
"    ). Advocacy groups also can provide patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Continence pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pelvic organ prolapse or stress urinary incontinence with a pessary is inexpensive, effective, and safe; contraindication to use and serious complications are rare. The use of these devices may be very appealing to some women, particularly those who wish to avoid surgery.",
"   </p>",
"   <p>",
"    A gynecologist or urologist experienced in fitting pessaries can size and place the pessary; some general practitioners may also have such training. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Urinary bladder catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indwelling catheters are associated with morbidity due to potential for urethral trauma, bladder and renal infection, and bladder and renal stones. They are indicated for short-term use in incontinent patients when wounds need to be protected. The indications and management of urinary bladder catheter is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238194\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When managing incontinence in persons with cognitive impairment, it should never be assumed that the cognitive impairment is the direct or main cause of incontinence. Other factors, especially comorbid conditions, medications, and functional impairment, should also be investigated and treated first [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/89\">",
"     89",
"    </a>",
"    ]. Goals of care and treatment preference discussions should include the needs and wishes of the caregivers who will oversee",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    implement treatment, especially as their preferences may differ from those of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best-studied treatment for incontinence in persons with dementia is prompted voiding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/4,91\">",
"     4,91",
"    </a>",
"    ]. Other methods such as habit training (timed voiding with the interval based upon the usual voiding schedule in the bladder diary) and scheduled voiding (timed voiding using an arbitrarily set interval, usually every two to three hours) do not improve incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/4\">",
"     4",
"    </a>",
"    ]. Nearly all studies were done in long-term care settings, and most subjects were women.",
"   </p>",
"   <p>",
"    Prompted voiding has three components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regular monitoring by caregivers, including encouragement for patients to report any leakage or desire to void",
"     </li>",
"     <li>",
"      Prompting to toilet on a scheduled basis (optimally based on a voiding diary, but usually operationalized as every two hours)",
"     </li>",
"     <li>",
"      Praise and positive feedback when individuals are continent and attempt to toilet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients most likely to respond to prompted voiding are able to state their name, transfer with the assistance of at most one caretaker, leak less than four times in a 12-hour period during the day, and void with prompting at least 75 percent of the time in an initial three day trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-third of patients will experience a decrease in leakage frequency with prompted voiding. The efficacy of prompted voiding is often limited by lack of consistent toileting by caretakers and general application without evaluation for other factors contributing to incontinence. &nbsp;",
"   </p>",
"   <p>",
"    Functional Incidental Training (FIT) combines prompted voiding with endurance and muscle strengthening exercises done at the time of toileting. In a trial of 107 cognitively and functionally impaired long-term care residents, FIT reduced wet checks by nearly half compared with increased incontinence in control patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/93\">",
"     93",
"    </a>",
"    ]. However, adoption of FIT is limited by the required increased aide time and labor costs.",
"   </p>",
"   <p>",
"    There are very few studies evaluating the efficacy of antimuscarinic drugs, with or without concomitant behavioral therapy, in persons with cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/91\">",
"     91",
"    </a>",
"    ]. In a randomized trial in 75 nursing home residents whose urge-type incontinence did not respond to prompted voiding, the addition of immediate-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    did not improve the overall frequency of incontinence, but significantly more patients on oxybutynin met the \"continence criteria\" of an average of one or less wet checks per day (40 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/94\">",
"     94",
"    </a>",
"    ]. A randomized trial of oxybutynin ER 5 mg daily in 50 cognitively-impaired nursing home residents found no significantly different decreases in incontinence, urinary frequency, or dryness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/95\">",
"     95",
"    </a>",
"    ]. However, this study was limited by small sample size and lack of dosage titration.",
"   </p>",
"   <p>",
"    Antimuscarinic agents are often avoided in this population out of concern for cognitive side effects, although the actual risk is unclear. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Adverse effects'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link&amp;anchor=H6#H6\">",
"     \"Drug prescribing for older adults\", section on 'Anticholinergic activity'",
"    </a>",
"    .) If antimuscarinic agents are used, monitoring for worsening mental status should be part of the instructions given to the caregiver. Antimuscarinic agents should particularly be used with caution in patients taking cholinesterase inhibitors for treatment of dementia, as concomitant use of these agents has been associated with functional decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reasonable approach for cognitively-impaired patients who have failed prompted voiding is a trial of low-dose antimuscarinic medications in patients for whom the goals of care are more curative than palliative, who do not have existing conditions that could be worsened by anticholinergic medications (e.g., constipation), and who are not on a cholinesterase inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Overactive bladder symptoms without incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with overactive bladder (OAB) symptoms (urgency, frequency, and nocturia) do not have incontinence but nonetheless experience significant bother from their symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/99\">",
"     99",
"    </a>",
"    ]. This condition has been referred to as \"OAB-dry,\" or \"dry OAB,\" and is one type of problem referred to as \"lower urinary tract symptoms\", or \"LUTS.\"",
"   </p>",
"   <p>",
"    Whether OAB-dry is a separate pathological entity from urge incontinence, or is part of a continuum, is not known. The OAB-dry symptoms could arise from a combination of specific pathophysiological changes and factors both within and outside of the lower urinary tract, with significant gender differences. Interpatient variability in the etiology of OAB-dry symptoms, even within gender, makes it difficult to consider OAB-dry patients as a group for specific treatment recommendations.",
"   </p>",
"   <p>",
"    There is limited data on the effectiveness of behavioral therapy in treatment of OAB-dry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/100\">",
"     100",
"    </a>",
"    ]. Although OAB-dry patients have been included in RCTs of antimuscarinic agents, there has been no systematic review of outcomes in the OAB-dry patients alone, and there are little data in published trials examining baseline differences in OAB-wet and OAB-dry subjects. Specific reports regarding drug treatment in OAB-dry patients come only from pooled secondary analyses of single agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Furthermore, there is concern that the pharmaceutical industry has heightened the public's conception of OAB-dry as a target for drug treatment.",
"   </p>",
"   <p>",
"    In the absence of strong evidence-based recommendations, a reasonable approach to patients presenting with OAB-dry symptoms would be to perform the same clinical evaluation as for OAB symptoms with incontinence. History may reveal that some of these patients currently have or previously had episodes of urge incontinence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    that they may be using specific coping strategies and behavioral modifications to prevent leakage.",
"   </p>",
"   <p>",
"    Patients with predominant complaints of frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nocturia should be specifically asked about types, timing, and amount of fluid intake. Patients with nocturia should be evaluated for causes of nocturnal polyuria and primary sleep disturbance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28122?source=see_link\">",
"     \"Nocturia: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If symptoms persist after addressing all possible contributing factors, treatment should be step-wise, starting with lifestyle changes and bladder retraining. Patients with bothersome urgency who do not respond to behavioral treatment might be considered for treatment with antimuscarinic agents (which are approved only for treatment of patients with incontinence), with careful weighing of the risks versus benefits of off-label use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Overflow urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of overflow urinary incontinence depends upon the etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outflow obstruction in women: Women with obstruction from previous vaginal or urethral surgery may be treated by unilateral suture removal or urethrolysis (remobilization of adhesions). Obstruction from a large cystocele or uterine prolapse can be treated surgically or with a pessary. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=see_link\">",
"       \"Laparoscopic surgery for repair of pelvic floor defects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=see_link\">",
"       \"Vaginal pessary treatment of prolapse and incontinence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detrusor underactivity: Treatment for patients with detrusor underactivity depends on the etiology. Sacral nerve stimulation may be beneficial for patients with idiopathic or neurogenic underactivity (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Electrical'",
"      </a>",
"      above). Drugs that impair detrusor contractility and increase urethral tone should be decreased or stopped and constipation should be treated. Intermittent clean catheterization may be used alone or in conjunction with the above approaches, if necessary. Sterile intermittent catheterization is preferred to an indwelling catheter to minimize infection risk in frail or institutionalized patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2007 NIH State of the Science Conference concluded the following regarding prevention of urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/104\">",
"     104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavioral and lifestyle changes that may reduce the risk for urinary incontinence include weight loss for obesity, smoking cessation, increasing physical",
"      <span class=\"nowrap\">",
"       activity/exercise",
"      </span>",
"      and improving diet.",
"     </li>",
"     <li>",
"      Pelvic floor muscle exercises and biofeedback are effective in preventing and reversing some urinary incontinence in the first year after vaginal delivery, or following pelvic or prostate surgery. Pelvic floor muscle exercises also decreased the one-year risk of developing incontinence in older women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Management of conditions associated with incontinence (eg, diabetes, neurologic conditions, impaired mobility, depression, constipation, and urinary urgency) may prevent incontinence, or improve the effectiveness of management.",
"     </li>",
"     <li>",
"      Specific medications and surgical procedures may adversely affect continence, and clinicians should include these risks in discussing treatment choice with patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adults with neurologic disease (eg, multiple sclerosis, spinal cord injury) often have inevitable bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sphincter impairment. Nevertheless, active management such as intermittent catheterization may prevent frank urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/4/32842/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Healthy voiding habits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised to drink an adequate amount of fluid, usually six cups daily or more when temperatures are high or when exercising. Most individuals empty the bladder approximately every three to four hours during the day; getting up once during the night to void is not abnormal in older persons. It is important to relax and not strain when voiding or moving the bowels. Keeping bowel movements regular is important for healthy urinary voiding.",
"   </p>",
"   <p>",
"    Patients should be reminded to seek professional help for urinary incontinence, bothersome lower urinary tract symptoms, nocturia more than once during the night to void, pain with urination, or hematuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Public restrooms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Web sites that give the locations of public restrooms are available for many major cities. Many such cities can be found linked at:",
"    <a class=\"external\" href=\"file://www.americanrestroom.org/index.html\">",
"     www.americanrestroom.org/index.html#locate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/8/22658?source=see_link\">",
"       \"Patient information: Urinary incontinence (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/60/11202?source=see_link\">",
"       \"Patient information: Pelvic muscle (Kegel) exercises (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/56/35714?source=see_link\">",
"       \"Patient information: Surgery to treat stress urinary incontinence in women (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/36/43586?source=see_link\">",
"       \"Patient information: Treatments for urge incontinence in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/16/9474?source=see_link\">",
"       \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=see_link\">",
"       \"Patient information: Pelvic floor muscle exercises (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stepped approach to the management of urinary incontinence is appropriate: lifestyle changes followed by behavioral methods and medications, with other minimally-invasive approaches, and surgery considered only for patients who do not have an adequate response to noninvasive treatments. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss can reduce stress incontinence in women. Other lifestyle interventions that may be helpful for all types of incontinence include managing fluid intake, avoiding caffeinated beverages and alcohol, and treating constipation and cough. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Lifestyle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder training for urge, stress, and mixed incontinence in cognitively-intact patients involves timed voiding and urgency suppression, which may be combined with biofeedback. For cognitively-impaired patients, prompted voiding can be helpful. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Bladder training'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvic muscle exercises (Kegel exercises) are recommended for urge, stress, and mixed incontinence. The following regimen can be performed: 3 sets of 8 to 12 slow-velocity contractions sustained for 6 to 8 seconds each, performed 3 to 4 times a week and continued for at least 15 to 20 weeks. Referral to physical therapists or trained nurse specialists may be helpful. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pelvic muscle exercises'",
"      </a>",
"      above and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=see_link\">",
"       \"Patient information: Pelvic floor muscle exercises (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continence pessaries may be used for women with stress incontinence as an adjunct or substitute for pelvic muscle exercises. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Continence pessaries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimuscarinic therapy for patients with urge and mixed urinary incontinence provide a small benefit over placebo. Use of these drugs can be limited by adverse effects, which may be reduced by slow titration and extended-release preparations. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antimuscarinics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, medications do not play an important role in the treatment of stress incontinence.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"      may offer some benefit. Oral estrogen increased incontinence in postmenopausal women in both the WHI and HERS studies, although topical estrogen may improve incontinence symptoms. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Duloxetine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Estrogen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally-invasive procedures, such as sacral nerve stimulation and intravesical botulinum toxin injection, may be helpful for some patients with refractory urge incontinence. Sacral nerve stimulation may also be effective for patients with idiopathic or neurogenic urinary retention. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Neurologic stimulation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other invasive procedures and surgery are largely reserved for treatment of stress incontinence and include periurethral injections, bladder neck suspension, sling procedures, and for very severe cases, implantation of an artificial sphincter. Surgical options for urge incontinence are limited and have significant morbidity. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of overflow incontinence is related to its etiology: pessary or surgery can help women with pelvic organ prolapse; drugs that impair detrusor contractility should be stopped; intermittent catheterization can be helpful in motivated patients. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Overflow urinary incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indwelling urinary catheters should be a last resort and are associated with high morbidity and costs. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Adjunctive measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention involves modification of healthy voiding habits; limiting alcohol, caffeinated, and carbonated beverages, and possibly some food products; and maintaining healthy weight. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/1\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/2\">",
"      Harris SS, Link CL, Tennstedt SL, et al. Care seeking and treatment for urinary incontinence in a diverse population. J Urol 2007; 177:680.",
"     </a>",
"    </li>",
"    <li>",
"     Management Recommendations. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications, Paris 2009. p.1774.",
"    </li>",
"    <li>",
"     DuBeau CE, Kuchel GA, Johnson T, et al.. Incontinence in the frail elderly. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications Ltd, Paris 2009. p.961.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/5\">",
"      DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc 1998; 46:683.",
"     </a>",
"    </li>",
"    <li>",
"     Altman  D, Lapitan MC, Nelson R, et al. Epidemiology of urinary and faecal incontinence and pelvic organ prolapse. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications Ltd, Paris 2009. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/7\">",
"      Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/8\">",
"      Getsios D, El-Hadi W, Caro I, Caro JJ. Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations. Pharmacoeconomics 2005; 23:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/9\">",
"      Schnelle JF, Leung FW, Rao SS, et al. A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. J Am Geriatr Soc 2010; 58:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/10\">",
"      Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009; 360:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/11\">",
"      Brown JS, Wing R, Barrett-Connor E, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care 2006; 29:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/12\">",
"      Wing RR, West DS, Grady D, et al. Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. J Urol 2010; 184:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/13\">",
"      Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol 2012; 187:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/14\">",
"      Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/15\">",
"      Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/16\">",
"      Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004; :CD001308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/17\">",
"      Wall LL, Davidson TG. The role of muscular re-education by physical therapy in the treatment of genuine stress urinary incontinence. Obstet Gynecol Surv 1992; 47:322.",
"     </a>",
"    </li>",
"    <li>",
"     Hay-Smith J, Berghmans BK, et al.. Adult conservative management. In: Incontinence, 4th Ed., Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications Ltd, Paris 2009. p.1025.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/19\">",
"      Hay-Smith J, M&oslash;rkved S, Fairbrother KA, Herbison GP. Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev 2008; :CD007471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/20\">",
"      Hay-Smith EJ, Herderschee R, Dumoulin C, Herbison GP. Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2011; :CD009508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/21\">",
"      Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med 2008; 148:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/22\">",
"      Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2010; :CD005654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/23\">",
"      Burgio KL, Engel BT. Biofeedback-assisted behavioral training for elderly men and women. J Am Geriatr Soc 1990; 38:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/24\">",
"      Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/25\">",
"      Herbison P, Plevnik S, Mantle J. Weighted vaginal cones for urinary incontinence. Cochrane Database Syst Rev 2002; :CD002114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/26\">",
"      Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006; 98:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/27\">",
"      Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/28\">",
"      Shamliyan T, Wyman JF, Ramakrishnan R, et al. Systematic Review: Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/29\">",
"      Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008; 112:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/30\">",
"      Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; 1:CD005429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/31\">",
"      Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999; 33:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/32\">",
"      Modi A, Weiner M, Craig BA, et al. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc 2009; 57:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/33\">",
"      Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging 2003; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/34\">",
"      Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000; 95:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/35\">",
"      Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/36\">",
"      Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/37\">",
"      Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/38\">",
"      Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/39\">",
"      Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; 185:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/40\">",
"      Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol 2003; 60:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/41\">",
"      Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/42\">",
"      Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf 2001; 24:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/43\">",
"      Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010; 75:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/44\">",
"      Kraus SR, Ruiz-Cerd&aacute; JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/45\">",
"      Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/46\">",
"      Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008; 71:449.",
"     </a>",
"    </li>",
"    <li>",
"     In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, November 29, 2004, p.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/48\">",
"      Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/49\">",
"      Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/50\">",
"      Zinner N, Susset J, Gittelman M, et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006; 60:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/51\">",
"      Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/52\">",
"      Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/53\">",
"      Alhasso A, Glazener CM, Pickard R, N'dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2005; :CD001842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/54\">",
"      Tyagi P, Tyagi V. Mirabegron, a &beta;���-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010; 13:713.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves Myrbetriq for overactive bladder. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310096.htm (Accessed on July 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/56\">",
"      Bhide AA, Digesu GA, Fernando R, Khullar V. Use of mirabegron in treating overactive bladder. Int Urogynecol J 2012; 23:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/57\">",
"      Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003; 170:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/58\">",
"      van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004; 111:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/59\">",
"      Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004; 93:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/60\">",
"      Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 2005; :CD004742.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2005/safety05.htm#Cymbalta (Accessed on June 30, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/62\">",
"      Cody JD, Richardson K, Moehrer B, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2009; :CD001405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/63\">",
"      Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/64\">",
"      Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005; 293:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/65\">",
"      Townsend MK, Curhan GC, Resnick NM, Grodstein F. Postmenopausal hormone therapy and incident urinary incontinence in middle-aged women. Am J Obstet Gynecol 2009; 200:86.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/66\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/67\">",
"      Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol 2008; 15:981.",
"     </a>",
"    </li>",
"    <li>",
"     Wyndaele JJ, Kovinda A, Madersbacher H, et al.. Neurologic urinary and faecal incontinence. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications Ltd, Plymouth 2009. p.793.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/69\">",
"      Finkbeiner AE. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 1985; 134:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/70\">",
"      Andersson KE. Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 2009; 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/71\">",
"      Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006; 176:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/72\">",
"      Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010; 184:616.",
"     </a>",
"    </li>",
"    <li>",
"     SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS) file://clinicaltrials.gov/ct2/show/NCT00409539 (Accessed on February 02, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/74\">",
"      Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 2007; 16:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/75\">",
"      Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008; 149:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/76\">",
"      Burgio KL, Goode PS, Richter HE, et al. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. J Urol 2010; 184:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/77\">",
"      Berghmans LC, Hendriks HJ, De Bie RA, et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int 2000; 85:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/78\">",
"      Goode PS, Burgio KL, Locher JL, et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. JAMA 2003; 290:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/79\">",
"      Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol 2001; 39:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/80\">",
"      van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/81\">",
"      Hassouna MM, Siegel SW, N&yuml;eholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000; 163:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/82\">",
"      Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol 2011; 186:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/83\">",
"      Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000; 56:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/84\">",
"      Finazzi-Agr&ograve; E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010; 184:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/85\">",
"      Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/86\">",
"      Voorham-van der Zalm PJ, Pelger RC, Stiggelbout AM, et al. Effects of magnetic stimulation in the treatment of pelvic floor dysfunction. BJU Int 2006; 97:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/87\">",
"      Suzuki T, Yasuda K, Yamanishi T, et al. Randomized, double-blind, sham-controlled evaluation of the effect of functional continuous magnetic stimulation in patients with urgency incontinence. Neurourol Urodyn 2007; 26:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/88\">",
"      Quek P. A critical review on magnetic stimulation: what is its role in the management of pelvic floor disorders? Curr Opin Urol 2005; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     https://www.cms.gov/transmittals/downloads/r8som.pdf (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/90\">",
"      Pfisterer MH, Johnson TM 2nd, Jenetzky E, et al. Geriatric patients' preferences for treatment of urinary incontinence: a study of hospitalized, cognitively competent adults aged 80 and older. J Am Geriatr Soc 2007; 55:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/91\">",
"      Fink HA, Taylor BC, Tacklind JW, et al. Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. Mayo Clin Proc 2008; 83:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/92\">",
"      Schnelle JF. Treatment of urinary incontinence in nursing home patients by prompted voiding. J Am Geriatr Soc 1990; 38:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/93\">",
"      Ouslander JG, Griffiths PC, McConnell E, et al. Functional incidental training: a randomized, controlled, crossover trial in Veterans Affairs nursing homes. J Am Geriatr Soc 2005; 53:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/94\">",
"      Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995; 43:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/95\">",
"      Lackner TE, Wyman JF, McCarthy TC, et al. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. J Am Med Dir Assoc 2011; 12:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/96\">",
"      Sink KM, Thomas J 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/97\">",
"      Braithwaite R. Avoid antimuscarinic drugs in people with dementia. BMJ 2012; 344:e3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/98\">",
"      Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/99\">",
"      Stewart W, Herzog R, Wein A, et al. The prevalence and impact of overactive bladder in the US: Results from the NOBLE program. Neurourol Urodyn 2001; 20:406.",
"     </a>",
"    </li>",
"    <li>",
"     Hay Smith J, Berghmans B, Burgio K, et al. Adult Conservative Management. In: Incontinence, 4th ed, Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publication Ltd., Plymouth, UK 2009. p.1120.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/101\">",
"      Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 2005; 48:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/102\">",
"      Nitti VW, Dmochowski R, Appell RA, et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006; 97:1262.",
"     </a>",
"    </li>",
"    <li>",
"     Fantl JA, Newman DK, Colling J, et al. Urinary Incontinence in Adults: Acute and Chronic Management. Clinical Practice Guideline, No. 2, 1996 Update. AHCPR Publication No. 96-0682, Public Health Service; Agency for Health Care Policy and Research, Rockville, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/104\">",
"      Landefeld CS, Bowers BJ, Feld AD, et al. National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults. Ann Intern Med 2008; 148:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/105\">",
"      Diokno AC, Sampselle CM, Herzog AR, et al. Prevention of urinary incontinence by behavioral modification program: a randomized, controlled trial among older women in the community. J Urol 2004; 171:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/4/32842/abstract/106\">",
"      DuBeau CE. Interpreting the effect of common medical conditions on voiding dysfunction in the elderly. Urol Clin North Am 1996; 23:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6881 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32842=[""].join("\n");
var outline_f32_4_32842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H47\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIFESTYLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dietary changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bladder training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pelvic muscle exercises",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Biofeedback",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Weighted vaginal cones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antimuscarinics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Oxybutynin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tolterodine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fesoterodine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Trospium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Solifenacin and darifenacin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Alpha adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Imipramine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H924545\">",
"      Beta-3 adrenergic receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Alpha adrenergic antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Combining pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488386438\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Investigational drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      COMBINING BEHAVIORAL AND PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      NEUROLOGIC STIMULATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Electrical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Magnetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Urge incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16094232\">",
"      Stress incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      ADJUNCTIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Pads and protective garments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Continence pessaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5238194\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Overactive bladder symptoms without incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Overflow urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Healthy voiding habits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Public restrooms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/46/14060\" title=\"table 1\">",
"      Quality of life measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/29/17885\" title=\"table 2\">",
"      Treatment urge incontinence in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/19/41275\" title=\"table 3\">",
"      Bladder retraining instructions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7192?source=related_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=related_link\">",
"      Laparoscopic surgery for repair of pelvic floor defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7178?source=related_link\">",
"      Management of nocturnal enuresis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28122?source=related_link\">",
"      Nocturia: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=related_link\">",
"      Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/60/11202?source=related_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/56/35714?source=related_link\">",
"      Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/36/43586?source=related_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41737?source=related_link\">",
"      Urinary incontinence in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19336?source=related_link\">",
"      Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_4_32843="Dyspnea patient questionnaire";
var content_f32_4_32843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dyspnea questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Please select up to three phrases that best describe your breathing discomfort. If you choose more than one phrase, please also note the phrase that most closely describes the sensation you feel. If none of these phrases applies, please write in your own description of your breathing discomfort.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing is shallow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel an urge to breathe more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My chest is constricted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing requires effort.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel a hunger for more air.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel out of breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I cannot get enough air.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breath does not go in all the way.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My chest feels tight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing requires work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel that I am smothering/suffocating.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel that I cannot get a deep breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel that I am breathing more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breath does not go out all the way.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing is heavy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other descriptions:",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32843=[""].join("\n");
var outline_f32_4_32843=null;
var title_f32_4_32844="Epinepherine actions";
var content_f32_4_32844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Beneficial effects and adverse effects of epinephrine in the treatment of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Beneficial effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist1_start\">",
"        At alpha-1 receptor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased vasoconstriction (at low doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased peripheral vascular resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreased mucosal edema (eg, in larynx)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        At beta-1 receptor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased heart rate (chronotropy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased force of cardiac contraction (inotropy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        At beta-2 receptor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreased mediator release from mast cells and basophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased bronchodilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased vasodilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Adverse effects",
"        <sup>",
"         *&bull;&Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Common and transient",
"       </td>",
"       <td>",
"        Anxiety, palpitations, pallor, tremor, fear, restlessness, dizziness, headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uncommon (typically occur after overdose)",
"       </td>",
"       <td>",
"        Ventricular arrhythmias, angina, myocardial infarction, pulmonary edema, sudden sharp increase in blood pressure, intracranial hemorrhage",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Risk of adverse effects may be increased in the following conditions:",
"     <br>",
"      - Use of tricyclic antidepressants, monoamine oxidase inhibitors, or cocaine",
"      <br>",
"       - Some preexisting cardiovascular, central nervous system, or thyroid diseases",
"       <br>",
"        <span class=\"bullet\">",
"         &bull;",
"        </span>",
"        Serious adverse effects such as those listed in the table potentially occur when epinephrine is given in overdose by any route, most commonly after an intravenous bolus injection, an overly rapid intravenous infusion, or an erroneous intravenous injection of a 1 mg/mL (1:1000) epinephrine solution instead of an appropriately diluted 0.1 mg/mL (1:10,000) or a 0.01 mg/mL epinephrine solution.",
"        <br>",
"         &Delta; Anaphylaxis can present as an acute coronary syndrome (ACS), arrhythmias, myocardial infarction, or angina, before or in the absence of epinephrine injection. This potentially occurs in patients with known coronary artery disease, patients in whom subclinical coronary artery disease is unmasked, and patients (including children) with transient coronary artery vasospasm in whom no cardiovascular abnormalities can be detected by electrocardiogram or echocardiography after recovery from anaphylaxis.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32844=[""].join("\n");
var outline_f32_4_32844=null;
var title_f32_4_32845="Estrogen levels in PCOS";
var content_f32_4_32845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Serum estrogen and gonadotropin concentrations in women with the polycystic ovary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean serum concentrations of luteinizing hormone (LH) (mIU/mL), follicle stimulating hormone (mIU/mL), estrone (pg/mL), and estradiol (pg/mL) in 10 normal women between Day&nbsp;2 to&nbsp;4 of their menstrual cycle and 19 women with the polycystic ovary syndrome (PCOS). Women with PCOS had, on average, higher serum LH and estrone concentrations than normal women. However, there was substantial overlap between the two groups and some women with PCOS had normal serum LH and/or estrone concentrations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: DeVane GW, Czekala NM, Judd HL, Yen, SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.&nbsp;Am J Obstet Gynecol 1975; 121:496.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32845=[""].join("\n");
var outline_f32_4_32845=null;
var title_f32_4_32846="Pathophysiology of DIC";
var content_f32_4_32846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of the clinical manifestations of disseminated intravascular coagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 438px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32846=[""].join("\n");
var outline_f32_4_32846=null;
var title_f32_4_32847="TruViewEV01";
var content_f32_4_32847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TruViewEV01",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Truview EVO video-laryngoscope in adult, pediatric and infant sizes for indirect laryngoscopy in routine and difficult airways, manufactured by Truphatek International Ltd., Israel. www.truphatek.com",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_4_32847=[""].join("\n");
var outline_f32_4_32847=null;
